0000950170-23-039366.txt : 20230808 0000950170-23-039366.hdr.sgml : 20230808 20230808073135 ACCESSION NUMBER: 0000950170-23-039366 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vigil Neuroscience, Inc. CENTRAL INDEX KEY: 0001827087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41200 FILM NUMBER: 231149346 BUSINESS ADDRESS: STREET 1: 100 FORGE ROAD STREET 2: SUITE 700 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-254-4445 MAIL ADDRESS: STREET 1: 100 FORGE ROAD STREET 2: SUITE 700 CITY: WATERTOWN STATE: MA ZIP: 02472 10-Q 1 vigl-20230630.htm 10-Q 10-Q
Q2false--12-310001827087http://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/us-gaap/2023#RelatedPartyMember0001827087us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-3000018270872022-04-012022-06-300001827087vigl:SeriesAConvertiblePreferredStockMember2020-09-182020-09-180001827087us-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:CommonStockMember2022-06-300001827087us-gaap:CommonStockMember2023-06-300001827087vigl:MarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087vigl:SeriesBConvertiblePreferredStockMember2021-08-132021-08-130001827087us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001827087us-gaap:RetainedEarningsMember2022-04-012022-06-300001827087vigl:SeriesBConvertiblePreferredStockMember2023-06-300001827087vigl:UnvestedRestrictedCommonStockMember2022-01-012022-06-300001827087us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001827087us-gaap:ConvertiblePreferredStockMember2021-12-3100018270872023-01-012023-06-300001827087us-gaap:CommonStockMember2022-12-310001827087vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-01-012023-06-300001827087vigl:SeriesAPreferredStockTrancheObligationMember2020-09-182020-09-180001827087vigl:OptionsToPurchaseCommonStockPerformanceBasedMember2023-01-012023-06-300001827087vigl:OptionsToPurchaseCommonStockServiceBasedMember2023-01-012023-06-300001827087vigl:SeriesAConvertiblePreferredStockMember2021-05-280001827087us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001827087vigl:RestrictedCashNonCurrentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001827087vigl:LaboratoryAndOfficeSpaceMember2023-01-012023-01-310001827087us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001827087vigl:LaboratoryAndOfficeSpaceMember2021-09-012021-09-300001827087us-gaap:AdditionalPaidInCapitalMember2022-03-310001827087vigl:SalesAgreementMember2023-03-210001827087vigl:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001827087us-gaap:RestrictedStockMember2023-06-300001827087vigl:LaboratorySpaceMember2021-07-310001827087us-gaap:CommonStockMember2023-03-310001827087vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember2021-11-012021-11-300001827087us-gaap:CommonStockMemberus-gaap:IPOMember2022-01-012022-03-3100018270872022-05-310001827087vigl:AtlasVentureFundXIILPMember2022-01-012022-06-300001827087us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001827087us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087vigl:TwoThousandTwentyEquityIncentivePlanMember2023-06-3000018270872023-07-310001827087us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001827087vigl:CorporateHeadquartersMember2023-01-012023-06-300001827087vigl:SeriesAConvertiblePreferredStockMember2021-05-282021-05-2800018270872023-01-012023-03-310001827087us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001827087vigl:RestrictedCashNonCurrentMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001827087us-gaap:CertificatesOfDepositMember2023-06-300001827087us-gaap:RetainedEarningsMember2022-06-300001827087us-gaap:FairValueMeasurementsRecurringMember2022-12-310001827087us-gaap:CommonStockMemberus-gaap:IPOMemberus-gaap:SeriesAPreferredStockMember2022-01-012022-01-310001827087us-gaap:EquipmentMember2021-02-280001827087us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001827087us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:RetainedEarningsMember2023-01-012023-03-310001827087vigl:MarketableSecuritiesMember2023-06-300001827087vigl:SeriesAConvertiblePreferredStockPurchaseAgreementMembersrt:MaximumMember2020-09-300001827087vigl:LaboratorySpaceMember2021-07-012021-07-310001827087us-gaap:AdditionalPaidInCapitalMember2023-03-310001827087us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001827087vigl:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember2023-01-012023-06-300001827087vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-01-012023-01-0100018270872022-01-012022-03-310001827087us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:SeriesAPreferredStockMember2020-09-182020-09-1800018270872023-04-012023-06-300001827087us-gaap:EmployeeStockOptionMember2023-06-300001827087vigl:RestrictedCashNonCurrentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:RetainedEarningsMember2021-12-310001827087us-gaap:StandbyLettersOfCreditMember2021-09-300001827087vigl:SeriesBConvertiblePreferredStockMember2021-08-130001827087vigl:FujifilmDiosynthBiotechnologiesTexasLlcMembersrt:MaximumMember2021-11-012021-11-300001827087us-gaap:RetainedEarningsMember2022-01-012022-03-310001827087us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-3000018270872022-03-310001827087us-gaap:RestrictedStockMember2023-01-012023-06-300001827087vigl:CorporateHeadquartersMember2021-10-310001827087us-gaap:USGovernmentDebtSecuritiesMembervigl:MarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001827087us-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100018270872023-03-310001827087vigl:OptionsToPurchaseCommonStockPerformanceBasedMember2022-01-012022-06-300001827087us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001827087vigl:UnvestedRestrictedCommonStockMember2023-01-012023-06-300001827087us-gaap:AdditionalPaidInCapitalMember2021-12-310001827087vigl:LaboratoryAndOfficeSpaceMember2023-01-310001827087us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001827087vigl:SeriesAPreferredStockTrancheObligationMember2021-05-280001827087vigl:SeriesAConvertiblePreferredStockPurchaseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-09-300001827087us-gaap:StandbyLettersOfCreditMember2021-09-012021-09-300001827087us-gaap:FairValueInputsLevel2Membervigl:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087vigl:PreFundedWarrantsMember2022-12-3100018270872022-06-300001827087vigl:SeriesAConvertiblePreferredStockMember2020-09-180001827087vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2023-03-012023-03-3100018270872022-01-012022-01-310001827087vigl:RestrictedCashNonCurrentMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:RetainedEarningsMember2022-12-310001827087us-gaap:AdditionalPaidInCapitalMember2023-06-300001827087us-gaap:CommonStockMemberus-gaap:IPOMemberus-gaap:SeriesBPreferredStockMember2022-01-012022-01-310001827087vigl:AtlasVentureFundXIILPMember2023-01-012023-06-300001827087us-gaap:CommonStockMember2022-01-012022-03-310001827087us-gaap:PrivatePlacementMember2022-08-012022-08-310001827087us-gaap:RetainedEarningsMember2023-06-3000018270872021-12-310001827087us-gaap:ConvertiblePreferredStockMember2023-01-012023-06-300001827087us-gaap:CommonStockMember2023-04-012023-06-300001827087vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-06-300001827087us-gaap:AdditionalPaidInCapitalMemberus-gaap:IPOMember2022-01-012022-03-310001827087us-gaap:RetainedEarningsMember2022-03-310001827087vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2023-01-012023-01-010001827087us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001827087us-gaap:IPOMember2022-01-012022-03-3100018270872023-06-300001827087vigl:LaboratoryAndOfficeSpaceMember2023-01-012023-06-300001827087vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2022-12-310001827087us-gaap:FairValueInputsLevel2Membervigl:MarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:CommonStockMember2023-01-012023-03-310001827087vigl:AtlasVentureFundXIILPMember2023-06-300001827087us-gaap:CommonStockMember2022-03-310001827087us-gaap:EmployeeStockOptionMember2022-12-310001827087us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-04-012023-06-300001827087us-gaap:RetainedEarningsMember2023-04-012023-06-3000018270872022-01-012022-06-300001827087vigl:MarketableSecuritiesUSGovernmentSecuritiesMember2023-04-012023-06-300001827087us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001827087us-gaap:ConvertiblePreferredStockMemberus-gaap:IPOMember2022-01-012022-03-310001827087vigl:FujifilmDiosynthBiotechnologiesTexasLlcMembersrt:MinimumMember2021-11-012021-11-300001827087vigl:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2022-08-120001827087us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001827087us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Membervigl:MarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001827087vigl:SeriesAPreferredStockTrancheObligationMember2020-12-310001827087vigl:OptionsToPurchaseCommonStockServiceBasedMember2022-01-012022-06-300001827087us-gaap:AdditionalPaidInCapitalMember2022-12-310001827087vigl:CorporateHeadquartersMember2023-06-300001827087vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2022-12-310001827087us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-3000018270872022-12-310001827087us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001827087vigl:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-12-310001827087vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember2023-06-300001827087vigl:MarketableSecuritiesUSGovernmentSecuritiesMember2022-01-012022-06-300001827087vigl:MarketableSecuritiesUSGovernmentSecuritiesMember2023-01-012023-06-300001827087vigl:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-06-300001827087vigl:CorporateHeadquartersMember2023-04-012023-06-300001827087us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087us-gaap:StandbyLettersOfCreditMember2023-01-012023-06-300001827087us-gaap:SubsequentEventMembervigl:SalesAgreementMember2023-08-072023-08-070001827087us-gaap:USGovernmentDebtSecuritiesMembervigl:MarketableSecuritiesMember2023-06-300001827087us-gaap:AdditionalPaidInCapitalMember2022-06-300001827087vigl:SeriesAConvertiblePreferredStockMember2023-06-300001827087vigl:MarketableSecuritiesMember2023-06-300001827087us-gaap:CommonStockMember2022-04-012022-06-300001827087vigl:PreFundedWarrantsMembersrt:MaximumMemberus-gaap:PrivatePlacementMember2022-08-120001827087vigl:PreFundedWarrantsMember2023-06-300001827087vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2023-06-300001827087us-gaap:CommonStockMember2021-12-310001827087us-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001827087vigl:LaboratorySpaceMember2023-01-012023-06-300001827087vigl:MarketableSecuritiesUSGovernmentSecuritiesMember2022-04-012022-06-300001827087vigl:LaboratoryAndOfficeSpaceMember2021-09-300001827087us-gaap:RetainedEarningsMember2023-03-31xbrli:purexbrli:sharesvigl:Securitiesiso4217:USDxbrli:sharesiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number 001-41200

 

VIGIL NEUROSCIENCE, INC.

(Exact name of Registrant as specified in its Charter)

 

Delaware

85-1880494

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

100 Forge Road, Suite 700

Watertown, MA

02472

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (857) 254-4445

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VIGL

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

The number of shares of Registrant’s Common Stock outstanding as of July 31, 2023 was 35,873,421, par value $0.0001 per share.

 

 


Table of Contents

 

Page

PART I

FINANCIAL INFORMATION

4

 

 

 

Item 1.

Financial Statements (Unaudited)

4

 

Condensed Consolidated Balance Sheets

4

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

5

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity

6

 

Condensed Consolidated Statements of Cash Flows

7

 

Notes to Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

28

Item 4.

Controls and Procedures

28

 

 

 

PART II

OTHER INFORMATION

29

 

 

 

Item 1.

Legal Proceedings

29

Item 1A.

Risk Factors

29

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

77

Item 3.

Defaults Upon Senior Securities

77

Item 4.

Mine Safety Disclosures

77

Item 5.

Other Information

77

Item 6.

Exhibits

78

Signatures

 

79

 

i


SUMMARY RISK FACTORS

We are subject to numerous risks and uncertainties, including those further described below in the section entitled “Risk Factors” in this Quarterly Report on Form 10-Q, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results of operations, future growth prospects, or cause a decline in the price of our common stock:

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable, and, if we achieve profitability, we may not be able to sustain it.
We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
We are early in our development efforts and have never successfully completed any clinical trials, and if we are unable to identify and advance therapeutic candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.
The results of early preclinical studies are not necessarily predictive of the results of later preclinical studies and any clinical trials of our therapeutic candidates, and interim, topline and preliminary data from our preclinical studies and planned and ongoing clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
We may expend our limited resources to pursue a particular therapeutic candidate or indication, such as our initial focus on developing VGL101 for ALSP, and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success. As such, our business is highly dependent on the clinical advancement of our programs and is especially dependent on the success of our lead candidate, VGL101.
We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our therapeutic candidates are based on new approaches, which makes it difficult to predict the time and cost of therapeutic candidate development and subsequently obtaining regulatory approval.
We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical trials, which could prevent us from receiving necessary regulatory approvals or commercializing any therapeutic candidates we develop on a timely basis, if at all.
Use of our therapeutic candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a therapeutic candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.
Our therapeutic candidates are subject to extensive regulation and compliance, which is costly and time-consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our therapeutic candidates.
We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.
If we are unable to obtain and maintain patent protection for our therapeutic programs and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our therapeutic programs and other proprietary technologies we may develop may be adversely affected.

 

1


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

the initiation timing, progress, results and cost of VGL101 and our small molecule agonist program designed to activate Triggering Receptor Expressed on Myeloid Cells 2, or TREM2, as well as our research and development programs and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our current and future programs;
the application of our precision medicine approach to develop microglia-targeted therapies for patients with rare, genetically defined neurodegenerative diseases and subsequently advance into neurodegenerative diseases affecting larger patient populations;
the expansion of our modality agnostic product pipeline to other microglial targets beyond TREM2;
the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, as well as the beneficial characteristics, therapeutic effects and other positive results;
our estimates of the number of patients that we will enroll and our ability to initiate, recruit and enroll patients in and conduct, and successfully complete, our clinical trials, including at the pace that we project;
the ability to efficiently discover, identify, research and develop product candidates;
the timing, scope and likelihood of regulatory filings and approvals, including timing of any Investigational New Drug applications, or INDs, and final U.S. Food and Drug Administration, or FDA, approval of our current product candidates or any future product candidates;
the timing, scope or likelihood of foreign regulatory filings and approvals;
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;
our ability to scale up our manufacturing and processing approaches to appropriately address our anticipated commercial needs, which will require significant resources;
the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;
our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;
our ability to commercialize our products, if approved;
the pricing and reimbursement of our product candidates, if approved;
the implementation of our business model, and strategic plans for our business, product candidates, and technology;
estimates of our future expenses, revenues and capital requirements and our needs for additional financing;
future agreements with third parties in connection with the development and commercialization of product candidates and any other approved product;
the size and growth potential of the markets for our product candidates and our ability to serve those markets;
our financial performance;
the rate and degree of market acceptance of our product candidates;
regulatory developments in the United States and foreign countries;

2


our ability to attract and retain key scientific or management personnel;
our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;
the success of competing therapies that are or may become available;
the impact of laws and regulations;
developments relating to our competitors and our industry;
the effect of a public health crisis, such as the COVID-19 pandemic, on any of the foregoing or other aspects of our business operations, including any negative impact on enrollment in our ongoing clinical trial as well as any other impacts on our existing and future clinical trials or our preclinical studies; and
other risks and uncertainties, including those listed under the caption “Risk Factors.”

In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. All statements other than statements of historical facts are statements that could be deemed forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed above under “Summary of the Material Risks Associated with Our Business” and under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission, or the SEC, as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

3


PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

VIGIL NEUROSCIENCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

June 30,
2023

 

 

December 31,
2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

58,741

 

 

$

186,605

 

Marketable securities

 

 

91,423

 

 

 

 

Prepaid expenses and other current assets

 

 

5,555

 

 

 

11,200

 

Total current assets

 

 

155,719

 

 

 

197,805

 

Property and equipment, net

 

 

1,898

 

 

 

1,184

 

Operating lease right-of-use assets

 

 

16,805

 

 

 

141

 

Financing lease right-of-use assets

 

 

60

 

 

 

70

 

Restricted cash

 

 

927

 

 

 

927

 

Other assets

 

 

 

 

 

266

 

Total assets

 

$

175,409

 

 

$

200,393

 

Liabilities, Convertible Preferred Stock and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,362

 

 

$

1,942

 

Accrued expenses and other current liabilities (1)

 

 

5,001

 

 

 

9,194

 

Operating lease liabilities

 

 

802

 

 

 

153

 

Financing lease liabilities

 

 

2

 

 

 

23

 

Total current liabilities

 

 

8,167

 

 

 

11,312

 

Operating lease liabilities, net of current portion

 

 

13,406

 

 

 

 

Total liabilities

 

 

21,573

 

 

 

11,312

 

Commitments and contingencies (Note 12)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized as of
  June 30, 2023 and December 31, 2022, respectively;
0 share issued and
  outstanding at June 30, 2023 and December 31, 2022, respectively

 

 

 

 

 

 

Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2023
  and December 31, 2022;
35,906,037 shares issued as of June 30, 2023 and
  
35,664,658 shares issued as of December 31, 2022; and 35,861,714 shares
  outstanding as of June 30, 2023 and
35,620,335 shares outstanding as of
  December 31, 2022

 

 

4

 

 

 

4

 

Additional paid-in capital

 

 

334,005

 

 

 

329,211

 

Accumulated other comprehensive income (loss)

 

 

(70

)

 

 

 

Accumulated deficit

 

 

(180,103

)

 

 

(140,134

)

Total stockholders’ equity

 

 

153,836

 

 

 

189,081

 

Total liabilities and stockholders’ equity

 

$

175,409

 

 

$

200,393

 

 

(1)
Includes related party amounts of $0 (accrued expenses and other current liabilities) at June 30, 2023; $78 (accrued expenses and other current liabilities) at December 31, 2022 (see Note 11).

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


VIGIL NEUROSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development (2)

 

$

14,903

 

 

$

12,097

 

 

$

28,737

 

 

$

22,462

 

General and administrative

 

 

7,010

 

 

 

4,945

 

 

 

13,951

 

 

 

9,912

 

Total operating expenses

 

 

21,913

 

 

 

17,042

 

 

 

42,688

 

 

 

32,374

 

Loss from operations

 

 

(21,913

)

 

 

(17,042

)

 

 

(42,688

)

 

 

(32,374

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

1,746

 

 

 

32

 

 

 

2,731

 

 

 

34

 

Other income (expense), net

 

 

(7

)

 

 

(5

)

 

 

(12

)

 

 

(9

)

Total other income (expense), net

 

 

1,739

 

 

 

27

 

 

 

2,719

 

 

 

25

 

Net loss

 

$

(20,174

)

 

$

(17,015

)

 

$

(39,969

)

 

$

(32,349

)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.52

)

 

$

(0.60

)

 

$

(1.04

)

 

$

(1.18

)

Weighted-average common shares outstanding, basic and diluted

 

 

38,657,205

 

 

 

28,150,051

 

 

 

38,601,916

 

 

 

27,409,264

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(20,174

)

 

$

(17,015

)

 

$

(39,969

)

 

$

(32,349

)

Unrealized gain (loss) on available for sale securities

 

 

(176

)

 

 

 

 

 

(70

)

 

 

 

Total comprehensive loss

 

$

(20,350

)

 

$

(17,015

)

 

$

(40,039

)

 

$

(32,349

)

 

(2)
Includes related party amounts of $7 and $50 for the three and six months ended June 30, 2023, and $75 and $142 for the three and six months ended June 30, 2022 (see Note 11).

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5


VIGIL NEUROSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share amounts)

(Unaudited)

 

 

Convertible
Preferred Stock

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated Other Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity (Deficit)

 

Balances at December 31, 2021

 

 

54,179,688

 

 

$

161,939

 

 

 

 

1,724,950

 

 

$

 

 

$

2,386

 

 

$

 

 

$

(71,829

)

 

$

(69,443

)

Conversion of convertible preferred stock to common stock upon closing of initial public offering

 

 

(54,179,688

)

 

 

(161,939

)

 

 

 

19,536,870

 

 

 

2

 

 

 

161,937

 

 

 

 

 

 

 

 

 

161,939

 

Issuance of common stock from initial public offering, net of issuance costs of $10.0 million

 

 

 

 

 

 

 

 

 

7,000,000

 

 

 

1

 

 

 

87,985

 

 

 

 

 

 

 

 

 

87,986

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

4,995

 

 

 

 

 

 

9

 

 

 

 

 

 

 

 

 

9

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,021

 

 

 

 

 

 

 

 

 

1,021

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(15,334

)

 

 

(15,334

)

Balances at March 31, 2022

 

 

 

 

$

 

 

 

 

28,266,815

 

 

$

3

 

 

$

253,338

 

 

$

 

 

$

(87,163

)

 

$

166,178

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

799

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

2

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,461

 

 

 

 

 

 

 

 

 

1,461

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(17,015

)

 

 

(17,015

)

Balances at June 30, 2022

 

 

 

 

$

 

 

 

 

28,267,614

 

 

$

3

 

 

$

254,801

 

 

$

 

 

$

(104,178

)

 

$

150,626

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2022

 

 

 

 

$

 

 

 

 

35,620,335

 

 

$

4

 

 

$

329,211

 

 

$

 

 

$

(140,134

)

 

$

189,081

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

45,449

 

 

 

 

 

 

214

 

 

 

 

 

 

 

 

 

214

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,734

 

 

 

 

 

 

 

 

 

1,734

 

Unrealized gain (loss) on available for sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

106

 

 

 

 

 

 

106

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(19,795

)

 

 

(19,795

)

Balances at March 31, 2023

 

 

 

 

$

 

 

 

 

35,665,784

 

 

$

4

 

 

$

331,159

 

 

$

106

 

 

$

(159,929

)

 

$

171,340

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

195,930

 

 

 

 

 

 

589

 

 

 

 

 

 

 

 

 

589

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,257

 

 

 

 

 

 

 

 

 

2,257

 

Unrealized gain (loss) on available for sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(176

)

 

 

 

 

 

(176

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20,174

)

 

 

(20,174

)

Balances at June 30, 2023

 

 

 

 

$

 

 

 

 

35,861,714

 

 

$

4

 

 

$

334,005

 

 

$

(70

)

 

$

(180,103

)

 

$

153,836

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

6


VIGIL NEUROSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(39,969

)

 

$

(32,349

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Stock-based compensation expense

 

 

3,991

 

 

 

2,482

 

Non-cash operating lease expense

 

 

681

 

 

 

447

 

Depreciation and amortization

 

 

176

 

 

 

36

 

Amortization of premium/discount on marketable securities

 

 

(1,000

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

2,593

 

 

 

(235

)

Other non-current assets

 

 

 

 

 

789

 

Accounts payable

 

 

419

 

 

 

(2,390

)

Accrued expenses and other current liabilities

 

 

(4,193

)

 

 

(473

)

Operating lease liabilities

 

 

(237

)

 

 

(444

)

Net cash used in operating activities

 

 

(37,539

)

 

 

(32,137

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of marketable securities

 

 

(102,493

)

 

 

 

Proceeds from maturities of marketable securities

 

 

12,000

 

 

 

 

Purchases of property and equipment

 

 

(614

)

 

 

(233

)

Net cash used in investing activities

 

 

(91,107

)

 

 

(233

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from issuance of common stock upon initial public offering, net of offering costs

 

 

 

 

 

89,872

 

Payments of finance lease obligations

 

 

(21

)

 

 

(21

)

Proceeds from stock options exercised

 

 

803

 

 

 

11

 

Net cash provided by financing activities

 

 

782

 

 

 

89,862

 

Net increase in cash and cash equivalents

 

 

(127,864

)

 

 

57,492

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

187,532

 

 

 

92,347

 

Cash, cash equivalents and restricted cash at end of period

 

$

59,668

 

 

$

149,839

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

Conversion of Series A & Series B Preferred Stock to common stock, net of Issuance costs

 

$

 

 

$

161,939

 

Deferred offering costs paid in the prior year

 

$

 

 

$

1,887

 

Right-of-use assets obtained in exchange for operating lease liabilities

 

$

14,292

 

 

$

77

 

Prepaid rent reclassified to right-of-use assets

 

$

2,887

 

 

$

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

$

 

 

$

129

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7


VIGIL NEUROSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of the Business and Basis of Presentation

Vigil Neuroscience, Inc., together with its consolidated subsidiary, Vigil Neuroscience Security Corporation (“Vigil” or the “Company”), is a clinical-stage, microglia-focused biotechnology company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia, the sentinel immune cells of the brain. The Company’s initial focus is on developing a pipeline of therapeutic candidates that it believes will activate and restore microglia function, with an initial focus in genetically defined subpopulations. The Company was incorporated in the State of Delaware in June 2020 and is located in Watertown, Massachusetts.

The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical studies and clinical trials, the ability to raise additional capital to fund operations, obtaining regulatory approval for therapeutic candidates, market acceptance of products, competition from substitute products, protection of proprietary intellectual property, compliance with government regulations, dependence on key personnel, reliance on third-party organizations and the clinical and commercial success of its therapeutic candidates. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

Liquidity

The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of June 30, 2023, the Company had cash, cash equivalents, and marketable securities of $150.2 million and an accumulated deficit of $180.1 million. In January 2022, the Company completed its initial public offering (“IPO”) of its common stock which resulted in net proceeds of $88.0 million. In August 2022, the Company completed a private placement financing, which resulted in net proceeds of $71.3 million. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its cash and cash equivalents will be sufficient to fund current operations for at least the next twelve months from the issuance of these condensed consolidated financial statements.

On March 21, 2023, the Company entered into an Open Market Sales Agreement, or the Sales Agreement, with Jefferies LLC, or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $100.0 million of shares of its common stock, through the Agent, as its sales agent. As of August 7, 2023, no shares were sold under the Sales Agreement.

The Company expects to seek additional funding through equity financings, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company’s stockholders.

If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

The condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Basis of Presentation

The accompanying condensed consolidated financial statements reflect the operations of the Company are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended

8


December 31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 21, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.

The accompanying condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary. Intercompany balances and transactions have been eliminated in consolidation.

2. Summary of Significant Accounting Policies

The Company's significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022, and notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 21, 2023, or the 2022 Form 10-K. Since the date of those financial statements, there have been no material changes to Vigil’s significant accounting policies except as noted below.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities when purchased of three months or less that are readily convertible to known amounts of cash to be cash equivalents. The carrying values of these instruments approximate their respective fair value due to the short-term maturity of these investments. At June 30, 2023 and December 31, 2022, the Company’s cash equivalents were in money market funds and government securities. As of each balance sheet date and periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits.

In connection with the Company’s lease agreement entered into in September 2021 (see Note 12), the Company is required to maintain a certificate of deposit (“CD”) of $0.9 million for the benefit of the landlord.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):

 

 

June 30, 2023

 

 

June 30, 2022

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

58,741

 

 

$

148,912

 

Restricted cash, non-current

 

 

927

 

 

 

927

 

Total cash, cash equivalents and restricted cash

 

$

59,668

 

 

$

149,839

 

 

Marketable securities

Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders’ equity in other comprehensive income. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company’s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even if the stated maturity of some individual securities may be one year or more beyond the balance sheet date.

The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be “other than temporary”, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.

9


Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company qualifies as an ‘‘emerging growth company’’ as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to ‘‘opt out’’ of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to ‘‘opt out’’ of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies.

In August 2020, the FASB issued ASU No. 2020-06, Debt, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. The ASU also simplifies the accounting for convertible instruments by removing the beneficial conversion feature and cash conversion feature separation models. This ASU may be applied on a full retrospective or modified retrospective basis. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and all other public entities, this ASU is effective for fiscal years beginning after December 15, 2021. Early adoption permitted. The Company expects to adopt this ASU in fiscal year 2024. The Company does not currently expect the adoption to materially impact its financial position and results of operations.

3. Fair Value Measurements and Financial Instruments

The following table presents the Company’s fair value hierarchy for its asset items that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, by level within the fair value hierarchy (in thousands):

 

 

Fair Value Measurement at June 30, 2023 Using:

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

50,702

 

 

$

 

 

$

 

 

$

50,702

 

Corporate bonds

 

 

 

 

 

2,589

 

 

 

 

 

 

2,589

 

Total cash equivalents

 

$

50,702

 

 

$

2,589

 

 

$

 

 

$

53,291

 

Marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government securities

 

 

 

 

 

76,584

 

 

 

 

 

 

76,584

 

Corporate bonds

 

 

 

 

 

14,839

 

 

 

 

 

 

14,839

 

Total marketable securities

 

$

 

 

$

91,423

 

 

$

 

 

$

91,423

 

Restricted cash (non-current)

 

 

927

 

 

 

 

 

 

 

 

 

927

 

Total

 

$

51,629

 

 

$

94,012

 

 

$

 

 

$

145,641

 

 

 

Fair Value Measurement at December 31, 2022 Using:

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents (money market)

 

$

156,219

 

 

$

 

 

$

 

 

$

156,219

 

Restricted cash (non-current)

 

 

927

 

 

 

 

 

 

 

 

 

927

 

Total

 

$

157,146

 

 

$

 

 

$

 

 

$

157,146

 

 

10


Marketable securities

The following table summarizes the Company’s marketable securities as of June 30, 2023 (in thousands):

 

 

 

At June 30, 2023

 

 

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Value

 

U.S. government securities

 

$

76,634

 

 

$

2

 

 

$

(52

)

 

$

76,584

 

Corporate bonds

 

$

14,859

 

 

$

4

 

 

$

(24

)

 

$

14,839

 

Total

 

$

91,493

 

 

$

6

 

 

$

(76

)

 

$

91,423

 

 

The following table summarizes the Company’s marketable securities by maturity as of June 30, 2023 (in thousands):

 

 

At June 30, 2023

 

Maturities in one year or less

 

$

86,107

 

Maturities between one and two years

 

 

5,316

 

Total

 

$

91,423

 

 

As of June 30, 2023, the Company held 33 securities, 29 of which were in an unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company evaluated its securities for potential other-than-temporary impairment and considered the decline in market value to be primarily attributable to current economic and market conditions. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. Given the Company's intent and ability to hold such securities until recovery, and the lack of a significant change in credit risk for these investments, the Company does not consider these investments to be impaired as of June 30, 2023. The Company did not recognize any credit losses during the three and six months ended June 30, 2023 and 2022. Additionally, there were no realized gains or losses on marketable securities for the three and six months ended June 30, 2023 and 2022.

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

June 30,
2023

 

 

December 31,
2022

 

Research and development

 

$

3,615

 

 

$

6,670

 

Construction related prepaid assets

 

 

 

 

 

3,769

 

Business insurance

 

 

762

 

 

 

133

 

Other

 

 

1,178

 

 

 

628

 

Total

 

$

5,555

 

 

$

11,200

 

 

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

June 30,
2023

 

 

December 31,
2022

 

Payroll and employee related

 

$

2,154

 

 

$

3,512

 

Research and development

 

 

1,621

 

 

 

2,894

 

Professional fees

 

 

931

 

 

 

986

 

Construction related

 

 

78

 

 

 

1,416

 

Other

 

 

217

 

 

 

386

 

Total

 

$

5,001

 

 

$

9,194

 

 

11


6. Stock-Based Compensation

2020 Equity Incentive Plan

The Company's 2020 Equity Incentive Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. As of June 30, 2023, there were 2,508,398 options outstanding under the 2020 Plan.

2021 Stock Option and Incentive Plan

The Company's 2021 Stock Option and Incentive Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. On January 1, 2023, the shares reserved for future grants under the 2021 Plan increased by 1,781,017 pursuant to the 2021 Plan Evergreen Provision. In March of 2023, as part of the Company's annual grant of equity, the Company granted 1,348,380 stock options to employees. As of June 30, 2023, there were 3,252,644 options outstanding under the 2021 Plan.

2021 Employee Stock Purchase Plan

The Company's 2021 Employee Stock Purchase Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. On January 1, 2023, the shares reserved for future grants under the 2021 ESPP increased by 286,127 pursuant to the 2021 Plan Evergreen Provision. As of June 30, 2023, a total of 572,254 shares of common stock were reserved for issuance under this plan. No stock-based compensation expense was recognized during the three and six months ended June 30, 2023 related to the 2021 ESPP.

Stock-Based Compensation Expense

The Company recorded stock-based compensation expense of $2.3 million and $4.0 million during the three and six months ended June 30, 2023, respectively, and recorded $1.5 million and $2.5 million during the three and six months ended June 30, 2022, respectively. Stock-based compensation expense was classified as follows in the condensed consolidated statements of operations and comprehensive loss (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

891

 

 

$

608

 

 

$

1,577

 

 

$

1,049

 

General and administrative

 

 

1,366

 

 

 

853

 

 

 

2,414

 

 

 

1,433

 

Total stock-based compensation

 

$

2,257

 

 

$

1,461

 

 

$

3,991

 

 

$

2,482

 

 

At June 30, 2023, there was approximately $24.8 million unrecognized stock-based compensation expense related to unvested options, which is expected to be recognized over a weighted-average period of 2.78 years. At June 30, 2023, there was approximately $0.1 million unrecognized stock-based compensation expense related to unvested restricted stock, which is expected to be recognized over a weighted-average period of 0.84 years.

 

7. Preferred Stock

Convertible Preferred Stock

The Series A preferred stock and Series B preferred stock, described in more detail below, converted into 10,285,077 shares and 9,251,793 shares of common stock in January 2022 as part of our IPO.

Series A Convertible Preferred Stock and Series A Preferred Stock Tranche Obligation

On September 18, 2020, the Company entered into the Series A Convertible Preferred Stock Purchase Agreement with its initial investors committing to purchase an aggregate of $50.0 million in shares of Series A convertible preferred stock. At the initial closing, 9,815,467 shares of Series A convertible preferred stock were issued by the Company at a purchase price of $2.547 per share, for gross cash proceeds of $25.0 million. The gross proceeds were offset by $0.2 million of issuance costs and $0.2 million related to the Series A Preferred Stock Tranche Obligation, discussed below.

12


Included in the terms of the September 2020 Series A Convertible Preferred Stock Purchase Agreement were certain rights (“Series A Preferred Stock Tranche Obligation”) granted to the investors who purchased the Series A convertible preferred stock in September 2020. The Series A Preferred Stock Tranche Obligation contingently obligated the investors to purchase, and the Company to sell, up to an aggregate of 7,852,373 shares of Series A convertible preferred stock at $2.547 per share upon the satisfaction of specified research and development milestones by the Company.

The Company concluded that the Series A Preferred Stock Tranche Obligation met the definition of a freestanding financial instrument, as the Series A Preferred Stock Tranche Obligation was legally detachable and separately exercisable from the Series A convertible preferred stock. Therefore, the Company allocated the proceeds from the September 2020 issuance between the Series A Preferred Stock Tranche Obligation and the Series A convertible preferred stock, including those issued in exchange for the SAFE. As the Series A convertible preferred stock is redeemable upon a deemed liquidation event at the election of the holder-controlled Board, and therefore outside of the control of the Company, the Series A Preferred Stock Tranche Obligation was classified as a liability and recorded at its fair value of $0.3 million at both inception and as of December 31, 2020. The Series A Preferred Stock Tranche Obligation was remeasured at fair value at each reporting period, with changes in fair value recorded in change in fair value of the Series A Preferred Stock Tranche Obligation in the condensed consolidated statements of operations and comprehensive loss (see Note 3).

On May 28, 2021, the Company issued 7,852,373 shares of its Series A convertible preferred stock at $2.547 per share, for which the Company received gross proceeds of $20.0 million, offset by issuance costs of $0.1 million. As a result of this issuance, the Series A Preferred Stock Tranche Obligation with a then fair value of approximately $0.3 million was settled and reclassified to Series A convertible preferred stock in the consolidated balance sheet.

Series B Convertible Preferred Stock Financing

On August 13, 2021, the Company issued 25,657,096 shares of its Series B convertible preferred stock at $3.5078 per share, for which the Company received gross proceeds of $90.0 million. Issuance costs were $0.4 million.

Upon issuance of each class of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed upon the issuance date of each class of the Convertible Preferred Stock or as of June 30, 2023 and December 31, 2022.

The holders of Convertible Preferred Stock had the followings rights and privileges:

Conversion

The holders of the Convertible Preferred Stock may convert, at any time, each share of the Convertible Preferred Stock into shares of common stock. In addition, upon either (a) the closing of the sale of shares of common stock to the public at a price of at least three times the Series A Original Issue Price (subject to adjustment) in an initial public offering with net proceeds to the Company of at least $50.0 million or (b) the written consent of the holders of the outstanding shares of Convertible Preferred Stock, the Convertible Preferred Stock will automatically convert into common stock.

The conversion ratio of each series of the Convertible Preferred Stock is determined by dividing the Original Issuance Price of each series by the Conversion Price of each series. The Original Issuance Price per share is $2.547 for Series A convertible preferred stock and $3.5078 for Series B convertible preferred stock. The Conversion Price per share at issuance was $7.063 for Series A convertible preferred stock and $9.7278 for Series B convertible preferred stock, each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, including adjustment if common stock is issued for less than the Original Issue Price of each series of Convertible Preferred Stock.

8. Common Stock

Each share of common stock entitles the holder to one vote for each share of common stock held. Common stockholders are entitled to receive dividends, as may be declared by the Company’s Board. During each of the three and six months ended June 30, 2023 and the three and six months ended June 30, 2022, no dividends have been declared or paid.

13


Pre-funded Warrants

In connection with the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 2,980,889 shares of common stock at a purchase price of $7.2999 per pre-funded warrant. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share of common stock, is immediately exercisable and will remain exercisable until exercised in full. The pre-funded warrants have no expiration date and the price of the pre-funded warrants does not include any discounts. The Company evaluated the pre-funded warrants for liability or equity classification in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the pre-funded warrants did not meet the definition of liability instruments and met the criteria for permanent equity. As of June 30, 2023, no pre-funded warrants were exercised.

The Company has reserved the following number of shares of common stock for the exercise of outstanding stock options and future issuance of stock-based awards.

 

 

June 30,
2023

 

 

December 31,
2022

 

Common stock options

 

 

5,761,042

 

 

 

4,440,811

 

Pre-funded warrants

 

 

2,980,889

 

 

 

2,980,889

 

Shares available for issuance under the 2021 Plan

 

 

1,673,053

 

 

 

1,682,909

 

Shares available for issuance under the 2021 ESPP

 

 

572,254

 

 

 

286,127

 

Total common stock reserved for future issuance

 

 

10,987,238

 

 

 

9,390,736

 

 

9. Net Loss per Share

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(20,174

)

 

$

(17,015

)

 

$

(39,969

)

 

$

(32,349

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic and diluted

 

 

38,657,205

 

 

 

28,150,051

 

 

 

38,601,916

 

 

 

27,409,264

 

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.52

)

 

$

(0.60

)

 

$

(1.04

)

 

$

(1.18

)

 

The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per common share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per common share for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

As of June 30,

 

 

2023

 

 

2022

 

Options to purchase common stock – service based

 

 

5,550,413

 

 

 

4,162,669

 

Options to purchase common stock – performance based

 

 

210,629

 

 

 

210,629

 

Unvested restricted common stock

 

 

53,715

 

 

 

112,311

 

Total

 

 

5,814,757

 

 

 

4,485,609

 

 

10. Leases

In February 2021, the Company entered into an equipment lease with lease term of 24 months with rent commencing in the third quarter of 2021. The lease includes an option to purchase the equipment at fair market value at the end of the lease term. The Company has notified the vendor of its intent to exercise the purchase option.

14


In July 2021, the Company entered into a lease for laboratory space in Cambridge, Massachusetts, with an initial term of one year commencing in April 2021, with a month-to-month option to renew at the end of the initial lease term. At inception, the Company determined that it was reasonably certain that it would elect options to renew the lease through September 2022 and have included these renewal options into the initial determination of the lease term. In 2022, the Company further extended the lease term through February 28, 2023 and terminated the lease as of February 28, 2023 due to the Company's move to Watertown, Massachusetts as noted below.

In October 2021, the Company entered into a lease for its corporate headquarters in Cambridge, Massachusetts with an initial term of 14 months. In 2022, the Company extended the lease through January 31, 2023 and terminated the lease as of January 31, 2023 due to the Company's move to Watertown, Massachusetts as noted below. The lease payments during both the three and six months ended June 30, 2023 was $74 thousand. The Company received their security deposit of approximately $49 thousand in the second quarter of 2023.

Watertown, MA Lease

In September 2021, the Company entered into a lease for laboratory and office space in Watertown, Massachusetts with an initial term of ten years from the rent commencement date of December 2022, and a five-year renewal option. The lease commenced for accounting purposes in the January 2023 when the leased space was made available for the Company’s use. As of the lease commencement date, the Company has determined that it is not reasonably certain to exercise the option to extend the lease and has not included the extension period in the lease term. The monthly lease payment is approximately $0.2 million with annual escalation of approximately 3%. The lease includes a $3.7 million construction allowance. At the lease commencement date, the Company recorded an initial lease liability of $14.3 million and a right-of-use asset of $17.3 million. The components of lease expense for the three and six months ended June 30, 2023 were $0.6 million and $1.1 million in operating lease expense, respectively, and $0.2 million and $0.4 million in variable lease expense, respectively. Variable lease expense generally includes common area maintenance, property taxes, and utilities.

At June 30, 2023, the weighted-average remaining lease terms related to the finance and operating leases are 0.1 years and 9.4 years, respectively.

The weighted-average discount rates used at the time that the leases were evaluated were 5.14% for the finance leases and 7.55% for the operating leases that were still active as of June 30, 2023.

The Watertown lease began in January 2023, with minimum base rent payments ranging from $1.9 million annually and increasing to $2.1 million annually over the next 5 years. Future minimum lease payments due under the Company’s operating and finance lease liabilities as of June 30, 2023 are as follows:

 

 

 

Operating
Leases

 

 

Financing
Leases

 

2023

 

 

886

 

 

 

2

 

2024

 

 

1,910

 

 

 

 

2025

 

 

1,968

 

 

 

 

2026

 

 

2,027

 

 

 

 

2027

 

 

2,088

 

 

 

 

2028 and thereafter

 

 

11,269

 

 

 

 

Total lease payments

 

 

20,148

 

 

 

2

 

Less: imputed interest

 

 

(5,940

)

 

 

 

Total future minimum lease payments

 

$

14,208

 

 

$

2

 

 

11. Related Party Transactions

Atlas

The Company entered into various lease agreements with Atlas Venture Fund XII, L.P., a principal stockholder of the Company, and incurred lease costs of $50 thousand for the six months ended June 30, 2023, and $142 thousand for the six months ended June 30, 2022. The lease payments are included in general and administrative expenses for office space and research and development expenses for lab space in the condensed consolidated statements of operations and comprehensive loss. The Company terminated the lease for the laboratory space as of February 28, 2023 due to the Company's move to Watertown, Massachusetts, and therefore had no operating lease right-of-use asset or lease liability recorded as of June 30, 2023. As of June 30, 2023, the Company has no costs in accrued expenses associated with the leases.

15


12. Commitments and Contingencies

License Agreement

The Company has a license agreement with Amgen (see Note 12 to the consolidated financial statements of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022).

Letter of Credit

In September 2021, in connection with the Watertown, Massachusetts lease, the Company entered into a $0.9 million standby letter of credit which initially expired on September 10, 2022 and was renewed to expire on September 11, 2023. The standby letter of credit will automatically renew for subsequent annual periods through December 2032. Remittance of funds from the letter of credit was not probable and the full amount was available as of June 30, 2023. The Company did not recognize a liability in the condensed consolidated balance sheet.

Purchase Commitment

In November 2021, the Company entered into a statement of work ("SOW") with FUJIFILM Diosynth Biotechnologies Texas, LLC for $3.8 million under its existing master services agreement for the manufacturing of VGL101. If the Company terminates the SOW before completion, it may be required to pay fees ranging from 0% to 100%. The amount due upon an early termination depends on the length of time prior to the commencement of specific stages of the SOW. The SOW is expected to incur costs over approximately 2 years. As of June 30, 2023, approximately 56% of work has been completed on this SOW.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenses will be incurred and can be reasonably estimated. As of June 30, 2023, the Company does not have any significant legal disputes that require a loss liability to be recorded.

401(k) Plan

The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code of 1986 (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions are discretionary and contributions in the amount of $0.3 million were made during the six months ended June 30, 2023.

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.

Legal Proceedings

The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

16


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with the “Selected Consolidated Financial Data” section of this Quarterly Report on Form 10-Q (this "Quarterly Report") and our consolidated financial statements and related notes included elsewhere in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing includes forward-looking statements that involve risks and uncertainties. Many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report, may materially and adversely affect our actual results, which may differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage biotechnology company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates, initially addressing genetically defined patient subpopulations, that we believe will activate and restore microglial function. Our first therapeutic candidates are designed to activate Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), a key microglial receptor protein that mediates responses to environmental signals in order to maintain brain health and whose dysfunction is linked to neurodegeneration. We have two main programs that are designed to target TREM2. Our lead product candidate, VGL101, is a fully human monoclonal antibody (mAb) TREM2 agonist (or activator) that is currently being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Our second program is a small molecule TREM2 agonists with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations. We expect to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for this program, and subject to FDA clearance of the IND, initiate clinical development in healthy volunteers.

We believe that each of the therapeutic candidates in our pipeline has the potential to be developed for multiple neurodegenerative diseases. Our precision medicine approach begins with rare, genetically defined diseases for which microglial dysfunction is believed to be a key driver of disease pathology and then utilizes findings from these efforts to inform expansion into larger and more common neurodegenerative diseases. We believe our strategy has the potential to mitigate downstream translational risk as we seek to advance our programs through early development and into the clinic. We believe this iterative, sequential approach is a key differentiator, potentially allowing us to generate clinical proof-of-concept (PoC) efficiently and leverage our initial development programs as well as research by others, in pursuing additional neurodegenerative disease opportunities.

Our lead product candidate, VGL101, is currently being studied in IGNITE, a Phase 2 proof-of-concept trial and the first-ever interventional trial for ALSP patients. ALSP is a rare, inherited, autosomal dominant neurological disease with high genetic penetrance. ALSP is caused by a loss-of-function mutation in the Colony Stimulating Factor 1 Receptor (CSF1R), a receptor that shares a common downstream signaling pathway with TREM2 and affects an estimated 10,000 people in the U.S., with similar prevalence in Europe and Japan. There are currently no approved therapies for ALSP, underscoring the unmet need for people living with this disease. The FDA has granted Fast Track designation and orphan drug designation for VGL101 for the treatment of ALSP. We plan to report six-month interim data from the first six patients enrolled in IGNITE during the fourth quarter of 2023. We are also conducting a Phase 1 SAD and MAD trial of VGL101 in healthy volunteers in the United States and Australia. In 2022, we reported interim topline data from the ongoing Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VGL101 in healthy volunteers. As of October 7, 2022, the trial had enrolled 82 healthy volunteers who received either VGL101 (n=68) at various doses up to 40 mg/kg or placebo (n=14). Based on these data, VGL101 was found to be generally well-tolerated at doses up to 40 mg/kg SAD and 20 mg/kg MAD. VGL101 showed a linear, predictable PK profile at all doses and a half-life that supported monthly IV dosing. Importantly, VGL101 achieved dose dependent, durable decreases in levels of soluble TREM2 ("sTREM2") in the cerebrospinal fluid (CSF) demonstrating proof of target engagement. VGL101 20 mg/kg repeat dosing was associated with robust reduction in sTREM2 levels and decreases were still observed 28 days after the third and final dose. VGL101 is the first antibody reported to demonstrate durability of TREM2 engagement in a clinical setting and showed durable increases in soluble CSF1R ("sCSF1R") levels in the CSF after repeat dosing. As of the date of this report, we have completed dosing of the 60 mg/kg SAD and MAD cohorts in Australia in which VGL101 continued to be safe and well tolerated. We plan to report the full data analysis from the Phase 1 trial during the third quarter of 2023.

17


Engagement with our stakeholders, including patients and scientific and provider communities, is central to our approach in rare neurodegenerative diseases. In 2021, we began ILLUMINATE, a natural history study of ALSP patients to better characterize the patient journey, inform our clinical trial design, and facilitate recruitment into our clinical trials. In December 2022, we reported interim data from the ongoing ILLUMINATE study comparing magnetic resonance imaging (MRI) findings and certain fluid biomarker levels in symptomatic ALSP participants versus prodromal (those with a confirmed CSF1R mutation and MRI findings but showing no clinical symptoms of ALSP) participants. At six months, volumetric MRI findings showed a greater disease progression for symptomatic ALSP participants versus prodromal participants, based on greater reductions in brain tissue volume and greater increases in white matter lesion and ventricular volume. Baseline levels of fluid biomarkers were found to be significantly different for ALSP participants including reduced sCSF1R levels for prodromal and symptomatic individuals versus healthy volunteers, and increased neurofilament light chain (NfL) levels by multiple-fold, indicative of active neurodegeneration, for symptomatic individuals versus prodromal and healthy individuals. In addition to ILLUMINATE, we established the world’s first patient-facing ALSP informational website to build disease awareness and actively support patient advocacy organizations. Through this work, we have created a strong global network of key opinion leaders (KOLs), centers of excellence, and genetic counseling practices that each treat ALSP patients and work with families affected by the disease. In May 2023, we announced the launch of ALSPAware, a new program providing genetic testing and counseling services for the diagnosis of ALSP. Developed with both patients and healthcare providers in mind, the program includes a single gene confirmatory test for individuals with a family history of ALSP, as well as a custom gene panel available for physicians to use in diagnosing late onset neurodegenerative diseases. Trained genetic counselors are available to facilitate testing and discuss results, and participants will have access to a range of specialized information and services created to support participants and their families. By increasing access to genetic testing for both individuals and healthcare providers, we believe ALSPAware has the potential to help reduce initial misdiagnosis of this disease, while also providing appropriate disease management services for those living with ALSP.

In addition to VGL101, we are developing novel small molecule TREM2 agonists designed to be suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on AD in genetically defined subpopulations. Genome wide association studies (GWAS) have shown that a specific mutation in a TREM2 variant (R47H) has one of the strongest associations with the development of AD, second in magnitude only to that associated with the apolipoprotein E4 (ApoE4) genotype. Our strategy in AD is to initially target genetically defined AD subpopulations with microglia dysregulation including those carrying TREM2 and other variants. Our small molecule product candidates have a different mechanism of action and bind to a different site than VGL101, providing potential additional optionality in positioning these molecules in different patient populations and potential differentiation from TREM2 antibody therapeutics. These highly active, selective and brain-penetrant small molecule agonists are designed to act as a molecular glue that potentiates the TREM2 signaling response to natural damage ligands. Vigil has established that its small molecule agonists demonstrate on-target TREM2 activation across both common and rare TREM2 variants. We plan to submit an IND application and, subject to FDA clearance of the IND, initiate clinical development of our lead small molecule TREM2 agonist candidate in the fourth quarter of 2023.

We believe our microglia focus, precision medicine approach, and pipeline, which spans multiple modalities, strongly position us to become a differentiated leader in the neurodegenerative therapeutic space.

Recent Developments

Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, research and development activities, business planning, raising capital, building our intellectual property portfolio and providing general and administrative support for these operations. To date, we have raised approximately $313.0 million in gross proceeds primarily from equity offerings, including $140.0 million from convertible preferred stock, $98.0 million from our initial public offering (IPO) of our common stock, $53.3 million in private placement sales of our common stock, and $21.7 million from the sale of pre-funded warrants. As of June 30, 2023, we had $150.2 million of cash, cash equivalents, and marketable securities.

We have incurred significant operating losses since the commencement of our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current therapeutic candidates or any future therapeutic candidates. Our accumulated deficit was $140.1 million at December 31, 2022 and $180.1 million at June 30, 2023, respectively. We expect to continue to incur significant losses for the foreseeable future as we advance our current and future therapeutic candidates through preclinical and clinical development, continue to build our operations and transition to operating as a public company.

Our net losses may fluctuate significantly from period to period, depending on the timing of expenditures on our research and development activities. Our primary use of cash is to fund operating expenses, which consist primarily of research and development and general and administrative expenses. The timing of payment of these expenses has an effect on cash used to fund operating expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

18


We expect to continue to incur net operating losses for at least the next several years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we:

continue our ongoing and planned research and development of our VGL101 and small molecule TREM2 agonist program;
initiate preclinical studies and clinical trials for any additional therapeutic candidates that we may pursue in the future;
expand our product pipeline based on TREM2 and other microglia targets across multiple therapeutic modalities, through internal discovery and development, or through strategic collaborations or alliances with academic organizations, pharmaceutical or biotechnology companies;
seek regulatory approvals for any therapeutic candidates that successfully complete clinical trials;
invest in capital equipment in order to expand our research and development activities;
attract, hire and retain additional clinical, scientific, quality control, and manufacturing management and administrative personnel;
add clinical, operational, financial and management information systems and personnel, including personnel to support our product development;
develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;
acquire or in-license other therapeutic candidates and technologies;
expand our operations in the United States and to other geographies;
incur additional legal, accounting, investor relations and other general and administrative expenses associated with operating as a public company; and
establish a sales, marketing and distribution infrastructure, either ourselves or in partnership with others, to commercialize any therapeutic candidates, if approved.

We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our therapeutic candidates. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant expenses related to product sales, marketing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. We may also require additional capital to pursue in-licenses or acquisitions of other drug candidates. Further, we expect to incur additional costs associated with operating as a public company.

We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenses related to other research and development activities.

As a result, we will require substantial additional funding to develop our therapeutic candidates and support our continuing operations. Until such time that we can generate significant revenue from product sales or other sources, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which could include proceeds from potential collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the Russia/Ukraine military conflict and otherwise. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development or commercialization of our therapeutic candidates or grant rights to develop and market therapeutic candidates that we would otherwise prefer to develop and market ourselves.

Our failure to obtain sufficient funds with acceptable terms could have a material adverse effect on our business, results of operations or financial condition, including requiring us to have to delay, reduce or eliminate our product development or future commercialization efforts. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the amount of increased expenses or timing, or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. We cannot provide assurance that we will ever be profitable or generate positive cash flow from operating activities. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our therapeutic candidates. If we obtain regulatory

19


approval for any of our therapeutic candidates, we expect to incur significant expenses related to product sales, marketing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. We may also require additional capital to pursue in-licenses or acquisitions of other drug candidates. Further, we expect to incur additional costs associated with operating as a public company.

Components of Our Results of Operations

Operating Expenses

Our operating expenses since inception have consisted solely of research and development expenses and general and administrative expenses.

Research and Development

Research and development expenses consist of costs incurred for our research activities, including our discovery efforts and the development of our programs. These expenses include:

employee related expenses, including salaries, related benefits, and stock-based compensation expense for employees engaged in research and development functions;
expenses incurred in connection with the manufacturing and clinical development of our VGL101 program;
expenses incurred in connection with the discovery and preclinical development of our small molecule TREM2 agonist program;
expenses incurred under agreements with third parties, such as consultants, clinical investigators, contractors and contract research organizations, or CROs, that assist with (i) the non-clinical and clinical studies of VGL101 and (ii) identification of additional potential therapeutic candidates in our small molecule TREM2 agonist program;
the cost of developing and scaling our manufacturing process and manufacturing therapeutic candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations, or CMOs; and
other expenses incurred as a result of research and development activities.

Research and development expenses account for a significant portion of our operating expenses. We expense research and development costs as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. When third-party service providers’ billing terms do not coincide with our period-end, we are required to make estimates of our obligations to those third parties incurred in a given accounting period and record accruals at the end of the period. We base these estimates on our knowledge of the research and development programs, services performed for the period, past history for related activities and the expected duration of the third-party service contract, where applicable. If timelines or contracts are modified based upon changes in the scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis. Actual results could differ from our estimates.

Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external costs, such as fees paid to CROs, CMOs, central laboratories and outside consultants in connection with our research and discovery, preclinical development, process development, manufacturing, clinical development, regulatory and quality activities. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs. Our internal resources conduct our research and discovery activities and manage our preclinical development and process development, manufacturing and clinical development activities.

20


The table below summarizes our research and development expenses incurred by program:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

($ in thousands)

 

 

($ in thousands)

 

Direct, external research and development expenses by program:

 

 

 

 

 

 

 

 

 

 

 

 

VGL101

 

$

5,504

 

 

$

4,842

 

 

$

9,511

 

 

$

8,423

 

Small molecule TREM2

 

 

3,657

 

 

 

2,871

 

 

 

8,035

 

 

 

5,477

 

Unallocated research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

External costs and other

 

 

757

 

 

 

858

 

 

 

1,250

 

 

 

1,740

 

Facilities, personnel-related, and other

 

 

4,985

 

 

 

3,526

 

 

 

9,941

 

 

 

6,822

 

Total research and development expenses

 

$

14,903

 

 

$

12,097

 

 

$

28,737

 

 

$

22,462

 

 

Research and development activities are central to our business model. Therapeutic candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase over the next several years as we expect to (i) continue clinical development of our VGL101 program, (ii) advance our small molecule TREM2 agonist program into initial clinical trials, (iii) develop VGL101 for other indications, including other rare leukodystrophies, and leukoencephalopathies, and (iv) expand our modality agnostic product pipeline to other microglia targets beyond TREM2.

The successful development and commercialization of our therapeutic candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our therapeutic candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:

the timing, design and successful completion of preclinical studies and clinical development activities;
the sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any therapeutic candidates we may develop;
successful enrollment and completion of clinical trials, including under the FDA’s Good Clinical Practices, Good Laboratory Practices, and any additional regulatory requirements from foreign regulatory authorities;
positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;
the receipt of regulatory marketing approvals from applicable regulatory authorities;
the establishment of arrangements with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;
the establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any therapeutic candidates we may develop;
patient recruitment and enrollment;
commercial launch of any therapeutic candidates we may develop, if approved, whether alone or in collaboration with others;
acceptance of the benefits and use of our therapeutic candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payors;
our ability to compete effectively with other therapies and treatment options;
maintenance of a continued acceptable safety, tolerability and efficacy profile of any therapeutic candidates we may develop following approval;
establishment and maintenance of healthcare coverage and adequate reimbursement by payors;
our ability to establish new licensing or collaboration arrangements;
the performance of our future collaborators, if any;

21


development and timely delivery of commercial-grade drug formulations that can be used in our planned clinical trials and, if approved, for commercial launch;
obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
launching commercial sales of our therapeutic candidates, if approved, whether alone or in collaboration with others; and
maintaining a continued acceptable safety profile of the therapeutic candidates following approval.

Any changes in the outcome of any of these variables with respect to the development of our therapeutic candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these therapeutic candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete clinical development of that therapeutic candidate. We may never obtain regulatory approval for any of our therapeutic candidates, and, even if we do, drug commercialization takes several years and millions of dollars in development costs.

General and Administrative

General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for personnel in executive, accounting, business development, legal, human resources and administrative functions. General and administrative expenses also include corporate facility costs not otherwise included in research and development expenses, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included in research and development expenses, as well as professional fees for legal, consulting, investor and public relations, accounting and audit services.

We expect that our general and administrative expenses will increase in the foreseeable future as we increase our headcount to support the continued research and development of our programs and the growth of our business. We also anticipate continuing to incur expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, compliance, director and officer insurance, investor and public relations and tax-related services associated with maintaining compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services.

Other Income (Expense)

Interest Income, net

Interest income, net primarily consists of interest earned from our cash, cash equivalents, and marketable securities. Our interest income has increased since we began investing our cash in marketable securities during the first quarter of 2023.

Other Expense, net

Other expense, net primarily consists of gains and losses from the remeasurement of foreign currency transactions into our functional currency.

22


Results of Operations

Three Months Ended June 30, 2023 Compared with Three Months Ended June 30, 2022

The following table summarizes our results of operations for the three months ended June 30, 2023 compared with three months ended June 30, 2022:

 

 

Three Months Ended June 30,

 

 

 

 

 

2023

 

 

2022

 

 

Change

 

 

($ in thousands)

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

14,903

 

 

$

12,097

 

 

$

2,806

 

General and administrative

 

 

7,010

 

 

 

4,945

 

 

 

2,065

 

Total operating expenses

 

 

21,913

 

 

 

17,042

 

 

 

4,871

 

Loss from operations

 

 

(21,913

)

 

 

(17,042

)

 

 

(4,871

)

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest income

 

 

1,746

 

 

 

32

 

 

 

1,714

 

Other income (expense), net

 

 

(7

)

 

 

(5

)

 

 

(2

)

Total other income (expense), net

 

 

1,739

 

 

 

27

 

 

 

1,712

 

Net loss

 

$

(20,174

)

 

$

(17,015

)

 

$

(3,159

)

 

Research and Development Expenses

Research and development expenses were $14.9 million for the three months ended June 30, 2023, as compared to $12.1 million for the three months ended June 30, 2022. The increase of $2.8 million consisted primarily of the following:

$1.5 million of facilities, personnel-related and other expenses, of which $1.0 million related to personnel-related costs, including salaries, bonuses, and other compensation-related costs, including stock-based compensation of $0.3 million, and $0.8 million in facilities related expenses, including lab lease expenses;
$0.8 million increase in small molecule TREM2 agonist program expenses, primarily driven by an increase in pre-clinical expenses; and
$0.7 million of VGL101 related expenses, including $0.6 million increase in clinical related expenses.

The increase in research and development expenses were partially offset by a decrease of $0.2 million in VGL101 pre-clinical related expenses.

General and Administrative Expenses

General and administrative expenses were $7.0 million for the three months ended June 30, 2023, as compared to $4.9 million for the three months ended June 30, 2022. The increase of $2.1 million consisted primarily of the following:

$1.0 million of personnel-related costs, including salaries, bonuses, and other compensation-related costs, including stock-based compensation of $0.5 million;
$0.8 million of other headcount-related expenses and costs, primarily driven by an increase of $0.3 million in facilities expenses and $0.3 million in human resources-related expenses; and
$0.2 million of professional fees, including legal and accounting expenses.

 

23


Six Months Ended June 30, 2023 Compared with Six Months Ended June 30, 2022

The following table summarizes our results of operations for the six months ended June 30, 2023 compared with six months ended June 30, 2022:

 

 

Six Months Ended June 30,

 

 

 

 

 

2023

 

 

2022

 

 

Change

 

 

($ in thousands)

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

28,737

 

 

$

22,462

 

 

$

6,275

 

General and administrative

 

 

13,951

 

 

 

9,912

 

 

 

4,039

 

Total operating expenses

 

 

42,688

 

 

 

32,374

 

 

 

10,314

 

Loss from operations

 

 

(42,688

)

 

 

(32,374

)

 

 

(10,314

)

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest income

 

 

2,731

 

 

 

34

 

 

 

2,697

 

Other income (expense), net

 

 

(12

)

 

 

(9

)

 

 

(3

)

Total other expense, net

 

 

2,719

 

 

 

25

 

 

 

2,694

 

Net loss

 

$

(39,969

)

 

$

(32,349

)

 

$

(7,620

)

 

Research and Development Expenses

Research and development expenses were $28.7 million for the six months ended June 30, 2023, as compared to $22.5 million for the six months ended June 30, 2022. The increase of $6.3 million consisted primarily of the following:

$3.1 million of facilities, personnel-related and other expenses, of which $2.2 million related to personnel-related costs, including salaries, bonuses, and other compensation-related costs, including stock-based compensation of $0.5 million, and $0.9 million in facilities related expenses, including lab lease expenses;
$2.6 million of small molecule TREM2 agonist program expenses, including $1.9 million increase in pre-clinical expenses, $0.4 million increase in consulting related expenses and $0.2 million increase in CMC expenses; and
$1.1 million increase in VGL101 primarily driven by the increase in clinical related expenses.

The increase in research and development expenses were partially offset by a decrease of $0.5 million in general research activities.

General and Administrative Expenses

General and administrative expenses were $14.0 million for the six months ended June 30, 2023, as compared to $9.9 million for the six months ended June 30, 2022. The increase of $4.1 million consisted primarily of the following:

$2.2 million of personnel-related costs, including salaries, bonuses, and other compensation-related costs, including stock-based compensation of $1.0 million;
$1.0 million of professional fees, including legal and accounting expenses; and
$0.9 million of other headcount-related expenses and costs, primarily driven by an increase of $0.8 million in facilities expenses.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our therapeutic candidates. Since our inception through June 30, 2023, we have funded our operations primarily with net proceeds from sales of our convertible preferred stock and common stock totaling gross proceeds of approximately $313.0 million. As of June 30, 2023, we had cash, cash equivalents, and marketable securities of $150.2 million.

In January 2022, we completed the initial public offering of our common stock, in which we issued an aggregate of 7,000,000 shares of common stock, at a price of $14.00 per share, for gross cash proceeds of $98.0 million, before underwriting discounts and commissions. We received approximately $88.0 million in net proceeds, after deducting underwriting discounts, commissions and offering expenses.

24


In August 2022, we also completed a private placement in which we issued 7,293,084 shares of common stock at a price of $7.30 per share and 2,980,889 pre-funded warrants at a purchase price of $7.2999, for gross proceeds of $75.0 million, before deducting fees to the placement agent and other offering expenses. We received net proceeds of $71.3 million.

Based on our current operating plan, we expect our current cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditures into the first quarter of 2025.

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022

 

 

($ in thousands)

 

Net cash used in operating activities

 

$

(37,539

)

 

$

(32,137

)

Net cash used by investing activities

 

 

(91,107

)

 

 

(233

)

Net cash provided by financing activities

 

 

782

 

 

 

89,862

 

Net increase in cash, cash equivalents and restricted cash

 

$

(127,864

)

 

$

57,492

 

 

Operating Activities

During the six months ended June 30, 2023, operating activities consisted primarily of our net loss of $40.0 million, $1.0 million of amortization of discount on marketable securities and $1.4 million of changes in operating assets and liabilities, partially offset by $4.0 million stock-based compensation expense and $0.7 million change in operating lease expenses. The net loss primarily consisted of $28.7 million of research and development expenses and $13.9 million of general and administrative expenses, partially offset by $2.7 million in interest income, net.

During the six months ended June 30, 2022, operating activities consisted primarily of our net loss of $32.3 million and $2.8 million of changes in operating assets and liabilities, partially offset by $2.5 million stock-based compensation expense and $0.4 million change in operating lease expenses. The net loss primarily consisted of $22.5 million of research and development expenses, and $9.9 million of general and administrative expenses.

Investing Activities

During the six months ended June 30, 2023, net cash used for investing activities consisted of $102.5 million of purchases of marketable securities and $0.6 million of capital expenditures, partially offset by $12.0 million proceeds from maturities of marketable securities.

During the six months ended June 30, 2022, net cash used by investing activities consisted of $0.2 million of purchases of property and equipment.

Financing Activities

During the six months ended June 30, 2023, net cash provided from financing activities consisted of $803 thousand from the exercise of options, partially offset by $21 thousand related to finance lease obligations.

During the six months ended June 30, 2022, net cash provided by financing activities consisted primarily of $89.9 million in net proceeds from the issuance of common stock upon initial public offering.

Our primary uses of cash are to fund our research and development activities related to our VGL101 and small molecule TREM2 agonist programs, hiring personnel, raising capital and providing general and administrative support for these operations.

25


We currently have no ongoing material financing commitments that are expected to affect our liquidity over the next five years, other than our lease obligations and a $0.9 million standby letter of credit we entered into in September 2021, in connection with a lease for laboratory and office space in Watertown, Massachusetts. The standby letter of credit expires in December 2032. See “Contractual Obligations and Commitments”.

Funding Requirements

To date, we have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until we successfully complete clinical development of, receive regulatory approval for, and commercialize, VGL101, and we do not know when, or if at all, that will occur. We expect our expenses and capital requirements to increase significantly in connection with our ongoing activities, particularly as we continue the research and development of and seek marketing approval for our VGL101 and small molecule TREM2 agonist program. In addition, if we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant expenses related to product sales, marketing, and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. We may also require additional capital to pursue in-licenses or acquisitions of other drug candidates. Further, we expect to incur additional costs associated with operating as a public company. Accordingly, we will require substantial additional funding to develop our therapeutic candidates and support our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our product development or future commercialization efforts.

Our future capital requirements will depend on many factors, including:

the initiation, scope, progress, timing, results and costs of product discovery, preclinical studies and clinical trials for our therapeutic candidates or any future candidates we may develop;
our ability to maintain our relationship with Amgen and any other key licensors or collaborators;
the scope, prioritization and number of our research and development programs;
the costs, timing and outcome of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;
our ability to establish and maintain collaborations on favorable terms, if at all;
the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we enter into;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any;
the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
the extent to which we acquire or in-license other therapeutic candidates and technologies;
the costs of securing manufacturing arrangements for commercial production;
the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our therapeutic candidates; and
our need to implement additional internal systems and infrastructure, including financial and reporting systems.

Identifying potential therapeutic candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our therapeutic candidates. In addition, our therapeutic candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

26


Until such time, if ever, as we can generate significant revenue from product sales or other sources, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include proceeds from potential collaborations, strategic partnerships or marketing, distribution, licensing or other similar arrangements with third parties. However, we may be unable to raise additional funds or enter into such agreements or arrangements on favorable terms, or at all. Market volatility resulting from the Russia/Ukraine military conflict or other factors could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.

If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or therapeutic candidates or to grant licenses on terms that may not be favorable to us. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development or commercialization of our therapeutic candidates or grant rights to develop and market therapeutic candidates that we would otherwise prefer to develop and market ourselves. We expect our existing cash, and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2025 at which point we would need to obtain substantial additional funding in connection with our continuing operations.

Contractual Obligations and Commitments

There have been no other material changes to the contractual obligations and commitments from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Critical Accounting Policies and Significant Judgements and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and the disclosure of our contingent liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012, or JOBS, permits an “emerging growth company” such as us to take advantage of an extended transition to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an “emerging growth company,” we are exempt from Sections 14A(a) and (b) of the Securities Exchange Act of 1934, as amended, which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay,” “say-on-frequency,” and “golden parachutes;” and (2) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer’s compensation to our median employee compensation. We also intend to rely on an exemption from the rule requiring us to provide an auditor’s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We will continue to remain an “emerging growth company” until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (3) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

27


Recently Issued Accounting Pronouncements

There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Information required by this Item is not applicable as we are electing scaled disclosure requirements available to Smaller Reporting Companies with respect to this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies judgement in evaluating the benefits of possible controls and procedures relative to their costs.

Our management has concluded that our condensed consolidated financial statements for the periods covered by and included in this Quarterly Report are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and fairly present, in all material respects, our financial position, results of operations and cash flows for each of the periods presented herein.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended June 30, 2023 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

28


PART II—OTHER INFORMATION

From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, including our financial statements and related notes and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section, before making an investment decision. These risks may materially and adversely affect our business, financial condition, results of operations and prospects. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment.

Risks Related to Our Limited Operating History, Business, and Financial Position

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable, and, if we achieve profitability, we may not be able to sustain it.

Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2020, and, to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying therapeutic candidates, establishing our intellectual property portfolio and conducting preclinical research and, more recently, clinical studies. As an early clinical organization, we have only recently initiated our first clinical trials and have not yet completed any clinical trials, obtained regulatory approvals, manufactured a commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability are speculative.

We have incurred significant operating losses since our inception. We do not have any products approved for sale and have not generated any product revenue since our inception. If our therapeutic candidates are not successfully developed and approved, we may never generate any, or any significant revenue. Our net loss was $40.0 million for the six months ended June 30, 2023. As of June 30, 2023, we had an accumulated deficit of $180.1 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our therapeutic candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for and potentially commercialize any of our therapeutic candidates.

To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue relative to cost of sales. This will require us to be successful in a range of challenging activities, including identifying lead therapeutic candidates, discovering additional therapeutic candidates, conducting preclinical studies prior to submitting INDs, obtaining clearance for such INDs, completing additional preclinical studies and clinical trials of our therapeutic candidates, obtaining regulatory approval for therapeutic candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our therapeutic candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

29


Our limited operating history may make it difficult to evaluate our technology and industry and predict our future performance. Though several companies have conducted or are conducting studies involving neurodegenerative diseases for which microglia deficiency is a key driver of disease pathology, the relevance of those studies to the evaluation of therapeutic candidates developed using our precision medicine approach may be difficult to ascertain. Our short history as an operating company and novel therapeutic approach make assessments of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. Failure to address these risks successfully will cause our business to suffer. Similarly, we expect that our financial condition and operating results will fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our stockholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.

In addition, as an early-stage company, we will encounter unforeseen expenses, difficulties, complications, delays and other known and unknown circumstances. As we advance our therapeutic candidates into and through the clinic, we will need to transition from a company with a research focus to a company capable of supporting clinical development and, if successful, commercial activities. We may fail in that transition.

We will require additional financing to achieve our goals, and failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.

The development of biopharmaceutical therapeutic candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we conduct preclinical studies of our development programs, initiate and conduct clinical trials for and in support of our therapeutic candidates and seek regulatory approvals for our current therapeutic candidates and any future therapeutic candidates we may develop. If we obtain regulatory approval for any of our therapeutic candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our therapeutic candidates.

Furthermore, we are incurring and expect to incur continued additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Failing to raise capital when needed or on attractive terms could force us to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operations into the first quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our therapeutic candidates.

Our future capital requirements will depend on many factors, including, but not limited to:

the type, number, scope, progress, expansions, results, costs and timing of our preclinical studies and clinical trials in support of the therapeutic candidates that we are pursuing or may choose to pursue in the future;
the clinical development plans we establish for our therapeutic candidates and related non-interventional natural history studies;
the costs and timing of manufacturing of our therapeutic candidates and commercial manufacturing if any therapeutic candidate is approved for sale;
the costs of establishing and maintaining clinical and commercial supply for the development and manufacture of our therapeutic candidates;
the costs, timing and outcome of regulatory review of our therapeutic candidates;
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
the costs of obtaining, maintaining, enforcing, and defending our patents and other intellectual property rights;

30


the costs associated with our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal control over financial reporting, corporate compliance and corporate governance;
the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;
the achievement of milestones or occurrence of other developments that trigger payments under existing license and any potential collaboration agreements;
the costs and timing of establishing or securing sales and marketing capabilities if any therapeutic candidate is approved;
regulatory approval and revenue, if any, received from commercial sales of our therapeutic candidates; and
our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products.

Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.

Our quarterly and annual operating results may fluctuate significantly in the future. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies to gain access to new technologies, or to out-license our technologies. Any such agreement may include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Under our exclusive license agreement with Amgen, for example, we are required to pay Amgen up to $80.0 million upon the achievement of specified regulatory milestones for the first mAb TREM2 agonist product (mAb product), and first small molecule TREM2 agonist product (small molecule product), upon achievement of specified regulatory milestones, as well as aggregate milestone payments of up to $350.0 million upon achievement of specific commercial milestones across all such mAb products and small molecule products, and tiered royalties of low to mid-single-digit percentages on annual net sales of the products covered by the license. These milestone payments may vary significantly from period to period and the variance could cause a significant fluctuation in our operating results from one period to the next.

In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee’s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.

Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including, but not limited to:

the timing and outcomes of preclinical studies and clinical trials for VGL101 and any therapeutic candidates from our discovery programs, or competing therapeutic candidates;
the timing and cost of, and level of investment in, research and development activities relating to our programs, which will change from time to time;
the cost of manufacturing our current therapeutic candidates and any future therapeutic candidates, which may vary depending on the FDA, European Medicines Agency (EMA) or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;
the timing and cost of meeting regulatory requirements established by the FDA or EMA or comparable foreign regulatory authorities;
any delays in regulatory review or approval of VGL101 or therapeutic candidates from any of our discovery programs;
our ability to enroll patients in clinical trials and the timing of enrollment;
expenditures that we will or may incur to acquire or develop additional therapeutic candidates and technologies or other assets;
the need or desire to conduct preclinical studies or clinical trials, in countries outside of the United States, or studies or trials that are otherwise larger, lengthier or more complex than anticipated, any of which may be unanticipated;

31


competition from existing and potential future products that compete with VGL101, our small molecule TREM2 agonist program or any of our other programs, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;
the level of demand for any of our therapeutic candidates, if approved, which may fluctuate significantly and be difficult to predict;
the risk/benefit profile, cost and reimbursement policies with respect to our therapeutic candidates, if approved, and existing and potential future products that compete with VGL101 or any of our discovery programs;
our ability to commercialize VGL101 or therapeutic candidates from any of our discovery programs, if approved, inside and outside of the U.S., either independently or working with third parties;
our ability to establish and maintain collaborations, licensing or other arrangements;
potential unforeseen business disruptions that increase our costs or expenses;
future accounting pronouncements or changes in our accounting policies;
the changing and volatile global economic and political environment, including inflation or political instability in particular foreign economies and markets; and
the impact of the Russia/Ukraine conflict on the global economy, including causing or contributing to global supply chain disruption, price fluctuations, including increased costs for raw materials, and other significant economic and social effects.

The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.

If we are unable to design and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decline.

Ensuring that we have adequate internal control over financial reporting in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Pursuant to the rules and regulations of the SEC regarding compliance with Section 404 of the Sarbanes-Oxley Act of 2002, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC or a smaller reporting company with less than $100 million in revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Failure to comply with the rules and regulations of the SEC could potentially subject us to sanctions or investigations by the SEC, the applicable stock exchange or other regulatory authorities, which would require additional financial and management resources. We have begun the process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with the rules and regulations of the SEC in the future, but we may not be able to complete our evaluation, testing and any required remediation in a timely fashion. An independent assessment of the effectiveness of our internal control over financial reporting could detect deficiencies in our internal control over financial reporting that our management’s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.

We can give no assurance that a material weakness in our internal controls over financial reporting will not be identified in the future. Maintaining adequate internal control over financial reporting and ensuring that we can produce accurate financial statements on a timely basis may distract our officers and employees and entail substantial costs. Any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. If we identify additional material weaknesses in our internal control over financial reporting; if we are unable to comply with the requirements of the SEC’s rules and regulations in a timely manner; or if we are unable to assert that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline, and we could also become subject to investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities, which could require additional financial and management resources.

32


Failure or security breaches of, loss or leakage of data from, or other disruptions in, our internal information technology systems, or those of our third-party CROs or other vendors, contractors or consultants, could result in a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.

We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential or protected information (including but not limited to intellectual property, proprietary business information and personal information). We also have outsourced elements of our operations to third parties, and, as a result, we manage a number of third-party clinical research organizations (CROs), vendors, and other contractors and consultants who have access to and maintain our confidential or protected information, systems, and/or infrastructure.

Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential or protected information that they maintain, our internal information technology systems and infrastructure and those of our third-party CROs, vendors and other contractors and consultants are vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security compromises or breaches from inadvertent or intentional actions by our employees, third-party CROs, vendors, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, digital extortion, business email compromise, and denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information, systems, or infrastructure), which may compromise our systems infrastructure, data, or that of our third-party CROs, vendors and other contractors and consultants, or lead to data compromise, misuse, misappropriation, or leakage. The risk of a security compromise, breach, or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, insider threats, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Also, we have implemented a hybrid work model, enabling our employees to split time between working from the office and working from home. As a result, we may have increased cyber security and data security risks, due to increased use of home wi-fi networks and virtual private networks, decreased physical oversight of employees, as well as increased disbursement of physical machines. While we implement IT controls to reduce the risk of a cyber security or data security compromise or breach, there is no guarantee that these measures will be adequate to safeguard all systems, data, or infrastructure, especially with an increased number of employees working remotely. The techniques used by cyber criminals change and evolve frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, insider threats, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Disruptions or security compromises or breaches resulting in a loss of, or damage to, our data, systems, infrastructure, or applications, or those of our third-party CROs, vendors and other contractors and consultants, or inappropriate use, access, or disclosure of confidential, protected, or proprietary information, could generate liability and reputational damage and the further development and commercialization, if approved, of VGL101 or any future therapeutic candidates could be delayed. The costs related to significant security compromises, breaches, or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. We may have limited recourse for disruptions, compromises, or breaches of the information technology systems or infrastructure of our third-party CROs, vendors and other contractors and consultants, and we may have to expend significant resources to respond to, mitigate, and remediate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.

Our data protection efforts and our investment in information technology do not preclude significant breakdowns, data leakages, breaches, compromises, or vulnerabilities in our systems, or those of our third-party CROs, vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. The loss of clinical trial data for VGL101 or any other therapeutic candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data.

Furthermore, security breaches, compromises, or significant disruptions of our internal information technology systems, data, or infrastructure, or those of our third-party CROs, vendors and other contractors and consultants, could result in the loss, misappropriation and/or unauthorized access, use, acquisition, or disclosure of, or the prevention of access to, confidential or protected information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use, acquisition, or disclosure of confidential, protected, or personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of protected information, including personal information, including through litigation or regulatory investigations or enforcement actions, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.

33


We may in the future rely on sales of our common shares through our at-the-market (ATM) offering program. Increased volatility and decreases in market prices of equity securities generally and of our common shares in particular may have an adverse impact on our willingness and/or ability to sell our common shares through our ATM offering. Decreases in these sales could affect the cost or availability of equity capital, which could in turn have an adverse effect on our business, including current operations, future growth, revenues, net income and the market prices of our common shares.

On March 21, 2023, we filed a Registration Statement on Form S-3, as amended (the “2023 Shelf”) with the SEC, which was declared effective on March 30, 2023 (File No. 333-270710) in relation to the registration of common stock, preferred stock, debt securities, warrants and units of any combination thereof. We also simultaneously entered into an Open Market Sale Agreement (Sale Agreement) with Jefferies LLC (the Sales Agent) to provide for the offering, issuance and sale of up to an aggregate amount of $100.0 million of our common stock from time to time in “at-the-market” offerings under the 2023 Shelf and subject to the limitations thereof. Under the terms of the Sale Agreement, we agreed to pay the Sales Agent cash commissions of up to 3.0% of the gross proceeds of sales of common stock under the Sale Agreement. As of August 7, 2023, we have not sold any shares of common stock under the ATM.

Given the volatility in the capital markets, we may not be willing or able to raise equity capital through our ATM program. We may, therefore, need to turn to other sources of funding that may have terms that are not favorable to us, or reduce our business operations given capital constraints. In addition, sales of a substantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. We cannot predict the effect that future sales of common stock or other equity-related securities would have on the market price of our common stock. Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid.

Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Sales Agent at any time throughout the term of the Sale Agreement. The number of shares that are sold by the Sales Agent after delivering a placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set with the Sales Agent in any instruction to sell shares, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares or the gross proceeds to be raised in connection with those sales, if any, that will be ultimately issued.

Risks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates

We are early in our development efforts. We have never successfully completed any clinical trials, and if we are unable to identify and advance therapeutic candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.

We are early in our development efforts, and we have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. We have invested substantially all of our research efforts to date in identifying potential therapeutic candidates and conducting preclinical and clinical studies. As an early stage company, our experience in conducting clinical trials is limited. Our lead therapeutic candidate, VGL101, is our only product candidate in clinical development. VGL101, a TREM2 agonist, currently is being studied in two clinical trials, notably a Phase 1 dose escalation clinical trial in healthy volunteers and a Phase 2 clinical trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In addition, we are conducting a non-interventional natural history study to study patients with ALSP.

In addition, we have a small molecule TREM2 agonist program that is being prepared for an investigational new drug (IND) filing. We may never advance these or any future therapeutic candidates to an IND filing or receive clearance from the FDA to commence additional clinical trials for our therapeutic candidates. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our therapeutic candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.

34


As a general matter, commencing clinical trials in the U.S. is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. For the FDA to accept an IND, we must complete toxicology and other preclinical studies pursuant to Good Laboratory Practices (GLPs), which may not be successful, or may take longer than we expect. The FDA may require us to complete additional preclinical studies or we may be required to satisfy other FDA requests prior to commencing clinical trials, and such requests may not currently be known or anticipated, which may cause the start of our first clinical trials to be delayed or prevent us from conducting clinical trials. Even after we receive and incorporate guidance from regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, impose stricter conditions than we currently expect or may prevent us from conducting clinical trials. There are equivalent processes and risks applicable to clinical trial applications in other countries, including the United Kingdom and countries in the European Union (EU).

The success of therapeutic candidates we may identify and develop will depend on many factors, including:

timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable, in accordance with FDA’s GLPs and any additional regulatory requirements from foreign regulatory authorities;
successful initiation, enrollment and completion of clinical trials, including under the FDA’s Good Clinical Practices (GCPs) and any additional regulatory requirements from foreign regulatory authorities;
positive results from our clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;
sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
receipt of regulatory marketing approvals from applicable regulatory authorities;
effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any therapeutic candidates we may develop;
establishment of arrangements with current Good Manufacturing Practice (cGMP) compliant third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;
establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any therapeutic candidates we may develop;
patient recruitment, enrollment and retention;
commercial launch of any therapeutic candidates we may develop, if approved, whether alone or in collaboration with others;
acceptance of the benefits and use of our therapeutic candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payors;
our ability to compete effectively with other therapies and treatment options;
demonstration of an acceptable safety, tolerability and efficacy profile of any therapeutic candidates we may develop following approval; and
establishment and maintenance of healthcare coverage and adequate reimbursement by payors.

If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any therapeutic candidates we may develop, which would materially harm our business. If we are unable to advance our therapeutic candidates to clinical development, obtain regulatory approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed.

We may expend our limited resources to pursue a particular therapeutic candidate or indication, such as our initial focus on developing VGL101 for ALSP, and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success. As such, our business is highly dependent on the clinical advancement of our programs and is especially dependent on the success of our lead candidate, VGL101.

One of our strategies is to identify and pursue clinical development of therapeutic candidates beyond VGL101. Given our limited human capital and financial resources, we must focus on research programs and therapeutic candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic candidates or for indications other than

35


ALSP that later prove to have greater commercial potential. We are highly dependent on the success of the ongoing and future clinical trials of VGL101, our lead therapeutic candidate, and an ongoing related natural history study, the outcomes of which are uncertain, to further develop our pipeline candidates for common neurodegenerative disease starting from patient segments with known genetic variations associated with microglial dysfunction. Because VGL101 is our first therapeutic candidate, if it encounters safety, efficacy, supply or manufacturing problems, developmental delays, regulatory or commercialization issues or other problems, the value of our pipeline could be greatly diminished and our development plans could be curtailed and our business would be significantly harmed.

Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and therapeutic candidates for specific indications may not yield any commercially viable therapeutic candidates. If we do not accurately evaluate the commercial potential or target market for a particular therapeutic candidate or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases, we may relinquish valuable rights to that therapeutic candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such therapeutic candidate.

At any time and for any reason, we may determine that one or more of our discovery programs or preclinical or clinical therapeutic candidates or programs does not have sufficient potential to warrant the allocation of resources toward such program or therapeutic candidate. Accordingly, we may choose not to develop a potential therapeutic candidate or elect to suspend, deprioritize or terminate one or more of our discovery programs or preclinical or clinical therapeutic candidates or programs. Suspending, deprioritizing or terminating a program or therapeutic candidate in which we have invested significant resources, means we will have expended resources on a program that will not provide a full return on our investment and may have missed the opportunity to have allocated those resources to potentially more productive uses, including existing or future programs or therapeutic candidates.

We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our therapeutic candidates are based on new approaches, which makes it difficult to predict the time and cost of therapeutic candidate development and subsequently obtaining regulatory approval.

We have focused our research and development efforts on therapeutic approaches for neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. No effective therapeutic options are available for patients with ALSP, and limited options exist for Alzheimer’s disease and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our therapeutic candidates for treating neurodegenerative diseases. Developing our therapeutic candidates for treatment of neurodegenerative diseases subjects us to a number of challenges, including demonstrating safety and efficacy and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.

We are pursuing a precision medicine approach to developing a broad range of therapeutics for neurodegenerative diseases. By targeting rare genetically defined neurodegenerative microgliopathies, our strategy is to advance our pipeline by reducing downstream translational risk, efficiently generating clinical proof of mechanism and proof of concept and expanding into multiple neurodegenerative indications where microglia-based therapeutics may have meaningful impact on disease progression and patient lives. This strategy may not prove to be successful. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable.

We currently conduct and in the future may plan to conduct clinical trials that utilize an “open-label” trial design, which are subject to various limitations that may exaggerate therapeutic effect or influence reporting of adverse events as patients in open-label clinical trials are aware when they are receiving treatment.

We currently conduct and in the future may plan to conduct clinical trials that utilize an “open-label” trial design. An “open-label” clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational therapeutic candidate or an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational therapeutic candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a “patient bias” where, on one hand, patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. On the other hand, patients who know that they are receiving an experimental treatment may expect and report negative outcomes, which may influence the reporting of adverse events during an open-label trial. In addition, open-label clinical trials may be subject to an “investigator bias” where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. In any event, results from an open-label trial may not be predictive of future clinical trial results, including blinded and/or controlled trials, that test any of our therapeutic candidates.

36


We may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any therapeutic candidates we develop on a timely basis, if at all.

The risk of failure in developing therapeutic candidates is high. It is impossible to predict when or if any therapeutic candidate would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any therapeutic candidate, we must complete preclinical development, submit an IND or foreign equivalent to permit initiation of clinical studies, and then conduct extensive clinical trials to demonstrate the safety and efficacy of the therapeutic candidate in humans. We have limited experience as a company in preparing and submitting regulatory filings and have not previously submitted a new drug application (NDA), or a biologics license application (BLA), or other comparable foreign regulatory submission for any therapeutic candidate.

Before we can commence clinical trials for a therapeutic candidate, we must complete extensive preclinical testing and studies that support our INDs and other regulatory filings. We cannot be certain of the timely identification of a therapeutic candidate or the completion or outcome of our preclinical testing and studies and cannot predict whether the FDA or other regulatory authorities will accept any additional proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of any therapeutic candidates. Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. As a result, we cannot be sure that we will be able to submit INDs or foreign equivalents for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or foreign equivalents will result in the FDA or other regulatory authorities allowing clinical trials to begin.

Clinical trials are expensive, difficult to design and implement and can take many years to complete, and their outcome is inherently uncertain. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. No therapeutic has been approved for the treatment of ALSP and the regulatory pathway for approval of a therapeutic for ALSP is uncertain. Given the lack of precedent, we may encounter difficulties in identifying and establishing clinical endpoints that FDA would consider clinically meaningful. Moreover, we have had limited interactions with the FDA and cannot be certain how many clinical trials of VGL101 or any other therapeutic candidates will be required or how such trials should be designed. Even after the FDA has received and commented on the design for our clinical trials, the Agency may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval. Consequently, despite future regulatory interactions and advice, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our therapeutic candidates. Additionally, because our initial target indications are rare diseases, we may face challenges identifying patients and enrolling clinical trials, which may delay or prevent completion of such trials. Clinical trials also may fail to demonstrate that our therapeutic candidates are safe for humans and effective for indicated uses. Successful completion of clinical trials is a prerequisite to submitting an NDA or BLA to the FDA or similar marketing applications to other regulatory authorities for each therapeutic candidate. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.

Other events that may prevent successful enrollment, initiation or timely completion of clinical development include:

we may be unable to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or completion of clinical trials;
delays in reaching a consensus with regulatory authorities on trial design;
delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
delays in opening clinical trial sites or obtaining required institutional review board (IRB) or independent ethics committee approval, or the equivalent review groups for sites outside the U.S., at each clinical trial site;
imposition of a clinical hold by regulatory authorities, including as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;
challenges identifying, enrolling and retaining participants in clinical trials;
negative or inconclusive results observed in clinical trials, including failure to demonstrate statistical significance, safety, purity or potency, which could lead us, or cause regulators to require us, to conduct additional clinical trials or abandon product development programs;
failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements and clinical trial protocols or to perform in accordance with the FDA’s GCPs;

37


failure by physicians to adhere to delivery protocols leading to variable results;
delays in the testing, validation, manufacturing and delivery of any therapeutic candidates we may develop to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;
failure of our third-party contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all;
delays in having patients complete participation in a trial or return for post-treatment follow-up;
issues with our clinical trial sites or patients dropping out of a trial;
we may need to add new or additional clinical trial sites;
selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;
inability of selected endpoints to capture therapeutic benefit of the therapeutic candidate;
occurrence of serious adverse events associated with the therapeutic candidate that are viewed to outweigh its potential benefits;
occurrence of serious adverse events associated with a therapeutic candidate in development by another company, which are viewed to outweigh its potential benefits, and which may negatively impact the perception of our therapeutic candidate due to a similarity in technology or approach;
changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial;
changes in the legal or regulatory regimes domestically or internationally related to patient rights and privacy; or
lack of adequate funding to continue the clinical trial.

We may encounter substantial delays in the commencement, enrollment or completion of our ongoing or planned clinical trials, which could prevent us from receiving necessary regulatory approvals or commercializing any therapeutic candidates we develop on a timely basis, if at all.

We could encounter delays in our development plans if a clinical trial is suspended, placed on clinical hold or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or other regulatory authorities or recommended for suspension or termination by the Data Safety Monitoring Board (DSMB) for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Additionally, if the results of any clinical trials are inconclusive, we may be required to perform additional clinical trials to support approval. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our therapeutic candidates.

Failure to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or similar regulatory authorities outside the U.S. may delay or prevent us from initiating or continuing clinical trials for our therapeutic candidates. Because the target patient populations for some of our therapeutic candidates, in particular for rare diseases such as the ones on which we are initially focused, are relatively small, it may be difficult to successfully identify patients for inclusion in clinical trials. This is especially important as we may offer to certain volunteers of our natural history study enrollment in our interventional clinical trial for ALSP and therefore any potential delays in enrollment in the natural history study could have adverse consequences for our clinical development program for VGL101.

38


In addition, we may experience delays or disruptions in the initiation of or enrollment in our clinical trials due to external factors such as changes in local site or IRB policies, availabilities or changes of site staff, or a public health crisis. Furthermore, some of our competitors have ongoing clinical trials for therapeutic candidates that treat the same indications we plan to target with our therapeutic candidates, such as Alzheimer’s disease and rare leukoencephalopathies and leukodystrophies, such as MLD and Krabbe, and may in the future initiate trials in our lead indication, ALSP. Accordingly, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ therapeutic candidates. Patient enrollment and trial competition may be affected by other factors including:

clinicians’ and patients’ perceived risks and benefits of the therapeutic candidate under trial, particularly therapeutic candidates developed using a novel and unproven therapeutic approach, such as VGL101, in relation to available or investigational drugs;
clinicians’ misdiagnosis of patients with existing neurodegenerative diseases in our targeted indications and our inability to recruit these patients successfully;
design of the trial protocol;
efforts to facilitate timely enrollment in clinical trials;
eligibility and exclusion criteria;
availability of competing therapies and clinical trials;
severity of the disease or disorder under investigation;
proximity and availability of clinical trial sites for prospective patients;
ability to obtain and maintain patient consent;
size of the patient population required for analysis of the trial’s primary endpoints;
ability to recruit clinical trial investigators with the appropriate competencies and experience;
risk that enrolled patients will drop out before completion of the trial;
performance of third party vendors, including CROs;
patient referral practices of physicians; and
ability to monitor patients adequately during and after treatment.

Our inability to identify patients appropriate for enrollment in our observational and interventional clinical trials, or to enroll a sufficient number of patients in such trials, would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our therapeutic candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we are unable to include symptomatic patients with the applicable genetic mutations and/or variations, this could limit our ability to seek participation in the FDA’s expedited development programs, including breakthrough therapy designation and fast track designation, or otherwise to seek to accelerate clinical development and regulatory timelines.

Even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty retaining patients in our clinical trials. In our ongoing and planned clinical trials that will include a placebo group, some of patients may perceive that they are not receiving the therapeutic candidate being tested, and they may decide to withdraw from our clinical trials to pursue other alternative therapies rather than continue the trial with the perception that they are receiving placebo. Difficulty enrolling or retaining a sufficient number of patients to conduct our clinical trials, may require us to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.

Our product development costs will increase if we experience delays in clinical testing or marketing approvals. Our preclinical studies or clinical trials may not begin as planned, may need to be restructured or may not be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our therapeutic candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our therapeutic candidates and harming our business and results of operations.

39


Use of our therapeutic candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a therapeutic candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.

We have not yet completed interventional clinical trials of any of our therapeutic candidates, and our understanding of the clinical safety profile of these candidates is still limited. There may be serious adverse events or undesirable side effects related to our therapeutic candidates. To our knowledge, no approved products target TREM2 and no TREM2 agonists are in clinical development for ALSP. Moreover, it is impossible to predict when or if any therapeutic candidates we may develop will prove safe in humans. As is the case with biopharmaceuticals generally, it is likely that there may be side effects and adverse events associated with use of our therapeutic candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition and prospects.

Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our therapeutic candidates may only be uncovered with a significantly larger number of patients exposed to the therapeutic candidate. Any undesirable side effects or unexpected characteristics associated with our therapeutic candidates in clinical trials may lead us to elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the therapeutic candidate, if approved. We may also be required to modify our trial plans based on findings after we commence our clinical trials. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.

As we test our therapeutic candidates in larger, longer and more extensive clinical trials, or as the use of these therapeutic candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported. Any findings of such side effects later in development or following any approval may harm our business, financial condition and prospects significantly.

Patients treated with our therapeutics, if approved, may experience previously unreported adverse reactions, and the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our therapeutic candidates.

If any of our therapeutic candidates reach the market, safety problems may thereafter occur or be identified and we may make the decision or be required by regulatory authorities to amend the labeling of our therapeutics, recall our therapeutics or even withdraw approval for our therapeutics, or, if applicable, pause or terminate any ongoing studies.

If there are safety concerns or serious adverse events associated with any therapeutic candidates we may develop, we may:

be delayed in obtaining marketing approval for therapeutic candidates, if at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
be subject to changes in the way the product is administered;
be required to perform additional clinical trials to support approval or be subject to additional post- marketing testing requirements;
have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (REMS);
be subject to the addition of labeling statements, such as warnings or contraindications;
be sued; or
experience damage to our reputation.

40


Our therapeutic candidates are subject to extensive regulation and compliance, which is costly and time-consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our therapeutic candidates.

The clinical research, development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our therapeutic candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., we are not permitted to market our therapeutic candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the therapeutic candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a therapeutic candidate for many reasons. Despite the time and expense invested in clinical development of therapeutic candidates, regulatory approval is never guaranteed. Neither we nor any current or future collaborator is permitted to market any of our therapeutic candidates in the U.S. until we receive approval from the FDA.

The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a therapeutic candidate for many reasons, including:

we or any of our current or future collaborators may be unable to demonstrate that a therapeutic candidate is safe and effective, and that therapeutic candidate’s clinical and other benefits outweigh its safety risks;
serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our therapeutic candidates;
such authorities may disagree with the design or implementation of our or our current or future collaborators’ clinical trials;
negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;
such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the U.S.;
such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
such authorities may not agree that the data collected from clinical trials of our therapeutic candidates are acceptable or sufficient to support the submission of an NDA or BLA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;
such authorities may disagree regarding the formulation, labeling and/or the specifications of our therapeutic candidates;
approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;
such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;
regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators’ clinical data insufficient for approval; or
such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.

With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our therapeutic candidates.

41


The results of early preclinical studies are not necessarily predictive of the results of later preclinical studies and any clinical trials of our therapeutic candidates, and interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.

The results from early preclinical studies of a therapeutic candidate may not predict the results of later preclinical studies and any clinical trials of the therapeutic candidate. Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain preclinical studies of VGL101 and other potential therapeutic candidates, and although VGL101 is currently being studied in a Phase 1 clinical trial in healthy volunteers and a Phase 2 clinical trial in ALSP patients, we have not completed any trials in ALSP patients, and we do not know whether performance in preclinical studies or ongoing clinical trials will be indicative of the performance of VGL101 in ALSP patients. Similarly, we do not know whether performance of our other potential therapeutic candidates in preclinical studies will be indicative of the performance in clinical trials. The positive results we have observed for our therapeutic candidates in early, GLP and non-GLP preclinical studies, animal and in vitro models may not be predictive of our future clinical trials in humans. This may be a result of technical challenges unique to that program or due to biology risk, which is unique to every program. As we progress our programs through clinical development, there may be new technical challenges that arise that cause an entire program to fail. Furthermore, for some indications that we are considering or pursuing there are no animal models that adequately mirror the human disease to predict any level of positive results. Unexpected observations or toxicities observed in these studies, or in IND-enabling studies for any of our other development programs, could delay clinical trials for VGL101 or our other development programs.

From time to time, we may publicly disclose interim, preliminary or topline data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Additionally, interim, topline or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular therapeutic candidate or product and the value of our company in general. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and companies that have believed their therapeutic candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain FDA approval. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial will be based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, therapeutic candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our therapeutic candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

We may not be successful in our efforts to expand our pipeline of therapeutic candidates.

We believe the central role that microglia play in sensing and coordinating the response to tissue damage and disease provides therapeutic opportunities for many neurodegenerative diseases, either through TREM2 activation or potentially other microglia targets. Over time, we plan to expand our pipeline, either through internal discovery and development, or through strategic collaborations or alliances with academic organizations, pharmaceutical or biotechnology companies.

Although our research and development efforts to date have resulted in a pipeline of potential programs and therapeutic candidates, we may not be able to identify other microglia targets and develop therapeutic candidates. We may also pursue opportunities to acquire or in-license additional businesses, technologies or therapeutic candidates, form strategic alliances or create joint ventures with third parties to complement or augment our existing business. However, we may not be able to identify any therapeutic candidates for our pipeline through such acquisition or in-license.

42


Even if we are successful in continuing to build and expand our pipeline, the potential therapeutic candidates that we identify may not be suitable for clinical development. For example, they may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will be successful in clinical trials or receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize therapeutic candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.

Clinical trial and product liability and other lawsuits against us or our contract development and manufacturing partners (CDMOs) could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of any therapeutic candidates we may develop.

We face an inherent risk of clinical trial and product liability and other exposure related to the testing of any therapeutic candidates we develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. We additionally rely on the services of CDMOs who manufacture our therapeutic candidates or conduct clinical trials on our behalf. Our agreements with CDMOs may require us to indemnify the CDMOs in the event of a third-party claim arising from the use or manufacture of our therapeutic candidates, which could divert our resources and incur substantial liabilities, possibly prior to the potential commercialization of our therapeutic candidates. The use of therapeutic candidates by us or our CDMOs in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims against us or our CDMOs might be made by patients who use the product, purchasers of our products, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves or our CDMOs against claims that our therapeutic candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for any therapeutic candidates we may develop;
injury to our reputation and significant negative media attention;
withdrawal of clinical trial participants and inability to continue clinical trials;
initiation of investigations by regulators;
significant costs to defend any related litigation;
substantial monetary awards to trial participants or patients;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue;
exhaustion of any available insurance and our capital resources;
decline in our stock price;
reduced resources of our management to pursue our business strategy; and
the inability to commercialize any therapeutic candidates we may develop.

If we expand our clinical trial activities or if we commence commercialization of any therapeutic candidates we will need to increase our insurance coverage beyond what is currently maintained. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If and when coverage is secured, our insurance policies may also have various exclusions and we may be subject to a product liability claim for which we have no coverage.

Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise, nor would such indemnity insulate us from potential reputational damage. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.

43


We may develop our current or future therapeutic candidates in combination with other therapies, which would expose us to additional risks.

We may develop our current or potential future therapeutic candidates in combination with one or more currently approved therapies or therapies in development. Even if any of our current or future therapeutic candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our therapeutic candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies, which could affect the status of our product candidates used in combination with these therapies. In addition, it is possible that in the future, existing therapies with which our therapeutic candidates are then approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our therapeutic candidates or our own products being removed from the market or being less successful commercially.

We may also evaluate our current or future therapeutic candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell any therapeutic candidate in combination with any such unapproved therapies that do not ultimately obtain marketing approval.

Furthermore, we cannot be certain that we will be able to obtain a steady supply of such therapies for use in developing combinations with our therapeutic candidates on commercially reasonable terms or at all. Any failure to obtain such therapies for use in clinical development and the expense of purchasing therapies in the market may delay our development timelines, increase our costs and jeopardize our ability to develop our therapeutic candidates as commercially viable therapies. If the FDA, EMA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future therapeutic candidates, we may be unable to obtain approval of or successfully market any one or all of the current or future therapeutic candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future therapeutic candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future therapeutic candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.

Where appropriate, we plan to secure approval from the FDA, EMA or comparable foreign regulatory authorities through the use of expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw the accelerated approval.

Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for one or more of our therapeutic candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA’s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to verify the drug’s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress.

44


Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA or comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign regulatory authorities could also require us to conduct further preclinical or clinical studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace. Moreover, even if we are able to obtain accelerated approval for any of our therapeutic candidates, there is no guarantee that post-approval studies will be able to confirm the clinical benefit, which could cause FDA to withdraw our approval.

We may seek fast track designation, breakthrough therapy designation, priority review and/or orphan drug designation from the FDA or similar designations from other regulatory authorities for one or more of our therapeutic candidates. Even if one or more of our therapeutic candidates receive any of these designations, we may be unable to obtain or maintain the benefits associated with such designation.

The FDA has established various designations to facilitate more rapid and efficient development and approval of certain types of drugs. Such designations include fast track designation, breakthrough therapy designation, priority review and orphan drug designation. Fast track designation is designed to facilitate the development and expedite the review of therapies for serious conditions that fill an unmet medical need. Programs with fast track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. Fast track designation applies to both the therapeutic candidate and the specific indication for which it is being studied. Although we have received fast track designation for VGL101, if VGL101 or any of our therapeutic candidates that may in the future receive fast track designation do not continue to meet the criteria for fast track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply or due to other issues, we will not receive the benefits associated with the fast track program. Fast track designation alone does not guarantee qualification for the FDA’s priority review procedures.

A breakthrough therapy, on the other hand, is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For therapeutic candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Designation as a breakthrough therapy is within the discretion of the FDA, and drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval and priority review. Even if one or more of our therapeutic candidates qualify as breakthrough therapies pursuant to FDA standards, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we may seek breakthrough therapy designation for one or more of our current or future therapeutic candidates, there can be no assurance that we will receive breakthrough therapy designation.

Even in the absence of obtaining fast track and/or breakthrough therapy designations, a sponsor can seek priority review at the time of submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria.

Regulatory authorities in some jurisdictions, including the U.S. and the EU, may also designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a therapeutic candidate as an orphan drug if it is a drug intended to treat a rare condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, the EMA’s Committee for Orphan Medicinal Products (COMP) evaluates orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a

45


life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Legislation has been proposed by the European Commission that, if implemented, has the potential in some cases to shorten the ten-year period of orphan marketing exclusivity. In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers, and it may entitle the therapeutic to exclusivity in the U.S. and the EU. Regulatory authorities may not grant our requests for orphan designation, or may require submission of additional data before making such determination. For example, even though we obtained orphan drug designation from the FDA in the U.S. for VGL101, we may not be able to obtain orphan drug designation from other health authorities where available. Further, even after obtaining orphan drug designation for a therapeutic candidate, including VGL101, we may not be able to obtain or maintain orphan drug exclusivity for that therapeutic candidate.

If any of our programs or therapeutic candidates receive fast track, breakthrough therapy, priority review, or orphan drug designation by the FDA or similar designations by other regulatory authorities, and even when received, there is no assurance that we will receive any benefits from such programs or that we will continue to meet the criteria to maintain such designation. Even if we obtain such designations, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A fast track, breakthrough therapy, priority review, or orphan drug designation does not ensure that a therapeutic candidate will receive marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may withdraw any such designation if it believes that the designation is no longer supported by data from our clinical development program.

Risks Related to Our Reliance on Third Parties

We may be required to make significant payments under our license agreement with Amgen Inc. for certain TREM2 agonists, and, if we breach our license agreement with Amgen related to these TREM2 agonists, we could lose the ability to continue the development and commercialization of TREM2 agonists.

In July 2020, we acquired an exclusive, royalty-bearing license to certain intellectual property rights owned or controlled by Amgen, to commercially develop, manufacture, use, distribute and sell therapeutic products containing compounds that bind to TREM2 (the Amgen Agreement). Under the Amgen Agreement, in consideration for the license, we made an upfront payment of $500,000 and also issued 6,928,566 shares of our Series A preferred stock to Amgen at the time of the initial closing with a subsequent 1,963,093 shares of our Series A preferred stock issued at the time of the milestone closing. As additional consideration for the license, we are required to pay Amgen up to $80.0 million in the aggregate upon the achievement of specified regulatory milestones for the first monoclonal antibody TREM2 agonist (mAb) product and the first small molecule TREM2 agonist product and aggregate milestone payments of up to $350.0 million upon the achievement of specific commercial milestones across all such mAb products and small molecule products. No regulatory or commercial milestones have been achieved to date under the license agreement. We are also required to pay tiered royalties of low to mid-single-digit percentages on annual net sales of the products covered by the license. If milestone or other non-royalty obligations become due, we may not have sufficient funds available to meet our obligations, which will materially adversely affect our business operations and financial condition. For more information on the terms of the license agreement with Amgen, see Note 12 to the consolidated financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

We are dependent on patents, know-how and proprietary technology in-licensed from Amgen. Our commercial success depends upon our ability to develop, manufacture, market and sell our therapeutic candidate or any future therapeutic candidates and use our and our licensor’s proprietary technologies without infringing the proprietary rights of third parties. Amgen may have the right to terminate the license agreement in full in the event we materially breach or default in the performance of any of the obligations under the license agreement. A termination of the license agreement with Amgen could result in the loss of significant rights and could harm our ability to develop and commercialize our therapeutic candidates.

Disputes may also arise between us and Amgen, as well as any future potential licensors, regarding intellectual property subject to a license agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;
whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
our right to sublicense patent and other rights to third parties under collaborative development relationships;
our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our therapeutic candidate and what activities satisfy those diligence obligations; and
the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.

46


If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates.

In addition, the Amgen Agreement under which we currently license intellectual property is complex, and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or other obligations under the Amgen Agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. For example, under the Amgen Agreement, Amgen shall have the right to terminate the agreement if we are deemed to have directly or indirectly conducted, enabled or participated in any distracting program (as defined in the Amgen Agreement), and do not elect to add the program to the agreement. There could be disagreements on whether a certain program would be considered as a distracting program. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangement on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.

We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.

We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including contract manufacturing organizations (CMOs) for the manufacturing of any therapeutic candidates we test in preclinical or clinical development, as well as CROs for the conduct of our preclinical testing and research and CROs for the conduct of our ongoing and planned clinical trials. For instance, VGL101 is a monoclonal antibody and is produced from a recombinant cell line only by permitted CMOs as set forth in the Amgen Agreement, the replacement of which would need to be approved by Amgen. We have established non-exclusive relationships with these CMOs for the manufacturing of VGL101 drug substance and drug product, and other third parties for testing, fill finish, and packaging and labeling. Any of these third parties may terminate their engagements with us at any time. A need to enter into alternative arrangements could delay our product development activities. Delays in CMO production of VGL101 drug substance or drug product would delay our ability to conduct and complete clinical trials. In addition, these third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.

Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for therapeutic candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols. Moreover, the FDA requires us to comply with GLPs for preclinical studies intended to support INDs and applications for marketing authorization, and with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. We also are required to register applicable clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Although we depend heavily on these parties, we control only certain aspects of their activity and therefore, we cannot be assured that these third parties will adequately perform all of their contractual obligations to us in compliance with regulatory and other legal requirements and our internal policies and procedures. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GLPs or GCPs, the preclinical and clinical data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to suspend, place on clinical hold or terminate these trials or require us to perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations, or that applicable preclinical studies comply with GLPs. In addition, our clinical trials must be conducted with product produced under conditions that comply with the FDA’s current Good Manufacturing Practices (cGMP). Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

47


Although we intend to design the clinical trials for any therapeutic candidates we may develop, CROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:

have staffing difficulties;
fail to comply with contractual obligations;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed; or
form relationships with other entities, some of which may be our competitors.

These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. We expect to have to negotiate budgets and contracts with CROs and trial sites, which may result in delays to our development timelines and increased costs. In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If these CROs, and any other third parties we engage do not perform preclinical studies and clinical trials in a satisfactory manner, if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, or if they breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of any therapeutic candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our therapeutic candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.

These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our therapeutic candidates. As a result, our financial results and the commercial prospects for our therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.

Our failure or any failure by these third parties to comply with these regulations, including to implement and maintain adequate standard operating procedures in order to comply, or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.

For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.

If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any therapeutic candidates we may develop.

48


We are dependent on third-party vendors to provide certain licenses, products and services and our business and operations, including clinical trials, could be disrupted by problems with or challenges faced by our significant third-party vendors.

We engage a number of third-party suppliers and service providers to supply critical goods and services, such as contract research services, contract manufacturing services and information technology services. Disruptions to the business, financial stability or operations of these suppliers and service providers, including due to strikes, labor disputes or other disruptions to the workforce, for instance, if, as a result of a pandemic, such as COVID-19, or government policy, employees are not able to come to work, or to their willingness and ability to produce or deliver such products or provide such services in a manner that satisfies the requirements put forth by the authorities, or in a manner that satisfies our own requirements, could affect our ability to develop and market our future therapeutic candidates on a timely basis. If these suppliers and service providers were unable or unwilling to continue to provide their products or services in the manner expected, or at all, we could encounter difficulty finding alternative suppliers. Even if we are able to secure appropriate alternative suppliers in a timely manner, costs for such products or services could increase significantly. Any of these events could adversely affect our results of operations and our business.

We depend, and may continue to depend on single-source suppliers for some of the components and materials used in the therapeutic candidates we are developing.

We depend, and may continue to depend, on single-source suppliers for some of the components and materials used in the therapeutic candidates we are developing. For example, we currently rely on a master services agreement with FUJIFILM (as defined in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) pursuant to which FUJIFILM is the sole provider to us of certain research, development, testing and manufacturing services for certain of our product candidates, including VGL101 (the FUJIFILM Agreement). In the event the FUJIFILM Agreement is terminated, our ability to meet the desired clinical development timelines may be materially impacted and our business will be implicated. We cannot ensure that any of our suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single- source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.

If we have to switch to a replacement supplier, the manufacture and delivery of any therapeutic candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our therapeutics, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines.

We may enter into collaborations, licenses and other similar arrangements with third parties for the research, development and commercialization of certain of the therapeutic candidates we may develop. If any such arrangements are not successful, we may not be able to capitalize on the market potential of those therapeutic candidates.

We may seek third-party collaborators for the research, development and commercialization of certain of the therapeutic candidates we may develop. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our partners dedicate to the development or commercialization of any therapeutic candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on the ability of such collaborators to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any arrangement that we enter into.

Collaborations involving our research programs or any therapeutic candidates we may develop pose numerous risks to us, including the following:

collaborators may not pursue development and commercialization of any therapeutic candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator’s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;

49


collaborators may delay programs, preclinical studies or clinical trials, provide insufficient funding for programs, preclinical studies or clinical trials, stop a preclinical study or clinical trial or abandon a therapeutic candidate, repeat or conduct new clinical trials or require a new formulation of a therapeutic candidate for clinical testing;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with any therapeutic candidates we may develop if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
collaborators may be acquired by a third party having competitive products or different priorities, causing the emphasis on our product development or commercialization program under such collaboration to be delayed, diminished or terminated;
collaborators would have significant discretion in determining the efforts and resources that they will apply to these collaborations;
collaborators may not perform their obligations as expected;
collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;
collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;
if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any therapeutic candidate licensed to it by us;
disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of any therapeutic candidates we may develop or that result in costly litigation or arbitration that diverts management attention and resources;
we may lose certain valuable rights under certain circumstances, including if we undergo a change of control;
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable therapeutic candidates we may develop;
collaboration agreements may not lead to development or commercialization of therapeutic candidates in the most efficient manner or at all; and
our collaborators’ business or operations could be disrupted due to a pandemic or other reasons outside of our control, which could have an adverse impact on their development and commercialization efforts or the prospects of our collaboration.

If our collaborations do not result in the successful development and commercialization of therapeutic candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments pursuant to the collaboration arrangement. If we do not receive the funding we expect under these agreements, our development of therapeutic candidates could be delayed, and we may need additional resources to develop therapeutic candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected.

Furthermore, all of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report apply to the activities of our collaborators.

These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. If we license rights to any therapeutic candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.

50


Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for our therapeutic programs and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our therapeutic programs and other proprietary technologies we may develop may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our therapeutic programs and other proprietary technologies we may develop. In order to protect our proprietary position, we have filed and intend to file additional patent applications in the U.S. and abroad relating to our therapeutic programs and other proprietary technologies we may develop; however, there can be no assurance that any such patent applications will issue as granted patents or that a granted patent will provide sufficient coverage for our therapeutic programs. If we are unable to obtain or maintain patent protection with respect to our therapeutic programs and other proprietary technologies we may develop, our business, financial condition, results of operations and prospects could be materially harmed.

The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect our therapeutic programs and other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover all of our technology, inventions and improvements. Our issued patents in the U.S. or other major markets may not cover all of our technologies or therapeutic candidates. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future. Moreover, even issued patents do not provide us with the right to practice our technology in relation to the commercialization of our therapeutics. The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our patented therapeutic candidates and practicing our proprietary technology. Our issued patents as well as patents that may issue in the future that we own or in-license may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or limit the length of the term of patent protection that we may have for our therapeutic candidates. Furthermore, our competitors may independently develop similar technologies.

Additionally, issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (USPTO) or in other jurisdictions, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our therapeutic programs and other proprietary technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.

In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future therapeutic candidates.

51


Our rights to develop and commercialize our therapeutic candidates are subject in part to the terms and conditions of a license granted to us by a third party. If we fail to comply with our obligations under our intellectual property license agreement, license agreements that we enter into in the future, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.

We are and expect to continue to be reliant upon third-party licensors for certain patent and other intellectual property rights that are important or necessary to the development of our therapeutic programs, therapeutic candidates, and proprietary technologies. For example, we rely on the Amgen Agreement for a license to technologies necessary for our monoclonal antibody TREM2 agonist program, including VGL101 and related molecules, intellectual property and manufacturing know-how, and our small molecule agonist program, including a portfolio of approximately 1,000 compounds. The Amgen Agreement imposes, and we expect that any future license agreement will impose, specified diligence, milestone payments, royalty, commercialization, development and other obligations on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses.

Furthermore, our licensors have, or may in the future have, the right to terminate a license if we materially breach the agreement and fail to cure such breach within a specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize therapeutic candidates and technology, lose patent protection, experience significant delays in the development and commercialization of our therapeutic candidates and technology, and incur liability for damages. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development and commercialization of certain of our therapeutic candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with any therapeutic candidates we may develop and our technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.

Disputes may arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted and obligations imposed under the license agreement and other interpretation-related issues;
our or our licensors’ ability to obtain, maintain and defend intellectual property and to enforce intellectual property rights against third parties;
the extent to which our technology, therapeutic candidates and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the license agreement;
the sublicensing of patent and other intellectual property rights under our license agreements;
our diligence, development, regulatory, commercialization, financial or other obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners; and
the priority of invention of patented technology.

In addition, any current or future license agreements to which we are a party, including our license agreement with Amgen, are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over intellectual property that we have licensed or any other dispute related to our license agreements prevent or impair our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates and technology. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

License agreements we may enter into in the future may be non-exclusive. Accordingly, third parties may also obtain non-exclusive licenses from such licensors with respect to the intellectual property licensed to us under such license agreements. Accordingly, these license agreements may not provide us with exclusive rights to use such licensed patent and other intellectual property rights, or may not provide us with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and any therapeutic candidates we may develop in the future.

52


Moreover, if some of our in-licensed patent and other intellectual property rights in the future become subject to third party interests such as co-ownership and we are unable to obtain an exclusive license to such third-party co-owners’ interest, in such patent and other intellectual property rights, the third-party co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. Additionally, we or our licensors may need the cooperation of any such co-owners of our licensed patent and other intellectual property rights in order to enforce them against third parties, and such cooperation may not be provided to us or our licensors.

Additionally, there could be instances where we may not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. In such instances, it is possible that our licensors’ filing, prosecution and maintenance of the licensed patents and patent applications, enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, and accordingly, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to file, prosecute, maintain, enforce and defend such patents and patent applications, or lose rights to those patents or patent applications, the rights we may license may be reduced or eliminated, our right to develop and commercialize any of our technology and any therapeutic candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting, maintaining, enforcing and defending patents and other intellectual property rights on our technology and any therapeutic candidates we are developing or may develop in all jurisdictions throughout the world would be prohibitively expensive, and accordingly, our intellectual property rights in some jurisdictions outside the U.S. could be less extensive than those in the U.S. In some cases, we or our licensors may not be able to obtain patent or other intellectual property protection for certain technology and therapeutic candidates outside the U.S. In addition, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we and our licensors may not be able to obtain issued patents or other intellectual property rights covering any therapeutic candidates we are developing or may develop and our technology in all jurisdictions outside the U.S. and, as a result, may not be able to prevent third parties from practicing our and our licensors’ inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. For example, third parties may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent or other intellectual property protection to develop their own products and, further, may export otherwise infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement is not as strong as that in the U.S.

Additionally, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain jurisdictions, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patent and other intellectual property rights or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our or our licensors’ patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent and other intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate and, if we or our licensors prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many jurisdictions also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties, and many jurisdictions limit the enforceability of patents against government agencies or government contractors. In these jurisdictions, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Issued patents covering therapeutic candidates we are developing or may develop could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.

Our owned and licensed patent rights may be subject to priority, validity, inventorship and enforceability disputes. If we or our licensors are unsuccessful in any of these proceedings, such patent rights may be narrowed, invalidated or held unenforceable. The foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

53


For example, if we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering any of our therapeutic candidates or our technology, the defendant could counterclaim that the patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, interference proceedings, derivation proceedings, post grant review, inter partes review and equivalent proceedings such as opposition, invalidation and revocation proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover one or more of our therapeutic candidates or our technology or no longer prevent third parties from competing with any therapeutic candidates we may develop or our technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Defense of these claims, regardless of their merit, would involve substantial expense and would be a distraction to management and other employees. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our therapeutic candidates or technology. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Changes in patent law in the U.S. or worldwide could diminish the value of patents in general, thereby impairing our ability to protect any therapeutic candidates we may develop and our technology.

Changes in either the patent laws or interpretation of patent laws in the U.S. and worldwide, including patent reform legislation such as the Leahy-Smith America Invents Act (the Leahy-Smith Act), could increase the uncertainties and costs surrounding the prosecution of any owned or in-licensed patent applications and the maintenance, enforcement or defense of any current in-licensed issued patents and issued patents we may own or in-license in the future. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO- administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March 2013, under the Leahy- Smith Act, the U.S. transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of patents to issue based on our in-licensed patent applications and issued patents we may own or in-license in the future, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

The Leahy-Smith Act also includes a number of significant changes that may affect patent litigation. These include additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim unpatentable even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to review patentability of our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

54


In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. As one example, in the case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable simply because they have been isolated from surrounding material. Moreover, in 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to patent-ineligible subject matter. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.

If we do not obtain patent term extension and data exclusivity for any therapeutic candidates we may develop, our business may be harmed.

Depending upon the timing, duration and specifics of any FDA marketing approval of any therapeutic candidates we may develop and our technology, U.S. patents that we own or license or may own may be eligible for limited patent term extension under Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought and within 60 days of FDA approval. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

We may be subject to claims challenging the inventorship or ownership of our patent and other intellectual property rights.

We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patent rights, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our therapeutic candidates or technology. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of our owned or in-licensed patent rights, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use intellectual property that is important to any therapeutic candidates we may develop or our technology. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

We may not be successful in obtaining necessary rights to a therapeutic candidate we may develop through acquisitions and in-licenses.

We currently own or exclusively license intellectual property rights covering certain aspects of our therapeutic programs. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our therapeutic programs and other proprietary technologies we may develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or therapeutic candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.

55


We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.

Some of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.

Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the development and commercialization of our therapeutic programs and other proprietary technologies we may develop.

Our commercial success depends in part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have also been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.

Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are commercializing or plan to commercialize our therapeutic programs and in which we are developing other proprietary technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot assure you that our therapeutic programs and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our therapeutic programs, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware or patents that may issue in the future from patent applications owned by third parties of which we are aware, but which we do not believe we infringe or that we believe we have valid defenses to any claims of patent infringement, could be found to be infringed by us, such as in connection with one or more of our therapeutic candidates. In addition, because patent applications can take many years to issue, and the scope of any patent claims that may ultimately issue are difficult to predict, there may be currently pending patent applications that may later result in issued patents that we may infringe and that, as a result, could harm our business.

In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by us. In this case, the holders of such patents may be able to block our ability to commercialize the infringing products or technologies unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.

Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or technologies, which may be

56


impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our therapeutic candidate or technologies, which could harm our business significantly. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. We could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.

We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. If we do not prevail in the patent proceedings the third parties may assert a claim of patent infringement directed at our therapeutic candidates.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Third parties, such as a competitor, may infringe our patent rights. In an infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the patent does not cover the technology in question. In addition, our patent rights may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. An adverse result in any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Such third party registered trademark owners may seek and obtain a court order that could prevent us from continuing to use our trademarks or trade names or order a payment of monetary damages. Our efforts to enforce, protect or defend our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.

57


We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.

The growth of our business may depend in part on our ability to acquire, in-license or use third-party proprietary rights. For example, our therapeutic candidates may require specific formulations to work effectively and efficiently, we may develop therapeutic candidates containing our compounds and pre-existing pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our therapeutic candidates, any of which could require us to obtain rights to use intellectual property held by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible.

We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business.

We maintain a large quantity of sensitive information, including confidential business and patient health information in connection with our preclinical and clinical studies, and are subject to laws and regulations governing the privacy and security of such information. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which adds to the complexity of processing personal data. Guidance on implementation and compliance practices are often updated or otherwise revised.

In the U.S., there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including health information privacy laws, security breach notification laws and consumer protection laws. Each of these laws is subject to varying interpretations and is constantly evolving. By way of example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes privacy and security requirements and breach reporting obligations with respect to individually identifiable health information upon “covered entities” (health plans, health care clearinghouses and certain health care providers), and their respective business associates (individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity). Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations. Even when HIPAA does not apply, failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act (the FTCA), 15 U.S.C § 45(a). The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.

In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, California enacted the California Consumer Privacy Act of 2018 (CCPA), which took effect on January 1, 2020 and became enforceable by the California Attorney General on July 1, 2020, and broadly defines personal information. The CCPA creates new individual privacy rights for consumers (as that term is broadly defined) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to California consumers about its data collection, use and sharing practices, provide such consumers with ways to opt-out of certain sales or transfers of personal information, provides for civil penalties for violations, and allows for a new private right of action for data breaches that has resulted in an increase in data breach litigation. Many aspects of the CCPA, including the expansion of the consumer rights granted therein under the California Privacy Rights Act (CPRA), and its interpretation remain unclear. As such, its full impact on our business and operations remains uncertain. Additionally, comprehensive privacy laws akin to the CCPA have been passed in Utah, Virginia and Colorado, and, with bills being proposed in several other states, it is quite possible that other U.S. states will follow suit. New privacy and data security laws have been proposed in more than half of the states in the U.S. and in the U.S. Congress. Further, in addition to the proposals for comprehensive consumer privacy laws, many states are considering more limited privacy bills that focus on specific issues such as biometric data. The existence of comprehensive privacy laws in different states in the country will make our compliance obligations more complex and costly.

As we conduct studies with subjects from outside of the U.S., we may be subject to additional, more stringent privacy laws in other jurisdictions. Most notably, we conduct studies in the EU, where in May 2018, a new privacy regime, the General Data Protection Regulation, the GDPR, took effect in the European Economic Area, the EEA. The GDPR governs the collection, use, disclosure, transfer

58


or other processing of personal data of individuals in the EEA. Among other things, the GDPR imposes new requirements regarding the security of personal data and notification of data breaches to the competent national data processing authorities, imposes limitations on retention of information, changes the lawful bases on which personal data can be processed, requires us to maintain records of our processing activities and to document data protection impact assessments where there is high risk processing, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the U.S. and other jurisdictions that the European Commission (EC) does not recognize as having “adequate” data protection laws (see below), and imposes substantial fines for breaches and violations (up to the greater of €20 million or 4% of our consolidated annual worldwide gross revenue).

Moreover, the United Kingdom leaving the EU could lead to further legislative and regulatory changes. Further to the U.K.’s exit from the EU on January 31, 2020, the GDPR ceased to apply in the U.K. at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the U.K.’s European Union (Withdrawal) Act 2018 incorporated the U.K. GDPR into U.K. law. The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.’s data protection regime, which is currently in line with the GDPR. The U.K. has announced plans to reform the country’s data protection legal framework in its Data Reform Bill, but these have been put on hold. Non-compliance with the U.K. GDPR may result in monetary penalties of up to £17.5 million or 4% of worldwide revenue, whichever is higher.

Further, the EC and the U.S. recently announced a political agreement on a new “Trans-Atlantic Data Privacy Framework”, which we will be required to implement when conducting restricted cross-border data transfers and doing so will require significant effort and cost. These and other future developments regarding the flow of data across borders could increase the cost and complexity of delivering our services in some markets and may lead to governmental enforcement actions, litigation, fines, and penalties or adverse publicity, which could adversely affect our business and financial position.

As these privacy, data protection and data security laws continue to evolve, we may be required to make changes to our business, including by taking on more onerous obligations in our contracts, limiting our storage, transfer and processing of data, implementing certain security controls and related technologies, and, in some cases, limiting our activities in certain locations. Changes in these laws may also increase our potential exposure through significantly higher potential penalties for non-compliance. In addition, due to the uncertainty and potentially conflicting interpretations of these laws, it is possible that such laws and regulations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. Any failure or perceived failure by us to comply with applicable laws or satisfactorily protect our systems, infrastructure, and confidential or protected information, including personal information could result in governmental enforcement actions, litigation, or negative publicity, any of which could inhibit our ability to grow our business.

Organizations are also increasingly subject to a wide variety of sophisticated attacks on their networks, systems, infrastructure, and endpoints, including the theft and subsequent misuse of employee credentials, denial-of-service attacks, ransomware attacks, digital extortion, business email compromises, malware, viruses, and social engineering (including phishing). The techniques used to obtain unauthorized access or to sabotage systems, networks, infrastructure, or physical facilities in which data is stored or through which data is transmitted, or on which our services and operations rely, evolve and change frequently and generally are not identified until they are launched against a target. We and our third party service providers may be unable to anticipate these techniques or to implement adequate preventative measures.

Compromise of our data security or of third parties with whom we do business or on which our services and operations rely, failure to prevent or mitigate the loss of confidential or protected information, including personal or business information, and delays in detecting, remediating, or providing prompt notice of any such compromise or loss could disrupt our operations, harm our reputation, result in loss of business or customers, subject us to litigation, government action or other additional costs and liabilities that could adversely affect our business, financial condition and operating results. Any reputational damage resulting from breach of our security measures could create distrust of our company. In addition, our insurance coverage may not be adequate to cover costs, expenses and losses associated with such events, and in any case, such insurance may not cover all of the types of costs, expenses and losses we could incur to investigate, respond to and remediate a security incident or compromise, including a security breach. As a result, we may be required to expend significant additional resources to protect against the threat of these disruptions and security breaches or to address and alleviate problems caused by such disruptions, compromises, incidents, or breaches, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants, including legal counsel, which could materially and adversely affect our business, financial condition and results of operations.

59


Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

others may be able to make products that are similar to our therapeutic candidate or utilize similar technology but that are not covered by the claims of the patents that we license or may own;
we might not have been the first to make the inventions covered by our current or future patent applications;
we might not have been the first to file patent applications covering our inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
it is possible that our current or future patent applications will not lead to issued patents;
any patent issuing from our current or future patent applications may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;
our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable;
the patents of others may harm our business; and
we may choose not to file for patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.

Risks Related to Government Regulation

Even if we obtain regulatory approval for any of our therapeutic candidates, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any therapeutic candidates, if approved, may face future development and regulatory difficulties.

Any therapeutic candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, compliance with applicable product tracking and tracing requirements, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval.

Even if marketing approval of a therapeutic candidate is granted, the approval may be subject to limitations on the indicated uses for which the therapeutic candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If a therapeutic candidate receives marketing approval, the accompanying label may limit the approved indicated use of the product, which could limit sales of the product. The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, relating to the promotion of prescription drugs, may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. Additionally, under FDORA, sponsors of approved drugs and biologics must provide six months’ notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product’s ability to be marketed.

In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:

restrictions on manufacturing such products;
restrictions on the labeling or marketing of products;

60


restrictions on product distribution or use;
requirements to conduct post-marketing studies or clinical trials;
issuance of warning letters or untitled letters;
refusal to approve pending applications or supplements to approved applications that we submit;
recalls or market withdrawals of products;
fines, restitution, or disgorgement of profits or revenues;
suspension or termination of ongoing clinical trials;
suspension or withdrawal of marketing approvals;
refusal to permit the import or export of our products;
product seizure; or
injunctions, consent decrees, or the imposition of civil or criminal penalties.

Obtaining and maintaining marketing approval or commercialization of our therapeutic candidates in the U.S. does not mean that we will be successful in obtaining marketing approval of our therapeutic candidates in other jurisdictions and vice-versa. Failure to obtain marketing approval in the U.S. or foreign jurisdictions would prevent any therapeutic candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.

In order to market and sell any therapeutic candidates we may develop in the EU and many other foreign jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval.

To obtain a marketing authorization for a product in the EU, an applicant must submit a marketing authorization application either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). We anticipate that the centralized procedure will be mandatory for the product candidates we are developing. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EU, and in the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway).

Under the centralized procedure, the EMA’s Committee Medicinal Products for Human Use, or CHMP, is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. The maximum timeframe for the evaluation of a marketing authorization application under the centralized procedure by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an application considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA’s recommendation. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.

The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the U.S., it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.

61


Our relationships with healthcare providers, patients and third-party payors are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.

Although we do not currently have any drugs on the market, our current and future operations are subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of VGL101 and future therapeutic candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research as well as market, sell and distribute VGL101 and future therapeutic candidates for which we obtain marketing approval. For more information regarding the risks related to these laws and regulations please see “Business – Government Regulation – Other Healthcare Laws” in our Annual Report on Form 10-K for the year ended December 31, 2022.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.

The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and individual imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.

We are subject to certain U.S. and certain foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.

U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government- affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.

Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

62


Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business.

The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government- paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the ACA and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see “Business – Government Regulation – Healthcare Reform” in our Annual Report on Form 10-K for the year ended December 31, 2022.

There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. The Inflation Reduction Act of 2022, or IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.  If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.

In addition, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA’s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.

We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing.

Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.

The commercial success of our therapeutic candidates will depend upon the degree of market acceptance of such therapeutic candidates by physicians, patients, healthcare payors and others in the medical community.

Our therapeutic candidates may not be commercially successful. Even if any of our therapeutic candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future therapeutic candidates will depend significantly on the broad adoption and use of the

63


resulting product by physicians and patients for approved indications. The degree of market acceptance of our therapeutics will depend on a number of factors, including:

demonstration of clinical efficacy and safety compared to other more-established products or treatment methods or other standards of care;
the indications for which our therapeutic candidates are approved;
the identification of patients eligible to receive our therapeutics for which our therapeutics are approved;
the limitation of our targeted patient population and other limitations or warnings contained in any labeling required by the FDA or comparable foreign regulatory authorities;
acceptance of a new drug for the relevant indication by healthcare providers and their patients;
the pricing and cost-effectiveness of our therapeutics, as well as the cost of treatment with our therapeutics in relation to alternative treatments and therapies;
our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;
the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our therapeutics in the absence of sufficient third-party coverage and adequate reimbursement;
any restrictions on the use of our therapeutics, and the prevalence and severity of any adverse effects;
potential product liability claims;
the timing of market introduction of our therapeutics as well as competitive drugs;
the effectiveness of our or any of our current or potential future collaborators’ sales and marketing strategies; and
unfavorable publicity relating to the product.

If any therapeutic candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our therapeutics may require significant resources and may never be successful.

Even if we are able to commercialize our therapeutic candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the U.S. and in other countries in which we seek to commercialize our products, which could harm our business.

In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our therapeutic candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. For more information please see “Business – Government Regulation – Coverage and Reimbursement” in our Annual Report on Form 10-K for the year ended December 31, 2022.

Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates.

64


We cannot be sure that coverage and reimbursement in the U.S., the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. In the U.S., third-party payors, and governmental healthcare plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the U.S. for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates. Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our product candidates, if any, may be.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous, radioactive, and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance.

In addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.

We could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs and claims associated with upgrades, maintenance and construction at our facilities or changes to our operating procedures, or injunctions limiting or altering our operations. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Legislation or other changes in U.S. tax law could adversely affect our business and financial condition.

The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future.

65


Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders’ tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.

Our ability to use our U.S. net operating loss carryforwards and certain other U.S. tax attributes may be limited.

Our ability to use our U.S. federal and state net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses.

Under the Tax Cuts and Jobs Act of 2017 (TCJA), as amended by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), unused U.S. federal net operating losses generated for tax years beginning after December 31, 2017 are not subject to expiration and may be carried forward indefinitely. Such U.S. federal net operating losses generally may not be carried back to prior taxable years, except that, net operating losses generated in 2018, 2019 and 2020 may be carried back to each of the five tax years preceding the tax years of such losses. Additionally, for taxable years beginning after December 31, 2020, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in any future taxable year. In addition, both our current and our future unused U.S. federal net operating losses and tax credits may be subject to limitations under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if we undergo an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in a corporation’s equity ownership by certain stockholders over a rolling three-year period. The completion of private placements and other transactions that have occurred since inception, may trigger such ownership change pursuant to Section 382 and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. Any such limitation, whether as the result of the mergers, prior private placements, sales of our common stock by our existing stockholders, or additional sales of our common stock by us after the mergers, could have a material adverse effect on our results of operations in future years. Our net operating losses and tax credits may also be impaired or restricted under state law.

Risks Related to Employee Matters and Managing our Growth

Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel.

We are highly dependent on the expertise of our executive officers. Although we have entered into employment agreements and/or offer letters with our executive officers, each of them may terminate their employment with us at any time. Our industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, clinical, regulatory, manufacturing and management skills and experience. We conduct our operations in the greater Boston area, a region that is home to many other pharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among pharmaceutical companies. Many of the other pharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our therapeutic candidates and to grow our business and operations as currently contemplated.

To induce valuable employees to remain at our company, in addition to salary, benefits, and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. For example, employment of our key employees is at-will, which means that any of our employees could leave our employment at any time, with or without notice.

In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

66


We will need to grow our size and capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

As of July 31, 2023, we had 61 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, clinical operations, manufacturing, regulatory affairs and, if any of our therapeutic candidates receives marketing approval, sales, marketing and distribution. We are continuing our efforts to recruit and hire the necessary employees to support our planned operations in the near term. However, competition for qualified employees among companies in the biotechnology and biopharmaceutical industry is intense, and no assurance can be given that we will be able attract, hire, retain and motivate the highly skilled employees that we need. Future growth will impose significant added responsibilities on members of management, including identifying, recruiting, integrating, maintaining and motivating additional employees and managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties. Our future financial performance and our ability to commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.

To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth and potentially with developing sales, marketing and distribution infrastructure, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources.

If we are not able to effectively manage growth and expand our organization, we may not be able to successfully implement the tasks necessary to further develop and commercialize VGL101, our other pipeline therapeutic candidates or any future therapeutic candidates and, accordingly, may not achieve our research, development and commercialization goals.

Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (i) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, including cGMP requirements, (iii) federal and state data privacy, security, fraud and abuse and other healthcare and employment laws and regulations in the U.S. and abroad or (iv) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We face significant competition, and if our competitors develop technologies or therapeutic candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.

The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. These characteristics also apply to the development and commercialization of treatments in neurodegenerative diseases, particularly AD. While we believe that our focus, expertise, scientific knowledge and intellectual property provide us with competitive advantages, we face competition from several different sources, including large and small biopharmaceutical companies, academic research institutions, government agencies and public and private research organizations, that conduct research, seek and obtain patent protection, and establish collaborative arrangements, sometimes exclusive, for research, development, manufacturing and commercialization.

67


Competition can arise from third parties which are pursuing therapeutics that target the same molecular targets as our product candidates, therapeutics that are being developed for the same diseases or disorders as our product candidates, or both, therapeutics that target the same molecular targets and are being developed for the same diseases or disorders as our product candidates. In general, we consider our closest competitors as third parties that are conducting clinical trials to evaluate such therapeutics.

We further define and evaluate competition based on the nature of the disease or disorder that is potentially addressed by our product candidates. For instance, we consider competition more broadly in the context of rare diseases and more narrowly for diseases or disorders that are common. That is, we are more apt to consider a third party a competitor if it is clinically developing a therapeutic for the same rare disease in which we are developing our product candidates, irrespective of the molecular target of the third party therapeutic. On the other hand, we are less inclined to consider a third party a competitor in the case of a common disease, unless the third party is clinically developing a therapeutic that targets the same molecular target as our product candidates. Nevertheless, the competitive landscape, particularly for common diseases, is highly complex and can be influenced by the success or failure of third party therapeutics that are being developed for the same disease or disorder as our product candidates. As a result, our share price may be positively or negatively influenced by the activities of such third parties irrespective of whether we consider them to be a competitor or not.

We are aware of third parties which are pursuing therapeutics that target the same molecular targets as our product candidates. Because our current product candidates target TREM2, we consider the following third parties to be our closest competitors: Alector, which is developing AL002, a TREM2 targeting antibody, for Alzheimer’s disease in collaboration with AbbVie, Inc.; and Denali, which is developing DNL919/TAK-920, a TREM2 targeting antibody, for Alzheimer’s disease in collaboration with Takeda Pharmaceutical Company Limited.

Regarding therapeutics that are being developed for the same diseases or disorders as our product candidates, we consider the main competitors as follows:

VGL101 for ALSP: we are not aware of any third parties that are clinically developing therapeutics for ALSP. Further, no products have been approved to treat ALSP. Academics have investigated the use of hematopoietic stem cell transplantation in a small number of ALSP patients, however, we believe this procedure has limited benefits and several key limitations.
Small molecule TREM2 agonists for AD: we are not aware of any third parties clinically developing small molecules that target TREM2 for AD. There are, however, many third parties pursuing clinical development of therapeutics for AD. As mentioned, Alector and Denali are each clinically developing TREM2 targeting antibody therapeutics. The University of Oxford in collaboration with Janssen Pharmaceutica NV has reported a Phase I trial of JNJ-40346527 (edicotinib), a small molecule CSF-1R antagonist. Elixiron Immunotherapeutics, Inc. has reported a Phase I trial of EI-1071, a small molecule that inhibits the tyrosine kinase activity of CSF-1R. In addition, there are others developing therapeutics for AD that do not target TREM2. Notable examples include those that are based on reduction of ß-amyloid plaques, such as ADUHELM® (aducanumab-avwa) and LEQEMBI™ (lecanemab-irmb), both of which are from Biogen, Inc. and were FDA approved in 2021 and 2023, respectively. Other ß-amyloid therapeutics and additional approaches for AD are being pursued by Roche (Genentech), Eli Lilly and others.

Many of our competitors have significant financial, technical, manufacturing, marketing, sales and supply resources or experience. These competitors also compete with us in recruiting qualified scientific and management personnel as well as establishing clinical trial sites and patient registration for clinical trials, and in acquiring new technologies. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products or technological approaches may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of the therapeutics we may develop could be adversely affected.

68


Risks Related to Ownership of Our Common Stock

If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.

The trading market for our common stock may be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If few securities or industry analysts commence coverage of us, our stock price could be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

As widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several years, most recently due, directly or indirectly, to the COVID-19 pandemic, record inflation, the Russia/Ukraine conflict, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions, whether due to another public health crisis or otherwise, will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, more dilutive, or not possible at all.

Failure to secure necessary financing in a timely manner and on favorable terms could have a material adverse event on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. Our stock price may decline due in part to the volatility of the stock market and the general economic downturn.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 80% of our outstanding voting stock as of July 31, 2023 based on the amounts reported in the most recent filings made by such significant stockholders under Section 13(d) and 13(g) of the Exchange Act.

These stockholders, acting together, may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that investors may feel are in their best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with each investor’s interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our ATM Facility or 2021 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock. Pursuant to our 2021 Stock Option and Grant Plan (2021 Plan), our management is authorized to grant stock options to our employees, directors and consultants. If the number of shares reserved under our 2021 Plan is increased pursuant to the terms of the 2021 Plan, our stockholders may experience additional dilution, which could cause our stock price to fall. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.

69


The administrator of the 2021 Plan is authorized to exercise its discretion to effect the repricing of stock options and stock appreciation rights and there may be adverse consequences to our business if the administrator of the 2021 Plan exercises such discretion.

Pursuant to our 2021 Plan, we are authorized to grant equity awards, including stock options and stock appreciation rights, to our employees, directors and consultants. The compensation committee is the administrator of the 2021 Plan and is authorized to exercise its discretion to reduce the exercise price of stock options or stock appreciation rights or effect the repricing of such awards. Although we do not anticipate needing to exercise this discretion in the near term, or at all, if the administrator of the 2021 Plan were to exercise such discretion without seeking prior stockholder approval, certain proxy advisory firms or institutional investors may be unsupportive of such actions and publicly criticize our compensation practices, and proxy advisory firms may recommend an “against” or “withhold” vote for members of our compensation committee. In addition, if we are required to hold an advisory vote on named executive officer compensation (known as the “say-on-pay” vote) at the time of, or subsequent to, any such repricing, it is likely that proxy advisory firms would issue an “against” recommendation on our say on pay vote and institutional investors may not be supportive of our say-on-pay vote. If proxy advisory firms or institutional investors are successful in aligning their views with our broader stockholder base and we are required to make changes to the composition of our board and its committees, or if we need to make material changes to our compensation and corporate governance practices, our business might be disrupted and our stock price might be negatively impacted. Even if we are able to successfully rationalize the exercise of such discretionary power, defending against any “against” or “withhold” recommendation for members of our compensation committee, any “against” recommendation on our say on pay vote or public criticism could be distracting to management, and responding to such positions from such firms or investors, even if remedied, can be costly and time-consuming.

In addition, if the administrator of the 2021 Plan does determine to reprice stock options or stock appreciation rights, even absent negative reactions from proxy advisory firms and institutional investors, and we could incur significant costs, including accounting and administrative costs and attorneys’ fees. We may also be required to recognize incremental compensation expense as such result of a repricing. These actions could cause our stock price to decrease and experience periods of increased volatility, which could result in material adverse consequences to our business.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or therapeutic candidates.

We do not have any committed external source of funds or other support for our development and commercialization efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.

As a result of our recurring losses from operations and recurring negative cash flows from operations, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively. If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or therapeutic candidates, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market therapeutic candidates that we would otherwise prefer to develop and market ourselves. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.

70


We are an “emerging growth company” and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in our Annual Report on Form 10-K;
not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act);
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation in our Annual Report on Form 10-K and our periodic reports and proxy statements; and
exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (ii) the date we qualify as a “large accelerated filer,” with at least $700.0 million of equity securities held by non-affiliates; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (iv) the last day of the fiscal year ending after the fifth anniversary of our initial public offering in January 2022.

Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company,” which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our Annual Report on Form 10-K and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.

71


Anti-takeover provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.

Our third amended and restated certificate of incorporation and our amended and restated bylaws, contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:

a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;
a prohibition on stockholder actions through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;
a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;
advance notice requirements for stockholder proposals and nominations for election to our board of directors;
a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;
a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and
the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.

In addition, Section 203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.

Any provision of our third amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.

Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein (Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders’ ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum

72


selection provisions purporting to require claims under the Securities Act be brought in federal court were “facially valid” under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.

General Risk Factors

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

We will continue to incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to continue to require that we incur substantial legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. We cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

In addition, as a public company we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, beginning with our most recent annual report on Form 10-K, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we may be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

The market price of our common stock may be volatile, and investors could lose all or part of their investment.

The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.

73


The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in increased unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, the current Russia-Ukraine conflict has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Continuing concerns over United States health care reform legislation have also contributed to increased volatility. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely.

Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this Quarterly Report, these factors include:

the timing and results of INDs, preclinical studies and clinical trials of our therapeutic candidates or those of our competitors;
the success of competitive products or announcements by potential competitors of their product development efforts;
our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
any delay in our regulatory filings for our therapeutic candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings;
adverse developments concerning our potential future in-house manufacturing facilities or CMOs;
regulatory actions with respect to our therapeutics or therapeutic candidates or our competitors’ products or therapeutic candidates;
actual or anticipated changes in our growth rate relative to our competitors;
the size and growth of our initial target markets;
unanticipated serious safety concerns related to the use of our therapeutic candidates;
regulatory or legal developments in the U.S. and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
significant lawsuits, including patent or stockholder litigation;
publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;
the recruitment or departure of key personnel;
announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
fluctuations in the valuation of companies perceived by investors to be comparable to us;
market conditions in the pharmaceutical and biotechnology sector;
changes in the structure of healthcare payment systems;
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;
announcement or expectation of additional financing efforts;
sales of our common stock by us, our insiders or our other stockholders;
expiration of market stand-off or lock-up agreements;

74


the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic;
general economic, political, industry and market conditions; and
other events or factors, many of which are beyond our control.

The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock.

A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and could cause a disruption to the development of our therapeutic candidates.

Although many activities have returned to normal, and the U.S. federal government has declared an end to the public health emergency related to the COVID-10 pandemic, the COVID-19 pandemic broadly affected the global economy, resulted in significant travel and work restrictions in many regions and put a significant strain on healthcare resources for an extended period of time. The ultimate extent of the impact of the COVID-19 pandemic on our business, financial condition and results of operations is uncertain and will depend on continued developments including any resurgence of COVID-19 and its variants. The continuation of the worldwide COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation and continued enrollment of our clinical trials, disrupt regulatory activities or have other adverse effects on our business, results of operations, financial condition and prospects. In addition, the COVID-19 pandemic has adversely impacted economies worldwide and may continue to cause substantial disruption in the financial markets and global supply chains, all of which could adversely affect our business, operations and ability to raise funds to support our operations.

To date, we have not experienced a material financial impact or significant business disruptions, including with our vendors, or impairments of any of our assets as a result of the ongoing COVID-19 pandemic. We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures. In the past, we have implemented temporary precautionary measures intended to help minimize the risk of the virus to our employees, including providing for social distancing, increased sanitization of our facilities, and providing access to rapid testing and personal protective equipment for our employees and may need to do so in the future. We expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners. We are continuing to monitor the potential impact of the COVID-19 pandemic, but even though many states within the U.S. are easing COVID-19 related restrictions, we cannot be certain what the overall impact of the ongoing COVID-19 pandemic will be on our business, financial condition, results of operations and prospects.

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, an ongoing military conflict between Russia and Ukraine, and record inflation. Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, geopolitical tensions, or record inflation.

U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has caused record inflation globally. We are continuing to monitor the situation in Ukraine and globally and assessing its potential impact on our business.

Although, to date, our business has not been materially impacted by the ongoing military conflict between Russia and Ukraine, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which the conflict in Ukraine, geopolitical tensions, or record inflation may impact our business. The extent and duration of the conflict in Ukraine, geopolitical tensions, record inflation and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Quarterly Report.

75


Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.

Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, in May 2023, the FDIC took control of First Republic Bank ("First Republic") and JPMorgan Chase & Co. has since acquired a substantial amount of assets and certain liabilities of First Republic. The U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee, however, that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.

We have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations as a result of these bank failures. However, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners, or industry as a whole may be adversely impacted in ways that we cannot predict at this time.

Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships, and in turn, us. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.

In addition, a critical vendor, contract development and manufacturing partners (CDMO), or business partner could be adversely affected by any of the liquidity or other risks that are described above as factors, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. Any CDMO, business partner, or supplier bankruptcy or insolvency, or any breach or default by a CDMO, business partner, or supplier, or the loss of any significant supplier relationships, could result in material adverse impacts on our current and/or projected business operations and financial condition.

76


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

None.

Use of Proceeds from Registered Securities

On January 6, 2022, the SEC declared effective our registration statement on Form S-1 (File No. 333-261230), as amended, filed in connection with our IPO, or the Registration Statement. Pursuant to the Registration Statement, we registered the offer and sale of 7,000,000 shares of our common stock with a proposed maximum aggregate offering price of approximately $136,850,000. Morgan Stanley & Co. LLC and Jefferies LLC acted as representatives of the underwriters for the offering. On January 11, 2022, we issued and sold 7,000,000 shares of our common stock at a price to the public of $14.00 per share. Upon completion of the IPO on January 11, 2022, we received net proceeds of approximately $91.1 million, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us of $3.1 million. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.

None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.

The offering terminated after the sale of all securities registered pursuant to the Registration Statement. There has been no material change in the expected use of the net proceeds from our IPO as described in the final prospectus dated January 6, 2022 and filed with the SEC on January 10, 2022, pursuant to Rule 424(b)(4) (File No. 333-261230) of the Securities Act, however, as previously disclosed, we are no longer planning to pursue the Phase 1b biomarker trial of VGL101 or the Phase 2 clinical trial of VGL101 for the treatment of cALD, which will reduce the use of proceeds used for those programs.
 

Item 3. Defaults Upon Senior Securities.

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

77


Item 6. Exhibits

Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).

 

Exhibit

Number

Description

3.1

 

Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Form 8-K (File No. 001-41200) filed on January 11, 2022).

 

 

 

3.2

 

Amended and Restated Bylaws of the Registrant. (incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K (File No. 001-41200) filed on January 11, 2022).

 

 

 

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1**

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2**

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS*

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

 

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

104*

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

** The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

78


SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Vigil Neuroscience, Inc.

Date: August 8, 2023

By:

/s/ Ivana Magovčević-Liebisch

Ivana Magovčević-Liebisch, PhD, JD

President and Chief Executive Officer

(Principal Executive Officer)

 

 

Date: August 8, 2023

By:

/s/ Jennifer Ziolkowski

Jennifer Ziolkowski

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

79


EX-31.1 2 vigl-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ivana Magovčević-Liebisch , certify that:

(1)
I have reviewed this quarterly report on Form 10-Q of Vigil Neuroscience, Inc.;
(2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4)
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5)
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 8, 2023

By:

/s/ Ivana Magovčević-Liebisch

Ivana Magovčević-Liebisch

President and Chief Executive Officer

 

(Principal Executive Officer)

 

 


EX-31.2 3 vigl-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jennifer Ziolkowski, certify that:

(1)
I have reviewed this quarterly report on Form 10-Q of Vigil Neuroscience, Inc.;
(2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4)
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5)
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 8, 2023

By:

/s/ Jennifer Ziolkowski

Jennifer Ziolkowski

Chief Financial Officer

 

(Principal Financial Officer and Accounting Officer)

 

 


EX-32.1 4 vigl-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Vigil Neuroscience, Inc. (the “Company”) for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 8, 2023

By:

/s/ Ivana Magovčević-Liebisch

Ivana Magovčević-Liebisch

President and Chief Executive Officer

 

(Principal Executive Officer)

 

 


EX-32.2 5 vigl-ex32_2.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Vigil Neuroscience, Inc. (the “Company”) for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 8, 2023

By:

/s/ Jennifer Ziolkowski

Jennifer Ziolkowski

Chief Financial Officer

 

(Principal Financial Officer and Accounting Officer)

 

 


EX-101.PRE 6 vigl-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 7 vigl-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.SCH 8 vigl-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Fair Value Measurements and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Prepaid Expense and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Related Party License Agreement link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Prepaid Expense and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment and Related Accumulated Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy for Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Marketable Securities by Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Fair Value Measurements - Schedule of Significant Unobservable Inputs Used in Valuation Model (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs Used in Valuation Model (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Fair Value Measurements - Rollforward of Changes in Fair Value of Financial Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Stock-Based Compensation - Summary of Options Activity to Purchase Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Determine Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Stock-Based Compensation - Schedule of Assumptions on Weighted-Average Basis to Determine Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Common Stock - Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Differs from Statutory Federal Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Income Taxes - Summary of Deferred Income Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100630 - Disclosure - Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100640 - Disclosure - Related Party License Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100650 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100660 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100670 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 9 vigl-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Lessee, Operating Lease, Liability, to be Paid, Year One Operating Leases, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Document Transition Report Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Outstanding Deferred Tax Assets, in Process Research and Development Research and development credits Money Market Funds [Member] Money Market Funds Payments of Stock Issuance Costs Stock issuance costs Debt Securities, Available-for-Sale Available for Sale securities fair value Total Investment Owned, Cost Investment amortized cost Investment Amortized Cost Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Fair Value, Inputs, Level 1 [Member] Level 1 Lessee, Operating Lease, Liability, to be Paid, Year Four Operating Leases, 2027 Payments to Suppliers and Employees, Total Payments to Suppliers and Employees Expense in connection with goods provided Fair Value Disclosures [Text Block] Fair Value Measurements and Financial Instruments Finance Lease, Liability, to be Paid Financing Lease, Total lease payments Temporary Equity, Shares Authorized Temporary equity, shares authorized Property, Plant and Equipment, Useful Life Property and equipment, useful life Amortization of premium discount on marketable securities. Amortization of Premium Discount on Marketable Securities Amortization of premium/discount on marketable securities Laboratory space. Laboratory Space [Member] Laboratory Space Prepaid Expense and Other Assets, Current [Abstract] Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Increase in valuation allowance Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Financing leases, 2023 Purchase commitment fee percentage. Purchase Commitment Fee Percentage Purchase commitment fee percentage Prepaid reservation fees. Prepaid Reservation Fees Prepaid reservation fees Maturities between one and two years Available-for-Sale Securities, Debt Maturities, One Through Two Years, Fair Value Available-for-sale securities, debt maturities, one through two years, fair value. Subsequent Events [Text Block] Subsequent Events Deferred IPO Deferred Offering Costs Due to Vendor Deferred offering costs due to vendor. Temporary Equity, Shares Issued Temporary equity, shares issued Share-based compensation arrangement by share-based payment award equity instruments other than options weighted-average remaining vesting period for unvested shares. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Vesting Period For Unvested Shares Remaining weighted-average vesting period for unvested shares Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value Hierarchy for Assets and Liabilities Construction Payable, Current Construction related Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Purchase an aggregate shares Temporary Equity Stock Purchase Commitment Temporary equity stock purchase commitment. Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Assets, Fair Value Disclosure [Abstract] Assets: Finance Lease, Liability, Noncurrent Finance lease liabilities, net of current portion Class of Stock [Line Items] Class Of Stock [Line Items] Expected term (years) Related Party Antidilution Obligation Expected Term1 Related party antidilution obligation expected term1. Related Party Transactions [Abstract] Balance Sheet Location [Axis] Balance Sheet Location Assets, Current Total current assets Liabilities and Equity Total liabilities and stockholders' equity Entity Address, State or Province Entity Address, State or Province Issuance of convertible preferred stock, fair value Stock Issued During Period, Value, New Issues Issuance of convertible preferred stock, net of issuance costs Conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Shares, Outstanding Number of Shares, Outstanding Number of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Granted Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Trading Symbol Trading Symbol Deferred Tax Assets, Net of Valuation Allowance Total deferred tax assets, net of valuation allowance Common Stock, Shares, Issued, Total Common Stock, Shares, Issued Common stock, shares, issued Deferred tax assets start-up costs. Deferred Tax Assets Start Up Costs Start-up costs Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Maximum aggregate milestone payments upon achievement of specific commercial milestones across all mab products Maximum Aggregate Milestone Payments Upon Achievement Of Specific Commercial Milestones Across All Mab Products Maximum aggregate milestone payments upon achievement of specific commercial milestones across all mab products. Cash and Cash Equivalents [Member] Cash Equivalents Lease termination date Lease Expiration Date Lessee, Operating Lease, Liability, to be Paid, Year Three Operating Leases, 2026 Total common stock reserved for future issuance Total common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Aggregate number of shares of common stock reserved for issuance AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Components of Deferred Tax Liabilities [Abstract] Deferred tax liabilities: Entity Address, City or Town Entity Address, City or Town Related Party Transaction [Line Items] Related Party Transaction [Line Items] Share-based compensation arrangement by share-based payment award options, exercised, weighted-average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Exercised Operating Lease, Weighted Average Discount Rate, Percent Operating lease, weighted-average discount rate Lessee, Operating Lease, Renewal Term Operating lease renewal term Property, Plant and Equipment [Table Text Block] Summary of Property and Equipment and Related Accumulated Depreciation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Number of Shares, Vested and exercisable Number of Shares, Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Number of Shares, Expired Subsequent Event Subsequent Event [Member] Subsequent Event Type [Axis] Finance Lease, Principal Payments Financing cash flows from finance leases Payments of finance lease obligations Additional Paid-in Capital [Member] Additional Paid-In Capital Series B Preferred stock Series B Preferred Stock [Member] Series B Convertible Preferred Stock Liabilities, Current [Abstract] Current liabilities: Preferred Stock, Convertible, Conversion Price Preferred stock conversion price per share Assets, Current [Abstract] Current assets: Counterparty Name [Axis] Preferred Stock, Par or Stated Value Per Share Preferred stock, par or stated value per share Expected value adjustment to Series A if second tranche milestones are not met Expected value adjustment if second tranche milestones are not met Expected value adjustment if second tranche milestones are not met. Statement of Stockholders' Equity [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Vested and expected to vest Weighted-Average Exercise Price Per Share, Vested and expected to vest Operating Lease, Liability, Current Operating lease liabilities Marketable Securities, Policy [Policy Text Block] Marketable securities Accrued expenses and other current liabilities. Accrued Expenses And Other Current Liabilities [Member] Accrued Expenses and Other Current Liabilities Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net Property and equipment, net Total property and equipment, net Series A Preferred Stock Series A Preferred Stock [Member] Series A Convertible Preferred Stock Class of Stock [Domain] Class of Stock Investment Income, Interest Interest income, net Marketable Securities U.S. Government Securities [Member] Marketable Securities U.S. Government Securities [Member] Marketable Securities (U.S. Government Securities) Marketable Securities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Vested and expected to vest Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statutory U.S. federal rate Conversion of convertible preferred stock to common stock upon closing of initial public offering,amount Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering,Amount Conversion of convertible preferred stock to common stock upon closing of initial public offering,amount Statement of Comprehensive Income [Abstract] Comprehensive loss: Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Finance Lease, Liability, Current Financing lease liabilities Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase common stock Plan Name [Domain] Plan Name Restricted Cash, Noncurrent Restricted cash Assets, fair value Assets, Fair Value Disclosure Assets, Fair Value Disclosure, Total Lessee, Operating Lease, Option to Extend Operating lease, option to extend Operating lease commencement year. Operating Lease Commencement Year Operating lease commencement year Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Number of securities. Number of Securities Series A convertible preferred stock. Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Liabilities, Current Total current liabilities Entity Tax Identification Number Entity Tax Identification Number Offering costs included in accounts payable and accrued expenses Unpaid Offering Costs Unpaid offering costs. Convertible preferred stock basis Preferred Stock, Conversion Basis Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Corporate Headquarters Corporate Headquarters [Member] Corporate headquarters. Financial Instruments [Domain] Accrued expenses related parties. Accrued Expenses Related Parties Accrued expenses, related parties Investment, Name [Axis] Construction in Progress [Member] Construction in Progress Award Type [Axis] Award Type Restricted Stock [Member] Restricted Stock Finance Lease, Weighted Average Remaining Lease Term Finance lease, weighted-average remaining lease term Plan Name [Axis] Plan Name Share-based compensation arrangement by share-based payment award equity instruments other than options outstanding unvested shares expected to vest. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Unvested Shares Expected To Vest Outstanding unvested shares, expected to vest Lessee, Operating Lease, Term of Contract Operating lease term Assets Total assets Amgen agreement. Amgen Agreement [Member] Amgen Agreement Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Unrecognized stock-based compensation expense related to unvested stock options not recognized Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Entity Registrant Name Entity Registrant Name Components of Deferred Tax Assets [Abstract] Deferred tax assets: Share-based compensation arrangement by share-based payment award fair value assumptions weighted-average fair value. Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Weighted-average fair value Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Proceeds from equity financings Operating lease, existence of option to extend [true false] Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Related Party, Type [Domain] Related Party Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Unrealized Gain (Loss) on Investments [Table Text Block] Summary of marketable securities Retained Earnings [Member] Accumulated Deficit Class of Stock [Axis] Class of Stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding as of beginning of period Minimum [Member] Minimum Investments Classified by Contractual Maturity Date [Table Text Block] Summary of marketable securities by maturity Proceeds from Stock Options Exercised Proceeds from stock option exercised Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Operating Lease, Liability, Total Operating Lease, Liability Operating lease liabilities Operating Leases, Total future minimum lease payments Lease construction allowance. Lease Construction Allowance Lease construction allowance Finance Lease, Liability, Total Finance Lease, Liability Financing lease liabilities Financing leases, Total future minimum lease payments Equity Component [Domain] Equity Component Options Common Stock Options Employee Stock Option [Member] Upfront consideration for license arrangement. Upfront Consideration For License Arrangement Upfront consideration for license arrangement Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used by operating activities: Measurement Frequency [Axis] Measurement Frequency Conversion of convertible preferred stock to common stock upon closing of initial public offering,shares Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering Conversion of convertible preferred stock to common stock upon closing of initial public offering Entity Current Reporting Status Entity Current Reporting Status Common Stock, Shares Authorized Common stock, shares authorized Research and Development Expense, Total Research and Development Expense Research and development Fair Value, by Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total Finance Lease, Right-of-Use Asset, after Accumulated Amortization Financing lease right-of-use assets Gross proceeds from issuance of preferred stock Proceeds from issuance of common stock upon initial public offering, net of offering costs Proceeds from Issuance of Convertible Preferred Stock Assets [Abstract] Assets Schedule of cash, cash equivalents and restricted cash. Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of Cash, Cash Equivalents and Restricted Cash Convertible Preferred Stock [Member] Convertible Preferred Stock Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2023 and December 31, 2022; 35,906,037 shares issued as of June 30, 2023 and 35,664,658 shares issued as of December 31, 2022; and 35,861,714 shares outstanding as of June 30, 2023 and 35,620,335 shares outstanding as of December 31, 2022 Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year Maturities in one year or less Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Valuation allowance Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Vested and exercisable Deferred offering costs paid in the prior year Deferred Offering Costs Paid in the Prior Year Deferred offering costs paid in the prior year. Shares Available for Issuance Under the 2020 Plan Two thousand twenty equity incentive plan. Two Thousand Twenty Equity Incentive Plan [Member] 2020 Equity Incentive Plan Furniture and Fixtures [Member] Furniture and Fixtures Share-based compensation arrangement by share-based payment award options, forfeited, weighted-average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Forfeited Current Fiscal Year End Date Current Fiscal Year End Date Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Operating Income (Loss) Loss from operations Share-based compensation arrangement by share-based payment award options, expired, weighted-average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Expired Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Expired Entity Ex Transition Period Time until series A milestone years. Time Until Series A Milestone Years Time until Series A milestones (years) Research and Development Expense [Member] Research and Development Stock-based compensation expense recognized Stock-based compensation Stock-based compensation expense Options to purchase common stock service based. Options To Purchase Common Stock Service Based [Member] Options to Purchase Common Stock – Service Based Equipment [Member] Equipment Lease Increase (Decrease) in Operating Lease Liability Operating lease liabilities Atlas Venture Fund XII LP. Atlas Venture Fund X I I L P [Member] Atlas Venture Fund XII, LP Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Increase decrease in tranche obligation. Increase Decrease In Tranche Obligation Change in fair value of Series A preferred stock tranche obligation Other income (expense), net Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Service-based stock options. Service Based Stock Options [Member] Service-Based Stock Options Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value Lab equipment. Lab Equipment [Member] Lab Equipment Operating Expenses [Abstract] Operating expenses: Accrued research and development current. Accrued Research And Development Current Research and development Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization FUJIFILM Diosynth Biotechnologies Texas, LLC FUJIFILM Diosynth Biotechnologies Texas LLC [Member] FUJIFILM diosynth biotechnologies Texas, LLC. Subsequent Events [Abstract] Commitments and Contingencies Disclosure [Abstract] Other Assets, Noncurrent, Total Other Assets, Noncurrent Other assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Grant of restricted stock Number of shares granted Other Accrued Liabilities, Current Other Common Stock Equity [Text Block] Depreciation expense on property and equipment Depreciation expense Depreciation, Total Depreciation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Vested and exercisable Weighted-Average Exercise Price Per Share, Vested and exercisable Letters of credit renewal period. Letters Of Credit Renewal Period Letter of credit renewal period Equity, Attributable to Parent [Abstract] Stockholders’ deficit: Stockholders' equity: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment Owned, Fair Value Investment Owned, at Fair Value, Beginning Balance Investment Owned, at Fair Value, Ending Balance Investment Fair Value Additional maximum consideration for license agreement upon achievement of specified regulatory milestones. Additional Maximum Consideration For License Agreement Upon Achievement Of Specified Regulatory Milestones Additional maximum consideration for license agreement upon achievement of specified regulatory milestones Earnings Per Share [Abstract] Noncash unrealized gains on available for sale securities. Noncash Unrealized Gains on Available for Sale Securities Unrealized gains on available for sale securities Unrealized gain (loss) on available for sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Share-based compensation arrangement by share-based payment award options, outstanding, weighted-average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Outstanding Weighted-Average Grant Date Fair Value, Outstanding Share-based compensation arrangement by share-based payment award options, vested and expected to vest, weighted-average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Vested and expected to vest Weighted-Average Grant Date Fair Value, Vested and expected to vest Loss Contingencies [Table] Loss Contingencies [Table] Investment, Name [Domain] Dividends, Common Stock, Total Dividends, Common Stock Common stock dividend declared Accounting Policies [Abstract] Lessee, Lease, Description [Table] Lessee Lease Description [Table] Lease annual payments. Lease Annual Payments Lease annual payments Liability Class [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Percentage of annual escalation. Percentage Of Annual Escalation Percentage of annual escalation Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share attributable to common stockholders, basic Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Commitments and Contingencies Commitments and contingencies (Note 12) Income Statement [Abstract] Unvested restricted common stock. Unvested Restricted Common Stock [Member] Unvested Restricted Common Stock Related Party, Type [Axis] Related Party State research and development tax credit carryforwards. State Research And Development Tax Credit Carryforwards State research and development tax credit carryforwards Performance Shares [Member] Performance-Based Stock Options Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized tax positions, interest and penalties Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of Shares, Vested and expected to vest Number of Shares, Vested and expected to vest Statistical Measurement [Domain] Statistical Measurement Loss Contingencies [Line Items] Loss Contingencies [Line Items] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Schedule of prepaid expenses and other current assets. Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block] Schedule of Prepaid Expenses and Other Current Assets All Award Types Award Type Document Period End Date Document Period End Date Statistical Measurement [Axis] Statistical Measurement Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Operating lease monthly payment Operating Lease, Payments Temporary Equity Conversion of convertible preferred stock to common stock upon closing of initial public offering,Shares Temporary Equity Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering Temporary equity conversion of convertible preferred stock to common stock upon closing of initial public offering. Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share attributable to common stockholders, diluted Deferred Tax Assets, Operating Loss Carryforwards, Domestic Federal net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Total Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, State and Local State net operating loss carryforwards Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Laboratory and office space. Laboratory And Office Space [Member] Laboratory and Office Space Related Party Transaction [Domain] Related Party Transaction Investment Gross Unrealized Losses Investment Unrealized Losses Investment Unrealized Losses Recurring Basis Fair Value, Recurring [Member] Series A preferred stock tranche obligation. Series A Preferred Stock Tranche Obligation [Member] Series A Preferred Stock Tranche Obligation Share-based compensation arrangement by share-based payment award options, vested and exercisable, weighted-average grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Vested and exercisable Weighted-Average Grant Date Fair Value, Vested and exercisable Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Temporary equity Conversion of convertible preferred stock to common stock upon closing of initial public offering,Amount Temporary Equity Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering, Amount Temporary equity conversion of convertible preferred stock to common stock upon closing of initial public offering, amount Deferred Tax Assets, Net Net deferred tax assets (liabilities) Risk-free rate Preferred Stock Tranche Obligation Risk Free Interest Rate Preferred stock tranche obligation risk free interest rate Number of securities in unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Purchase commitment statement of work completed percentage. Purchase Commitment Statement of Work Completed Percentage Purchase commitment statement of work completed percentage Related party antidilution obligation. Related Party Antidilution Obligation [Member] Related Party Antidilution Obligation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Options exercised during period Number of Shares, Exercised Options exercised Liabilities and Equity [Abstract] Liabilities, Convertible Preferred Stock and Stockholders' Equity Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration] Prepaid expenses and other current assets. Prepaid Expenses And Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Private Placement [Member] Private Placement Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, that would impact effective tax rate Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Credit Facility [Domain] Credit Facility Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Equity [Abstract] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Leases, Less: imputed interest Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Exercised Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Equity Components [Axis] Equity Components Local Phone Number Local Phone Number Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Sale of Stock [Axis] Sale of Stock Shares Available for Issuance Under the 2021 Plan Two thousand twenty once stock option and incentive plan. Two Thousand Twenty One Stock Option And Incentive Plan [Member] 2021 Stock Option and Incentive Plan Federal research and development tax credit carryforwards. Federal Research And Development Tax Credit Carryforwards Federal research and development tax credit carryforwards Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table] Statement of Cash Flows [Abstract] Investment Gross Unrealized Gains Investment unrealized gain. Investment Unrealized Gain Effective income tax rate reconciliation other permanent differences. Effective Income Tax Rate Reconciliation Other Permanent Differences Other permanent differences Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Lessee operating lease liability payments due year five and thereafter. Lessee Operating Lease Liability Payments Due Year Five and Thereafter Operating Leases, 2028 and thereafter Common Stock, Par or Stated Value Per Share Common stock, par or stated value per share Federal and state research and development tax credit carryforwards expire period. Federal And State Research And Development Tax Credit Carryforwards Expire Period Federal and state research and development tax credit carryforwards expire period. Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Unrecognized stock-based compensation expense period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Vested and expected to vest Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Maximum [Member] Maximum Credit losses recognized on securities Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Common Stock and Additional Paid-in Capital Common Stock Including Additional Paid in Capital [Member] Proceeds from Issuance of Private Placement Net proceeds from offering Temporary Equity, Shares Outstanding Temporary equity balance, shares Temporary equity balance, shares Temporary equity, shares outstanding Related Party Transaction [Axis] Related Party Transaction Fair Value, Inputs, Level 3 [Member] Level 3 APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Pre-funded warrants. Pre-Funded Warrants [Member] Pre-Funded Warrants Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Payables and Accruals [Abstract] General and Administrative Expense [Member] General and Administrative Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of Shares, Forfeited Leases of Lessee Disclosure [Text Block] Leases Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share City Area Code City Area Code Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Pending tax examinations. Pending Tax Examinations Pending tax examinations Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other Accruals and other Common Stock, Voting Rights Common stock, voting rights Series A convertible preferred stock purchase agreement. Series A Convertible Preferred Stock Purchase Agreement [Member] Series A Convertible Preferred Stock Purchase Agreement Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation General and Administrative Expense, Total General and Administrative Expense General and administrative Temporary Equity, Liquidation Preference Temporary equity, liquidation preference Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding, basic Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Period for cumulative change in ownership. Period For Cumulative Change In Ownership Period for cumulative change in ownership Lease increased annual payments. Lease Increased Annual Payments Lease increased annual payments Statement [Table] Statement [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Document Fiscal Period Focus Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid Operating Leases, Total lease payments Related Party Transactions Disclosure [Text Block] Related Party Transactions Lessee, Operating Lease, Liability, to be Paid, Year Two Operating Leases, 2025 Accrued Professional Fees, Current Professional fees Statement [Line Items] Statement [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share, amount Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Ending balance Beginning balance Lease, Cost, Total Lease, Cost Lease, Cost Subsequent Event [Line Items] Subsequent Event [Line Items] Asset Class [Domain] Asset Class Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of Deferred Income Tax Assets and Liabilities Series B convertible preferred stock. Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock Common Stock [Member] Common Stock Restricted Cash (Non-Current) Restricted cash non-current. Restricted Cash Non Current [Member] Restricted Cash, Noncurrent Unrealized gain (loss) on available for sale securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Purchase price per share Temporary Equity, Par or Stated Value Per Share Temporary equity, par value Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-based Compensation Expense Other Assets, Current Other Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Marketable Securities Marketable Securities [Member] marketable securities. Prepaid rent reclassified to right-of-use assets. Prepaid Rent Reclassified to Right-of-use Assets Prepaid rent reclassified to right-of-use assets Related Party License Agreement Related Party License Agreement Disclosure [Text Block] Related party license agreement disclosure. Cover [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Research and development expense related party. Research And Development Expense Related Party Research and development expense related party Sale of Stock [Domain] Sale of Stock Security Exchange Name Security Exchange Name Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Preferred Stock, Shares Issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Authorized Preferred stock, shares authorized Issuance costs Issuance Costs Issuance costs. Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross Total property and equipment Maximum shares value to be issued under agreement Maximum Stock Value to be Issued under Agreement Maximum gtock value to be issued under agreement. Other assets in accounts payable and accrued expenses Other Assets in Accounts Payable and Accrued Expenses Other assets in accounts payable and accrued expenses. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease liabilities Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Forfeited Financial Instrument [Axis] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Cumulative change in ownership percentage. Cumulative Change In Ownership Percentage Cumulative change in ownership percentage Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Entity Emerging Growth Company Entity Emerging Growth Company Convertible Preferred Stock, Shares Issued upon Conversion Issuance of convertible preference shares Amendment Flag Amendment Flag Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses and Other Current Liabilities Marketable Securities, Current Marketable securities IPO [Member] Initial Public Offering (IPO) Issuance of convertible preferred stock with fair value. Issuance Of Convertible Preferred Stock With Fair Value Issuance of convertible preferred stock with fair value Amgen Inc. Amgen Inc [Member] Amgen, Inc. Equity Method Investment, Ownership Percentage Ownership percentage of outstanding shares of capital stock Variable Lease, Payment Variable lease expense State net operating loss carryforwards expire period. State Net Operating Loss Carryforwards Expire Period State net operating loss carryforwards expire period Leases [Abstract] Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Warrants exercised US Government Debt Securities [Member] Available for sale securities (U.S. government securities) U.S. Government Securities Non cash operating lease expense. Non Cash Operating Lease Expense Non-cash operating lease expense Securities Act File Number Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Line of Credit Facility, Expiration Date Letter of credit expiration date Deferred Tax Assets, Gross Total deferred tax assets Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Operating Leases, 2023 Finance Lease, Weighted Average Discount Rate, Percent Finance lease, weighted-average discount rate Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Aggregate Intrinsic Value, Vested and exercisable Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total cash, cash equivalents and restricted cash Probability of meeting Series A milestones Probability of meeting milestones Probability of meeting milestones. Cash Equivalents (Money Market) Cash Equivalents [Member] Cash Equivalents Share-Based Payment Arrangement [Abstract] Total Accrued expenses and other current liabilities Accrued expenses and other current liabilities. Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Options to purchase common stock performance based. Options To Purchase Common Stock Performance Based [Member] Options to Purchase Common Stock – Performance Based Deferred Tax Assets, Valuation Allowance, Total Deferred Tax Assets, Valuation Allowance Valuation allowance Less valuation allowance Line of credit facility renewed expiration date1. Line Of Credit Facility Renewed Expiration Date1 Renewed to expire date Operating Expenses Total operating expenses Debt and Equity Securities, Realized Gain (Loss), Total Debt and Equity Securities, Realized Gain (Loss) Realized gain or losses on marketable securities Total Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Entity Address, Address Line Two Entity Address, Address Line Two Deferred Tax Assets, Goodwill and Intangible Assets Intangible assets Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 0 share issued and outstanding at June 30, 2023 and December 31, 2022, respectively Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Investment Type [Axis] Sales Agreement Sales Agreement [Member] Sales agreement. Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price per share Unrecognized stock-based compensation expense related to unvested restricted stock not recognized Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Conversion of Series A & Series B Preferred Stock to common stock, net of Issuance costs Conversion of Stock, Amount Issued Certificates of Deposit [Member] Certificate of Deposit Earnings Per Share [Text Block] Net Loss per Share Entity Address, Address Line One Entity Address, Address Line One Cash, cash equivalents and marketable securities. Cash Cash Equivalents and Marketable Securities Cash, cash equivalents and marketable securities Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Antidilutive Securities [Axis] Antidilutive Securities Prepaid research and development expense current. Prepaid Research And Development Expense Current Research and development Other liabillities, current Other Liabilities, Current Subsequent Event Type [Domain] Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards Schedule of Stock by Class [Table Text Block] Income Statement Location [Axis] Income Statement Location Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Stock-based compensation fair value assumptions, expected dividend yield Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Business insurance Prepaid Insurance Increase decrease in accrued expenses and other current liabilities. Increase Decrease In Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Long-Term Purchase Commitment, Amount Purchase commitment fee Fair Value, Inputs, Level 2 [Member] Level 2 Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Number of shares issued Share Price Fair value of common stock Construction related prepaid assets current. Construction Related Prepaid Assets Current Construction related prepaid assets Title of 12(b) Security Title of 12(b) Security Temporary Equity, Carrying Amount, Attributable to Parent Temporary equity, balance Temporary equity, balance Convertible preferred stock Operating lease commencement month and year. Operating Lease Commencement Month And Year Operating lease commencement month and year Investments [Domain] Leaseholds and Leasehold Improvements [Member] Leasehold Improvements Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Schedule Of Future Minimum Lease Payments Due Under Operating And Finance Lease Liabilities Table [Text Block] Schedule of future minimum lease payments due under operating and finance lease liabilities. Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities Letter of credit Long-term Line of Credit, Total Long-Term Line of Credit Contract manufacturing costs Contract Manufacturing Costs Contract manufacturing costs. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Subsequent Event [Table] Subsequent Event [Table] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Change in fair value of the related party antidilution obligation Change In Fair Value Of Related Party Antidilution Obligation Change in fair value of related party antidilution obligation. Percentage of capital stock to issue temporary equity. Percentage Of Capital Stock To Issue Temporary Equity Percentage of capital stock to issue temporary equity Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Defined Contribution Plan, Employer Discretionary Contribution Amount Discretionary and contributions amount Beginning balance, Shares Ending balance shares Common Stock, Shares, Outstanding Common stock, shares, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free rate Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Income Statement Location [Domain] Income Statement Location Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Granted Lease monthly payment. Lease Monthly Payment Lease monthly payment Document Type Document Type Convertible Preferred stock converted to common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Stock issued during period, shares, conversion of convertible securities Preferred stock tranche obligation classified as liability and recorded at fair value Preferred Stock Tranche Obligation Classified as Liability and Recorded at Fair Value Preferred Stock Tranche Obligation classified as liability and recorded at fair value. Risk-free rate Related Party Antidilution Obligation Risk Free Interest Rate Related party antidilution obligation risk free interest rate. Fair Value by Liability Class [Domain] Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Document Quarterly Report Document Quarterly Report Counterparty Name [Domain] Lease security deposit Security Deposit Shares Available for Issuance Under the 2021 ESPP Two thousand twenty one employee stock purchase plan. Two Thousand Twenty One Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited/cancelled Net Cash Provided by (Used in) Financing Activities Net cash proceeds from financing activities Net cash provided by financing activities Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Increase in common stock reserved Entity Filer Category Entity Filer Category Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing and financing activities: Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Expired Balance Sheet Location [Domain] Balance Sheet Location Other non-current assets Increase (Decrease) in Other Noncurrent Assets Computer software and equipment. Computer Software And Equipment [Member] Computer Software and Equipment Deferred tax liabilities depreciation. Deferred Tax Liabilities Depreciation Depreciation Payments to Acquire Marketable Securities Purchases of marketable securities Purchases of marketable securities Asset Class [Axis] Asset Class Nonoperating Income (Expense) Total other expense, net Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Liabilities Total liabilities Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Equity, Attributable to Parent Balance Balance Total stockholders' equity Probability of finance event occurring Related Party Antidilution Obligation Probability of Finance Event Occurring Percentage Related party antidilution obligation probability of finance event occurring percentage. Net Income (Loss) Net loss Net loss Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Research and development credits Nonoperating Income (Expense) [Abstract] Other income (expense): Standby Letters of Credit [Member] Standby Letter of Credit Business Description and Basis of Presentation [Text Block] Nature of the Business and Basis of Presentation Proceeds from Issuance Initial Public Offering Net proceeds from issuance initial public offering Security Owned and Sold, Not yet Purchased Fair Value, Security Name [Domain] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State income taxes (NoFB) Corporate Bonds Corporate Debt Securities [Member] Preferred Stock [Text Block] Preferred Stock Statement of Financial Position [Abstract] Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding, diluted Weighted-average common shares outstanding, diluted Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of Effective Income Tax Rate Differs from Statutory Federal Income Tax Rate Credit Facility [Axis] Credit Facility Common stock issued, price per share Issuance Price per share Shares Issued, Price Per Share Effective Income Tax Rate Reconciliation, Percent Effective Tax Rate Operating Lease, Weighted Average Remaining Lease Term Operating lease, weighted-average remaining lease term Use of Estimates, Policy [Policy Text Block] Use of Estimates Deferred tax liabilities right of use asset. Deferred Tax Liabilities Right Of Use Asset Right-of-use asset Income Tax Disclosure [Text Block] Income Taxes Security Owned and Sold, Not yet Purchased, at Fair Value [Axis] Long-Term Purchase Commitment, Period Purchase commitment period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Outstanding Weighted-Average Exercise Price Per Share, Outstanding Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Percentage of cumulative number of shares issued and outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Measurement Frequency [Domain] Measurement Frequency Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment included in accounts payable and accrued expenses Purchases of property and equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested during period Common stock issued Stock Issued During Period, Shares, New Issues Issuance of convertible preferred stock, net of issuance costs, shares Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Payroll and employee related Operating Lease, Expense Non-cash operating lease expense Operating lease expense Share purchase price per pre funded warrant. Share Purchase Price Per Pre funded Warrant Share purchase price per pre funded warrant Proceeds from maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Income Tax Disclosure [Abstract] EX-101.CAL 10 vigl-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2023
Jul. 31, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Registrant Name VIGIL NEUROSCIENCE, INC.  
Entity Central Index Key 0001827087  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol VIGL  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   35,873,421
Entity Shell Company false  
Entity File Number 001-41200  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1880494  
Entity Address, Address Line One 100 Forge Road,  
Entity Address, Address Line Two Suite 700  
Entity Address, City or Town Watertown  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02472  
City Area Code 857  
Local Phone Number 254-4445  
Document Quarterly Report true  
Document Transition Report false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Current assets:      
Cash and cash equivalents $ 58,741   $ 186,605
Marketable securities 91,423    
Prepaid expenses and other current assets 5,555   11,200
Total current assets 155,719   197,805
Property and equipment, net 1,898   1,184
Operating lease right-of-use assets 16,805   141
Financing lease right-of-use assets 60   70
Restricted cash 927   927
Other assets     266
Total assets 175,409   200,393
Current liabilities:      
Accounts payable 2,362   1,942
Accrued expenses and other current liabilities [1] 5,001   9,194
Operating lease liabilities 802   153
Financing lease liabilities 2   23
Total current liabilities 8,167   11,312
Operating lease liabilities, net of current portion 13,406    
Total liabilities 21,573   11,312
Commitments and contingencies (Note 12)  
Stockholders' equity:      
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 0 share issued and outstanding at June 30, 2023 and December 31, 2022, respectively  
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2023 and December 31, 2022; 35,906,037 shares issued as of June 30, 2023 and 35,664,658 shares issued as of December 31, 2022; and 35,861,714 shares outstanding as of June 30, 2023 and 35,620,335 shares outstanding as of December 31, 2022 4   4
Additional paid-in capital 334,005   329,211
Accumulated other comprehensive income (loss) (70)    
Accumulated deficit (180,103)   (140,134)
Total stockholders' equity 153,836 $ 171,340 189,081
Total liabilities and stockholders' equity $ 175,409   $ 200,393
[1] Includes related party amounts of $0 (accrued expenses and other current liabilities) at June 30, 2023; $78 (accrued expenses and other current liabilities) at December 31, 2022 (see Note 11).
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Preferred Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common stock, par or stated value per share $ 0.0001 $ 0.0001
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares, issued 35,906,037 35,664,658
Common stock, shares, outstanding 35,861,714 35,620,335
Accrued Expenses and Other Current Liabilities    
Other liabillities, current $ 0 $ 78
Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration] us-gaap:RelatedPartyMember us-gaap:RelatedPartyMember
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
Research and development [1] $ 14,903 $ 12,097 $ 28,737 $ 22,462
General and administrative 7,010 4,945 13,951 9,912
Total operating expenses 21,913 17,042 42,688 32,374
Loss from operations (21,913) (17,042) (42,688) (32,374)
Other income (expense):        
Interest income, net 1,746 32 2,731 34
Other income (expense), net (7) (5) (12) (9)
Total other expense, net 1,739 27 2,719 25
Net loss $ (20,174) $ (17,015) $ (39,969) $ (32,349)
Net loss per share attributable to common stockholders, basic $ (0.52) $ (0.6) $ (1.04) $ (1.18)
Net loss per share attributable to common stockholders, diluted $ (0.52) $ (0.6) $ (1.04) $ (1.18)
Weighted-average common shares outstanding, basic 38,657,205 28,150,051 38,601,916 27,409,264
Weighted-average common shares outstanding, diluted 38,657,205 28,150,051 38,601,916 27,409,264
Comprehensive loss:        
Net loss $ (20,174) $ (17,015) $ (39,969) $ (32,349)
Unrealized gain (loss) on available for sale securities (176)   (70)  
Total comprehensive loss $ (20,350) $ (17,015) $ (40,039) $ (32,349)
[1] Includes related party amounts of $7 and $50 for the three and six months ended June 30, 2023, and $75 and $142 for the three and six months ended June 30, 2022 (see Note 11).
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Research and development expense related party $ 7 $ 75 $ 50 $ 142
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Initial Public Offering (IPO)
Initial Public Offering (IPO)
Convertible Preferred Stock
Initial Public Offering (IPO)
Common Stock
Initial Public Offering (IPO)
Additional Paid-In Capital
Balance at Dec. 31, 2021 $ (69,443)     $ 2,386   $ (71,829)        
Temporary equity balance, shares at Dec. 31, 2021   54,179,688                
Temporary equity, balance at Dec. 31, 2021   $ 161,939                
Beginning balance, Shares at Dec. 31, 2021     1,724,950              
Temporary Equity Conversion of convertible preferred stock to common stock upon closing of initial public offering,Shares               (54,179,688)    
Conversion of convertible preferred stock to common stock upon closing of initial public offering,shares                 19,536,870  
Temporary equity Conversion of convertible preferred stock to common stock upon closing of initial public offering,Amount               $ (161,939)    
Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering,Amount             $ 161,939   $ 2 $ 161,937
Issuance of convertible preferred stock, net of issuance costs             $ 87,986   $ 1 $ 87,985
Issuance of convertible preferred stock, net of issuance costs, shares                 7,000,000  
Exercise of stock options 9     9            
Options exercised     4,995              
Stock-based compensation expense 1,021     1,021            
Net loss (15,334)         (15,334)        
Balance at Mar. 31, 2022 166,178   $ 3 253,338   (87,163)        
Ending balance shares at Mar. 31, 2022     28,266,815              
Balance at Dec. 31, 2021 (69,443)     2,386   (71,829)        
Temporary equity balance, shares at Dec. 31, 2021   54,179,688                
Temporary equity, balance at Dec. 31, 2021   $ 161,939                
Beginning balance, Shares at Dec. 31, 2021     1,724,950              
Net loss (32,349)                  
Balance at Jun. 30, 2022 150,626   $ 3 254,801   (104,178)        
Ending balance shares at Jun. 30, 2022     28,267,614              
Balance at Mar. 31, 2022 166,178   $ 3 253,338   (87,163)        
Beginning balance, Shares at Mar. 31, 2022     28,266,815              
Exercise of stock options 2     2            
Options exercised     799              
Stock-based compensation expense 1,461     1,461            
Net loss (17,015)         (17,015)        
Balance at Jun. 30, 2022 150,626   $ 3 254,801   (104,178)        
Ending balance shares at Jun. 30, 2022     28,267,614              
Balance at Dec. 31, 2022 $ 189,081   $ 4 329,211   (140,134)        
Beginning balance, Shares at Dec. 31, 2022 35,620,335   35,620,335              
Exercise of stock options $ 214     214            
Options exercised     45,449              
Stock-based compensation expense 1,734     1,734            
Unrealized gain (loss) on available for sale securities 106       $ 106          
Net loss (19,795)         (19,795)        
Balance at Mar. 31, 2023 171,340   $ 4 331,159 106 (159,929)        
Ending balance shares at Mar. 31, 2023     35,665,784              
Balance at Dec. 31, 2022 $ 189,081   $ 4 329,211   (140,134)        
Beginning balance, Shares at Dec. 31, 2022 35,620,335   35,620,335              
Net loss $ (39,969)                  
Balance at Jun. 30, 2023 $ 153,836   $ 4 334,005 (70) (180,103)        
Ending balance shares at Jun. 30, 2023 35,861,714   35,861,714              
Balance at Mar. 31, 2023 $ 171,340   $ 4 331,159 106 (159,929)        
Beginning balance, Shares at Mar. 31, 2023     35,665,784              
Exercise of stock options 589     589            
Options exercised     195,930              
Stock-based compensation expense 2,257     2,257            
Unrealized gain (loss) on available for sale securities (176)       (176)          
Net loss (20,174)         (20,174)        
Balance at Jun. 30, 2023 $ 153,836   $ 4 $ 334,005 $ (70) $ (180,103)        
Ending balance shares at Jun. 30, 2023 35,861,714   35,861,714              
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited)
$ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
Stock issuance costs $ 10.0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (39,969) $ (32,349)
Adjustments to reconcile net loss to net cash used by operating activities:    
Stock-based compensation expense 3,991 2,482
Non-cash operating lease expense 681 447
Depreciation and amortization 176 36
Amortization of premium/discount on marketable securities (1,000)  
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 2,593 (235)
Other non-current assets   789
Accounts payable 419 (2,390)
Accrued expenses and other current liabilities (4,193) (473)
Operating lease liabilities (237) (444)
Net cash used in operating activities (37,539) (32,137)
Cash flows from investing activities:    
Purchases of marketable securities (102,493)  
Proceeds from maturities of marketable securities 12,000  
Purchases of property and equipment (614) (233)
Net cash used in investing activities (91,107) (233)
Cash flows from financing activities:    
Proceeds from issuance of common stock upon initial public offering, net of offering costs   89,872
Payments of finance lease obligations (21) (21)
Proceeds from stock option exercised 803 11
Net cash provided by financing activities 782 89,862
Net increase in cash and cash equivalents (127,864) 57,492
Cash, cash equivalents and restricted cash at beginning of period 187,532 92,347
Cash, cash equivalents and restricted cash at end of period 59,668 149,839
Supplemental disclosure of non-cash investing and financing activities:    
Conversion of Series A & Series B Preferred Stock to common stock, net of Issuance costs   161,939
Deferred offering costs paid in the prior year   1,887
Right-of-use assets obtained in exchange for operating lease liabilities 14,292 77
Prepaid rent reclassified to right-of-use assets $ 2,887  
Purchases of property and equipment included in accounts payable and accrued expenses   $ 129
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of the Business and Basis of Presentation
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation

1. Nature of the Business and Basis of Presentation

Vigil Neuroscience, Inc., together with its consolidated subsidiary, Vigil Neuroscience Security Corporation (“Vigil” or the “Company”), is a clinical-stage, microglia-focused biotechnology company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia, the sentinel immune cells of the brain. The Company’s initial focus is on developing a pipeline of therapeutic candidates that it believes will activate and restore microglia function, with an initial focus in genetically defined subpopulations. The Company was incorporated in the State of Delaware in June 2020 and is located in Watertown, Massachusetts.

The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical studies and clinical trials, the ability to raise additional capital to fund operations, obtaining regulatory approval for therapeutic candidates, market acceptance of products, competition from substitute products, protection of proprietary intellectual property, compliance with government regulations, dependence on key personnel, reliance on third-party organizations and the clinical and commercial success of its therapeutic candidates. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

Liquidity

The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of June 30, 2023, the Company had cash, cash equivalents, and marketable securities of $150.2 million and an accumulated deficit of $180.1 million. In January 2022, the Company completed its initial public offering (“IPO”) of its common stock which resulted in net proceeds of $88.0 million. In August 2022, the Company completed a private placement financing, which resulted in net proceeds of $71.3 million. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its cash and cash equivalents will be sufficient to fund current operations for at least the next twelve months from the issuance of these condensed consolidated financial statements.

On March 21, 2023, the Company entered into an Open Market Sales Agreement, or the Sales Agreement, with Jefferies LLC, or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $100.0 million of shares of its common stock, through the Agent, as its sales agent. As of August 7, 2023, no shares were sold under the Sales Agreement.

The Company expects to seek additional funding through equity financings, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company’s stockholders.

If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

The condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Basis of Presentation

The accompanying condensed consolidated financial statements reflect the operations of the Company are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended

December 31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 21, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.

The accompanying condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary. Intercompany balances and transactions have been eliminated in consolidation.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company's significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022, and notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 21, 2023, or the 2022 Form 10-K. Since the date of those financial statements, there have been no material changes to Vigil’s significant accounting policies except as noted below.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities when purchased of three months or less that are readily convertible to known amounts of cash to be cash equivalents. The carrying values of these instruments approximate their respective fair value due to the short-term maturity of these investments. At June 30, 2023 and December 31, 2022, the Company’s cash equivalents were in money market funds and government securities. As of each balance sheet date and periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits.

In connection with the Company’s lease agreement entered into in September 2021 (see Note 12), the Company is required to maintain a certificate of deposit (“CD”) of $0.9 million for the benefit of the landlord.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):

 

 

June 30, 2023

 

 

June 30, 2022

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

58,741

 

 

$

148,912

 

Restricted cash, non-current

 

 

927

 

 

 

927

 

Total cash, cash equivalents and restricted cash

 

$

59,668

 

 

$

149,839

 

 

Marketable securities

Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders’ equity in other comprehensive income. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company’s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even if the stated maturity of some individual securities may be one year or more beyond the balance sheet date.

The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be “other than temporary”, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company qualifies as an ‘‘emerging growth company’’ as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to ‘‘opt out’’ of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to ‘‘opt out’’ of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies.

In August 2020, the FASB issued ASU No. 2020-06, Debt, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. The ASU also simplifies the accounting for convertible instruments by removing the beneficial conversion feature and cash conversion feature separation models. This ASU may be applied on a full retrospective or modified retrospective basis. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and all other public entities, this ASU is effective for fiscal years beginning after December 15, 2021. Early adoption permitted. The Company expects to adopt this ASU in fiscal year 2024. The Company does not currently expect the adoption to materially impact its financial position and results of operations.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Financial Instruments
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements and Financial Instruments

3. Fair Value Measurements and Financial Instruments

The following table presents the Company’s fair value hierarchy for its asset items that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, by level within the fair value hierarchy (in thousands):

 

 

Fair Value Measurement at June 30, 2023 Using:

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

50,702

 

 

$

 

 

$

 

 

$

50,702

 

Corporate bonds

 

 

 

 

 

2,589

 

 

 

 

 

 

2,589

 

Total cash equivalents

 

$

50,702

 

 

$

2,589

 

 

$

 

 

$

53,291

 

Marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government securities

 

 

 

 

 

76,584

 

 

 

 

 

 

76,584

 

Corporate bonds

 

 

 

 

 

14,839

 

 

 

 

 

 

14,839

 

Total marketable securities

 

$

 

 

$

91,423

 

 

$

 

 

$

91,423

 

Restricted cash (non-current)

 

 

927

 

 

 

 

 

 

 

 

 

927

 

Total

 

$

51,629

 

 

$

94,012

 

 

$

 

 

$

145,641

 

 

 

Fair Value Measurement at December 31, 2022 Using:

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents (money market)

 

$

156,219

 

 

$

 

 

$

 

 

$

156,219

 

Restricted cash (non-current)

 

 

927

 

 

 

 

 

 

 

 

 

927

 

Total

 

$

157,146

 

 

$

 

 

$

 

 

$

157,146

 

 

Marketable securities

The following table summarizes the Company’s marketable securities as of June 30, 2023 (in thousands):

 

 

 

At June 30, 2023

 

 

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Value

 

U.S. government securities

 

$

76,634

 

 

$

2

 

 

$

(52

)

 

$

76,584

 

Corporate bonds

 

$

14,859

 

 

$

4

 

 

$

(24

)

 

$

14,839

 

Total

 

$

91,493

 

 

$

6

 

 

$

(76

)

 

$

91,423

 

 

The following table summarizes the Company’s marketable securities by maturity as of June 30, 2023 (in thousands):

 

 

At June 30, 2023

 

Maturities in one year or less

 

$

86,107

 

Maturities between one and two years

 

 

5,316

 

Total

 

$

91,423

 

 

As of June 30, 2023, the Company held 33 securities, 29 of which were in an unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company evaluated its securities for potential other-than-temporary impairment and considered the decline in market value to be primarily attributable to current economic and market conditions. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. Given the Company's intent and ability to hold such securities until recovery, and the lack of a significant change in credit risk for these investments, the Company does not consider these investments to be impaired as of June 30, 2023. The Company did not recognize any credit losses during the three and six months ended June 30, 2023 and 2022. Additionally, there were no realized gains or losses on marketable securities for the three and six months ended June 30, 2023 and 2022.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Prepaid Expense and Other Current Assets
6 Months Ended
Jun. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]  
Prepaid Expenses and Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

June 30,
2023

 

 

December 31,
2022

 

Research and development

 

$

3,615

 

 

$

6,670

 

Construction related prepaid assets

 

 

 

 

 

3,769

 

Business insurance

 

 

762

 

 

 

133

 

Other

 

 

1,178

 

 

 

628

 

Total

 

$

5,555

 

 

$

11,200

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

June 30,
2023

 

 

December 31,
2022

 

Payroll and employee related

 

$

2,154

 

 

$

3,512

 

Research and development

 

 

1,621

 

 

 

2,894

 

Professional fees

 

 

931

 

 

 

986

 

Construction related

 

 

78

 

 

 

1,416

 

Other

 

 

217

 

 

 

386

 

Total

 

$

5,001

 

 

$

9,194

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

6. Stock-Based Compensation

2020 Equity Incentive Plan

The Company's 2020 Equity Incentive Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. As of June 30, 2023, there were 2,508,398 options outstanding under the 2020 Plan.

2021 Stock Option and Incentive Plan

The Company's 2021 Stock Option and Incentive Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. On January 1, 2023, the shares reserved for future grants under the 2021 Plan increased by 1,781,017 pursuant to the 2021 Plan Evergreen Provision. In March of 2023, as part of the Company's annual grant of equity, the Company granted 1,348,380 stock options to employees. As of June 30, 2023, there were 3,252,644 options outstanding under the 2021 Plan.

2021 Employee Stock Purchase Plan

The Company's 2021 Employee Stock Purchase Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. On January 1, 2023, the shares reserved for future grants under the 2021 ESPP increased by 286,127 pursuant to the 2021 Plan Evergreen Provision. As of June 30, 2023, a total of 572,254 shares of common stock were reserved for issuance under this plan. No stock-based compensation expense was recognized during the three and six months ended June 30, 2023 related to the 2021 ESPP.

Stock-Based Compensation Expense

The Company recorded stock-based compensation expense of $2.3 million and $4.0 million during the three and six months ended June 30, 2023, respectively, and recorded $1.5 million and $2.5 million during the three and six months ended June 30, 2022, respectively. Stock-based compensation expense was classified as follows in the condensed consolidated statements of operations and comprehensive loss (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

891

 

 

$

608

 

 

$

1,577

 

 

$

1,049

 

General and administrative

 

 

1,366

 

 

 

853

 

 

 

2,414

 

 

 

1,433

 

Total stock-based compensation

 

$

2,257

 

 

$

1,461

 

 

$

3,991

 

 

$

2,482

 

 

At June 30, 2023, there was approximately $24.8 million unrecognized stock-based compensation expense related to unvested options, which is expected to be recognized over a weighted-average period of 2.78 years. At June 30, 2023, there was approximately $0.1 million unrecognized stock-based compensation expense related to unvested restricted stock, which is expected to be recognized over a weighted-average period of 0.84 years.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Preferred Stock
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Preferred Stock

7. Preferred Stock

Convertible Preferred Stock

The Series A preferred stock and Series B preferred stock, described in more detail below, converted into 10,285,077 shares and 9,251,793 shares of common stock in January 2022 as part of our IPO.

Series A Convertible Preferred Stock and Series A Preferred Stock Tranche Obligation

On September 18, 2020, the Company entered into the Series A Convertible Preferred Stock Purchase Agreement with its initial investors committing to purchase an aggregate of $50.0 million in shares of Series A convertible preferred stock. At the initial closing, 9,815,467 shares of Series A convertible preferred stock were issued by the Company at a purchase price of $2.547 per share, for gross cash proceeds of $25.0 million. The gross proceeds were offset by $0.2 million of issuance costs and $0.2 million related to the Series A Preferred Stock Tranche Obligation, discussed below.

Included in the terms of the September 2020 Series A Convertible Preferred Stock Purchase Agreement were certain rights (“Series A Preferred Stock Tranche Obligation”) granted to the investors who purchased the Series A convertible preferred stock in September 2020. The Series A Preferred Stock Tranche Obligation contingently obligated the investors to purchase, and the Company to sell, up to an aggregate of 7,852,373 shares of Series A convertible preferred stock at $2.547 per share upon the satisfaction of specified research and development milestones by the Company.

The Company concluded that the Series A Preferred Stock Tranche Obligation met the definition of a freestanding financial instrument, as the Series A Preferred Stock Tranche Obligation was legally detachable and separately exercisable from the Series A convertible preferred stock. Therefore, the Company allocated the proceeds from the September 2020 issuance between the Series A Preferred Stock Tranche Obligation and the Series A convertible preferred stock, including those issued in exchange for the SAFE. As the Series A convertible preferred stock is redeemable upon a deemed liquidation event at the election of the holder-controlled Board, and therefore outside of the control of the Company, the Series A Preferred Stock Tranche Obligation was classified as a liability and recorded at its fair value of $0.3 million at both inception and as of December 31, 2020. The Series A Preferred Stock Tranche Obligation was remeasured at fair value at each reporting period, with changes in fair value recorded in change in fair value of the Series A Preferred Stock Tranche Obligation in the condensed consolidated statements of operations and comprehensive loss (see Note 3).

On May 28, 2021, the Company issued 7,852,373 shares of its Series A convertible preferred stock at $2.547 per share, for which the Company received gross proceeds of $20.0 million, offset by issuance costs of $0.1 million. As a result of this issuance, the Series A Preferred Stock Tranche Obligation with a then fair value of approximately $0.3 million was settled and reclassified to Series A convertible preferred stock in the consolidated balance sheet.

Series B Convertible Preferred Stock Financing

On August 13, 2021, the Company issued 25,657,096 shares of its Series B convertible preferred stock at $3.5078 per share, for which the Company received gross proceeds of $90.0 million. Issuance costs were $0.4 million.

Upon issuance of each class of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed upon the issuance date of each class of the Convertible Preferred Stock or as of June 30, 2023 and December 31, 2022.

The holders of Convertible Preferred Stock had the followings rights and privileges:

Conversion

The holders of the Convertible Preferred Stock may convert, at any time, each share of the Convertible Preferred Stock into shares of common stock. In addition, upon either (a) the closing of the sale of shares of common stock to the public at a price of at least three times the Series A Original Issue Price (subject to adjustment) in an initial public offering with net proceeds to the Company of at least $50.0 million or (b) the written consent of the holders of the outstanding shares of Convertible Preferred Stock, the Convertible Preferred Stock will automatically convert into common stock.

The conversion ratio of each series of the Convertible Preferred Stock is determined by dividing the Original Issuance Price of each series by the Conversion Price of each series. The Original Issuance Price per share is $2.547 for Series A convertible preferred stock and $3.5078 for Series B convertible preferred stock. The Conversion Price per share at issuance was $7.063 for Series A convertible preferred stock and $9.7278 for Series B convertible preferred stock, each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, including adjustment if common stock is issued for less than the Original Issue Price of each series of Convertible Preferred Stock.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Common Stock

8. Common Stock

Each share of common stock entitles the holder to one vote for each share of common stock held. Common stockholders are entitled to receive dividends, as may be declared by the Company’s Board. During each of the three and six months ended June 30, 2023 and the three and six months ended June 30, 2022, no dividends have been declared or paid.

Pre-funded Warrants

In connection with the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 2,980,889 shares of common stock at a purchase price of $7.2999 per pre-funded warrant. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share of common stock, is immediately exercisable and will remain exercisable until exercised in full. The pre-funded warrants have no expiration date and the price of the pre-funded warrants does not include any discounts. The Company evaluated the pre-funded warrants for liability or equity classification in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the pre-funded warrants did not meet the definition of liability instruments and met the criteria for permanent equity. As of June 30, 2023, no pre-funded warrants were exercised.

The Company has reserved the following number of shares of common stock for the exercise of outstanding stock options and future issuance of stock-based awards.

 

 

June 30,
2023

 

 

December 31,
2022

 

Common stock options

 

 

5,761,042

 

 

 

4,440,811

 

Pre-funded warrants

 

 

2,980,889

 

 

 

2,980,889

 

Shares available for issuance under the 2021 Plan

 

 

1,673,053

 

 

 

1,682,909

 

Shares available for issuance under the 2021 ESPP

 

 

572,254

 

 

 

286,127

 

Total common stock reserved for future issuance

 

 

10,987,238

 

 

 

9,390,736

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Net Loss per Share

9. Net Loss per Share

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(20,174

)

 

$

(17,015

)

 

$

(39,969

)

 

$

(32,349

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic and diluted

 

 

38,657,205

 

 

 

28,150,051

 

 

 

38,601,916

 

 

 

27,409,264

 

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.52

)

 

$

(0.60

)

 

$

(1.04

)

 

$

(1.18

)

 

The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per common share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per common share for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

As of June 30,

 

 

2023

 

 

2022

 

Options to purchase common stock – service based

 

 

5,550,413

 

 

 

4,162,669

 

Options to purchase common stock – performance based

 

 

210,629

 

 

 

210,629

 

Unvested restricted common stock

 

 

53,715

 

 

 

112,311

 

Total

 

 

5,814,757

 

 

 

4,485,609

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Leases
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Leases

10. Leases

In February 2021, the Company entered into an equipment lease with lease term of 24 months with rent commencing in the third quarter of 2021. The lease includes an option to purchase the equipment at fair market value at the end of the lease term. The Company has notified the vendor of its intent to exercise the purchase option.

In July 2021, the Company entered into a lease for laboratory space in Cambridge, Massachusetts, with an initial term of one year commencing in April 2021, with a month-to-month option to renew at the end of the initial lease term. At inception, the Company determined that it was reasonably certain that it would elect options to renew the lease through September 2022 and have included these renewal options into the initial determination of the lease term. In 2022, the Company further extended the lease term through February 28, 2023 and terminated the lease as of February 28, 2023 due to the Company's move to Watertown, Massachusetts as noted below.

In October 2021, the Company entered into a lease for its corporate headquarters in Cambridge, Massachusetts with an initial term of 14 months. In 2022, the Company extended the lease through January 31, 2023 and terminated the lease as of January 31, 2023 due to the Company's move to Watertown, Massachusetts as noted below. The lease payments during both the three and six months ended June 30, 2023 was $74 thousand. The Company received their security deposit of approximately $49 thousand in the second quarter of 2023.

Watertown, MA Lease

In September 2021, the Company entered into a lease for laboratory and office space in Watertown, Massachusetts with an initial term of ten years from the rent commencement date of December 2022, and a five-year renewal option. The lease commenced for accounting purposes in the January 2023 when the leased space was made available for the Company’s use. As of the lease commencement date, the Company has determined that it is not reasonably certain to exercise the option to extend the lease and has not included the extension period in the lease term. The monthly lease payment is approximately $0.2 million with annual escalation of approximately 3%. The lease includes a $3.7 million construction allowance. At the lease commencement date, the Company recorded an initial lease liability of $14.3 million and a right-of-use asset of $17.3 million. The components of lease expense for the three and six months ended June 30, 2023 were $0.6 million and $1.1 million in operating lease expense, respectively, and $0.2 million and $0.4 million in variable lease expense, respectively. Variable lease expense generally includes common area maintenance, property taxes, and utilities.

At June 30, 2023, the weighted-average remaining lease terms related to the finance and operating leases are 0.1 years and 9.4 years, respectively.

The weighted-average discount rates used at the time that the leases were evaluated were 5.14% for the finance leases and 7.55% for the operating leases that were still active as of June 30, 2023.

The Watertown lease began in January 2023, with minimum base rent payments ranging from $1.9 million annually and increasing to $2.1 million annually over the next 5 years. Future minimum lease payments due under the Company’s operating and finance lease liabilities as of June 30, 2023 are as follows:

 

 

 

Operating
Leases

 

 

Financing
Leases

 

2023

 

 

886

 

 

 

2

 

2024

 

 

1,910

 

 

 

 

2025

 

 

1,968

 

 

 

 

2026

 

 

2,027

 

 

 

 

2027

 

 

2,088

 

 

 

 

2028 and thereafter

 

 

11,269

 

 

 

 

Total lease payments

 

 

20,148

 

 

 

2

 

Less: imputed interest

 

 

(5,940

)

 

 

 

Total future minimum lease payments

 

$

14,208

 

 

$

2

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

11. Related Party Transactions

Atlas

The Company entered into various lease agreements with Atlas Venture Fund XII, L.P., a principal stockholder of the Company, and incurred lease costs of $50 thousand for the six months ended June 30, 2023, and $142 thousand for the six months ended June 30, 2022. The lease payments are included in general and administrative expenses for office space and research and development expenses for lab space in the condensed consolidated statements of operations and comprehensive loss. The Company terminated the lease for the laboratory space as of February 28, 2023 due to the Company's move to Watertown, Massachusetts, and therefore had no operating lease right-of-use asset or lease liability recorded as of June 30, 2023. As of June 30, 2023, the Company has no costs in accrued expenses associated with the leases.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

12. Commitments and Contingencies

License Agreement

The Company has a license agreement with Amgen (see Note 12 to the consolidated financial statements of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022).

Letter of Credit

In September 2021, in connection with the Watertown, Massachusetts lease, the Company entered into a $0.9 million standby letter of credit which initially expired on September 10, 2022 and was renewed to expire on September 11, 2023. The standby letter of credit will automatically renew for subsequent annual periods through December 2032. Remittance of funds from the letter of credit was not probable and the full amount was available as of June 30, 2023. The Company did not recognize a liability in the condensed consolidated balance sheet.

Purchase Commitment

In November 2021, the Company entered into a statement of work ("SOW") with FUJIFILM Diosynth Biotechnologies Texas, LLC for $3.8 million under its existing master services agreement for the manufacturing of VGL101. If the Company terminates the SOW before completion, it may be required to pay fees ranging from 0% to 100%. The amount due upon an early termination depends on the length of time prior to the commencement of specific stages of the SOW. The SOW is expected to incur costs over approximately 2 years. As of June 30, 2023, approximately 56% of work has been completed on this SOW.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenses will be incurred and can be reasonably estimated. As of June 30, 2023, the Company does not have any significant legal disputes that require a loss liability to be recorded.

401(k) Plan

The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code of 1986 (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions are discretionary and contributions in the amount of $0.3 million were made during the six months ended June 30, 2023.

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.

Legal Proceedings

The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities when purchased of three months or less that are readily convertible to known amounts of cash to be cash equivalents. The carrying values of these instruments approximate their respective fair value due to the short-term maturity of these investments. At June 30, 2023 and December 31, 2022, the Company’s cash equivalents were in money market funds and government securities. As of each balance sheet date and periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits.

In connection with the Company’s lease agreement entered into in September 2021 (see Note 12), the Company is required to maintain a certificate of deposit (“CD”) of $0.9 million for the benefit of the landlord.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):

 

 

June 30, 2023

 

 

June 30, 2022

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

58,741

 

 

$

148,912

 

Restricted cash, non-current

 

 

927

 

 

 

927

 

Total cash, cash equivalents and restricted cash

 

$

59,668

 

 

$

149,839

 

Marketable securities

Marketable securities

Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders’ equity in other comprehensive income. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company’s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even if the stated maturity of some individual securities may be one year or more beyond the balance sheet date.

The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be “other than temporary”, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company qualifies as an ‘‘emerging growth company’’ as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to ‘‘opt out’’ of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to ‘‘opt out’’ of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies.

In August 2020, the FASB issued ASU No. 2020-06, Debt, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. The ASU also simplifies the accounting for convertible instruments by removing the beneficial conversion feature and cash conversion feature separation models. This ASU may be applied on a full retrospective or modified retrospective basis. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and all other public entities, this ASU is effective for fiscal years beginning after December 15, 2021. Early adoption permitted. The Company expects to adopt this ASU in fiscal year 2024. The Company does not currently expect the adoption to materially impact its financial position and results of operations.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):

 

 

June 30, 2023

 

 

June 30, 2022

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

58,741

 

 

$

148,912

 

Restricted cash, non-current

 

 

927

 

 

 

927

 

Total cash, cash equivalents and restricted cash

 

$

59,668

 

 

$

149,839

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]  
Schedule of Fair Value Hierarchy for Assets and Liabilities

The following table presents the Company’s fair value hierarchy for its asset items that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, by level within the fair value hierarchy (in thousands):

 

 

Fair Value Measurement at June 30, 2023 Using:

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

50,702

 

 

$

 

 

$

 

 

$

50,702

 

Corporate bonds

 

 

 

 

 

2,589

 

 

 

 

 

 

2,589

 

Total cash equivalents

 

$

50,702

 

 

$

2,589

 

 

$

 

 

$

53,291

 

Marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government securities

 

 

 

 

 

76,584

 

 

 

 

 

 

76,584

 

Corporate bonds

 

 

 

 

 

14,839

 

 

 

 

 

 

14,839

 

Total marketable securities

 

$

 

 

$

91,423

 

 

$

 

 

$

91,423

 

Restricted cash (non-current)

 

 

927

 

 

 

 

 

 

 

 

 

927

 

Total

 

$

51,629

 

 

$

94,012

 

 

$

 

 

$

145,641

 

 

 

Fair Value Measurement at December 31, 2022 Using:

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents (money market)

 

$

156,219

 

 

$

 

 

$

 

 

$

156,219

 

Restricted cash (non-current)

 

 

927

 

 

 

 

 

 

 

 

 

927

 

Total

 

$

157,146

 

 

$

 

 

$

 

 

$

157,146

 

Summary of marketable securities

The following table summarizes the Company’s marketable securities as of June 30, 2023 (in thousands):

 

 

 

At June 30, 2023

 

 

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Value

 

U.S. government securities

 

$

76,634

 

 

$

2

 

 

$

(52

)

 

$

76,584

 

Corporate bonds

 

$

14,859

 

 

$

4

 

 

$

(24

)

 

$

14,839

 

Total

 

$

91,493

 

 

$

6

 

 

$

(76

)

 

$

91,423

 

Summary of marketable securities by maturity

The following table summarizes the Company’s marketable securities by maturity as of June 30, 2023 (in thousands):

 

 

At June 30, 2023

 

Maturities in one year or less

 

$

86,107

 

Maturities between one and two years

 

 

5,316

 

Total

 

$

91,423

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Prepaid Expense and Other Current Assets (Tables)
6 Months Ended
Jun. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

June 30,
2023

 

 

December 31,
2022

 

Research and development

 

$

3,615

 

 

$

6,670

 

Construction related prepaid assets

 

 

 

 

 

3,769

 

Business insurance

 

 

762

 

 

 

133

 

Other

 

 

1,178

 

 

 

628

 

Total

 

$

5,555

 

 

$

11,200

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

June 30,
2023

 

 

December 31,
2022

 

Payroll and employee related

 

$

2,154

 

 

$

3,512

 

Research and development

 

 

1,621

 

 

 

2,894

 

Professional fees

 

 

931

 

 

 

986

 

Construction related

 

 

78

 

 

 

1,416

 

Other

 

 

217

 

 

 

386

 

Total

 

$

5,001

 

 

$

9,194

 

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock-based Compensation Expense Stock-based compensation expense was classified as follows in the condensed consolidated statements of operations and comprehensive loss (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

891

 

 

$

608

 

 

$

1,577

 

 

$

1,049

 

General and administrative

 

 

1,366

 

 

 

853

 

 

 

2,414

 

 

 

1,433

 

Total stock-based compensation

 

$

2,257

 

 

$

1,461

 

 

$

3,991

 

 

$

2,482

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock (Tables)
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards

The Company has reserved the following number of shares of common stock for the exercise of outstanding stock options and future issuance of stock-based awards.

 

 

June 30,
2023

 

 

December 31,
2022

 

Common stock options

 

 

5,761,042

 

 

 

4,440,811

 

Pre-funded warrants

 

 

2,980,889

 

 

 

2,980,889

 

Shares available for issuance under the 2021 Plan

 

 

1,673,053

 

 

 

1,682,909

 

Shares available for issuance under the 2021 ESPP

 

 

572,254

 

 

 

286,127

 

Total common stock reserved for future issuance

 

 

10,987,238

 

 

 

9,390,736

 

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share (Tables)
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(20,174

)

 

$

(17,015

)

 

$

(39,969

)

 

$

(32,349

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic and diluted

 

 

38,657,205

 

 

 

28,150,051

 

 

 

38,601,916

 

 

 

27,409,264

 

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.52

)

 

$

(0.60

)

 

$

(1.04

)

 

$

(1.18

)

Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per common share for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

As of June 30,

 

 

2023

 

 

2022

 

Options to purchase common stock – service based

 

 

5,550,413

 

 

 

4,162,669

 

Options to purchase common stock – performance based

 

 

210,629

 

 

 

210,629

 

Unvested restricted common stock

 

 

53,715

 

 

 

112,311

 

Total

 

 

5,814,757

 

 

 

4,485,609

 

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Tables)
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities Future minimum lease payments due under the Company’s operating and finance lease liabilities as of June 30, 2023 are as follows:

 

 

 

Operating
Leases

 

 

Financing
Leases

 

2023

 

 

886

 

 

 

2

 

2024

 

 

1,910

 

 

 

 

2025

 

 

1,968

 

 

 

 

2026

 

 

2,027

 

 

 

 

2027

 

 

2,088

 

 

 

 

2028 and thereafter

 

 

11,269

 

 

 

 

Total lease payments

 

 

20,148

 

 

 

2

 

Less: imputed interest

 

 

(5,940

)

 

 

 

Total future minimum lease payments

 

$

14,208

 

 

$

2

 

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)
1 Months Ended
Aug. 07, 2023
Aug. 31, 2022
Jan. 31, 2022
Jun. 30, 2023
Mar. 21, 2023
Dec. 31, 2022
Class of Stock [Line Items]            
Cash, cash equivalents and marketable securities       $ 150,200,000    
Accumulated deficit       $ 180,103,000   $ 140,134,000
Net proceeds from issuance initial public offering     $ 88,000,000      
Sales Agreement            
Class of Stock [Line Items]            
Maximum shares value to be issued under agreement         $ 100,000,000  
Sales Agreement | Subsequent Event            
Class of Stock [Line Items]            
Common stock issued 0          
Private Placement            
Class of Stock [Line Items]            
Net proceeds from offering   $ 71,300,000        
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Additional Information (Details)
$ in Millions
Jun. 30, 2023
USD ($)
Certificate of Deposit  
Summary Of Significant Accounting Policies [Line Items]  
Lease security deposit $ 0.9
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Cash and cash equivalents $ 58,741 $ 186,605 $ 148,912  
Restricted cash 927 927 927  
Total cash, cash equivalents and restricted cash $ 59,668 $ 187,532 $ 149,839 $ 92,347
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy for Assets and Liabilities (Details) - Recurring Basis - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Assets:    
Assets, fair value $ 145,641 $ 157,146
Level 1    
Assets:    
Assets, fair value 51,629 157,146
Level 2    
Assets:    
Assets, fair value 94,012  
Cash Equivalents (Money Market)    
Assets:    
Assets, fair value   156,219
Cash Equivalents (Money Market) | Level 1    
Assets:    
Assets, fair value   156,219
Restricted Cash (Non-Current)    
Assets:    
Assets, fair value 927 927
Restricted Cash (Non-Current) | Level 1    
Assets:    
Assets, fair value 927 $ 927
Cash Equivalents    
Assets:    
Assets, fair value 53,291  
Cash Equivalents | Level 1    
Assets:    
Assets, fair value 50,702  
Cash Equivalents | Level 2    
Assets:    
Assets, fair value 2,589  
Cash Equivalents | Corporate Bonds    
Assets:    
Assets, fair value 2,589  
Cash Equivalents | Corporate Bonds | Level 2    
Assets:    
Assets, fair value 2,589  
Cash Equivalents | Money Market Funds    
Assets:    
Assets, fair value 50,702  
Cash Equivalents | Money Market Funds | Level 1    
Assets:    
Assets, fair value 50,702  
Marketable Securities    
Assets:    
Assets, fair value 91,423  
Marketable Securities | Level 2    
Assets:    
Assets, fair value 91,423  
Marketable Securities | U.S. Government Securities    
Assets:    
Assets, fair value 76,584  
Marketable Securities | U.S. Government Securities | Level 2    
Assets:    
Assets, fair value 76,584  
Marketable Securities | Corporate Bonds    
Assets:    
Assets, fair value 14,839  
Marketable Securities | Corporate Bonds | Level 2    
Assets:    
Assets, fair value $ 14,839  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Financial Instruments - Summary of Marketable Securities (Details) - Marketable Securities
$ in Thousands
Jun. 30, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Investment Amortized Cost $ 91,493
Investment Gross Unrealized Gains 6
Investment Gross Unrealized Losses (76)
Investment Fair Value 91,423
U.S. Government Securities  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Investment Amortized Cost 76,634
Investment Gross Unrealized Gains 2
Investment Gross Unrealized Losses (52)
Investment Fair Value 76,584
Corporate Bonds  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Investment Amortized Cost 14,859
Investment Gross Unrealized Gains 4
Investment Gross Unrealized Losses (24)
Investment Fair Value $ 14,839
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Financial Instruments - Summary of Marketable Securities by Maturity (Details) - Marketable Securities
$ in Thousands
Jun. 30, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Maturities in one year or less $ 86,107
Maturities between one and two years 5,316
Total $ 91,423
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements and Financial Instruments - Additional Information (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
Securities
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Securities
Jun. 30, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Number of Securities | Securities 33   33  
Number of securities in unrealized loss position | Securities 29   29  
Credit losses recognized on securities | $ $ 0 $ 0 $ 0 $ 0
Marketable Securities        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Realized gain or losses on marketable securities | $ $ 0 $ 0 $ 0 $ 0
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]    
Research and development $ 3,615 $ 6,670
Construction related prepaid assets   3,769
Business insurance 762 133
Other 1,178 628
Total $ 5,555 $ 11,200
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Payroll and employee related $ 2,154 $ 3,512
Research and development 1,621 2,894
Professional fees 931 986
Construction related 78 1,416
Other 217 386
Total [1] $ 5,001 $ 9,194
[1] Includes related party amounts of $0 (accrued expenses and other current liabilities) at June 30, 2023; $78 (accrued expenses and other current liabilities) at December 31, 2022 (see Note 11).
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 01, 2023
Mar. 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Aggregate number of shares of common stock reserved for issuance     10,987,238   10,987,238   9,390,736
Stock-based compensation expense     $ 2,257,000 $ 1,461,000 $ 3,991,000 $ 2,482,000  
Options              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Aggregate number of shares of common stock reserved for issuance     5,761,042   5,761,042   4,440,811
Unrecognized stock-based compensation expense related to unvested stock options not recognized     $ 24,800,000   $ 24,800,000    
Unrecognized stock-based compensation expense period of recognition         2 years 9 months 10 days    
Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Unrecognized stock-based compensation expense related to unvested restricted stock not recognized     $ 100,000   $ 100,000    
Unrecognized stock-based compensation expense period of recognition         10 months 2 days    
2020 Equity Incentive Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of options outstanding     2,508,398   2,508,398    
2021 Stock Option and Incentive Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Aggregate number of shares of common stock reserved for issuance     1,673,053   1,673,053   1,682,909
Number of shares granted   1,348,380          
Increase in common stock reserved 1,781,017            
Number of options outstanding     3,252,644   3,252,644    
2021 Employee Stock Purchase Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Aggregate number of shares of common stock reserved for issuance     572,254   572,254   286,127
Increase in common stock reserved 286,127            
Stock-based compensation expense     $ 0   $ 0    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation $ 2,257 $ 1,461 $ 3,991 $ 2,482
Research and Development        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation 891 608 1,577 1,049
General and Administrative        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation $ 1,366 $ 853 $ 2,414 $ 1,433
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Preferred Stock - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended
Aug. 13, 2021
May 28, 2021
Sep. 18, 2020
Jan. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2020
Sep. 30, 2020
Class Of Stock [Line Items]                
Gross proceeds from issuance of preferred stock           $ 89,872    
Net proceeds from issuance initial public offering       $ 88,000        
Series A Convertible Preferred Stock Purchase Agreement | Maximum                
Class Of Stock [Line Items]                
Temporary equity, shares issued               7,852,373
Series A Convertible Preferred Stock Purchase Agreement | Research and Development                
Class Of Stock [Line Items]                
Purchase price per share               $ 2.547
Series A Convertible Preferred Stock                
Class Of Stock [Line Items]                
Purchase an aggregate shares     $ 50,000          
Temporary equity, shares issued   7,852,373 9,815,467          
Purchase price per share   $ 2.547 $ 2.547          
Issuance Price per share         $ 2.547      
Gross proceeds from issuance of preferred stock   $ 20,000 $ 25,000          
Issuance costs   100            
Preferred stock conversion price per share         7.063      
Series A Preferred Stock Tranche Obligation                
Class Of Stock [Line Items]                
Issuance costs     200          
Preferred stock tranche obligation classified as liability and recorded at fair value   $ 300         $ 300  
Series B Convertible Preferred Stock                
Class Of Stock [Line Items]                
Temporary equity, shares issued 25,657,096              
Purchase price per share $ 3.5078              
Issuance Price per share         3.5078      
Gross proceeds from issuance of preferred stock $ 90,000              
Issuance costs $ 400              
Preferred stock conversion price per share         $ 9.7278      
Convertible Preferred Stock                
Class Of Stock [Line Items]                
Net proceeds from issuance initial public offering         $ 50,000      
Series A Preferred Stock                
Class Of Stock [Line Items]                
Issuance costs     $ 200          
Series A Preferred Stock | Common Stock | Initial Public Offering (IPO)                
Class Of Stock [Line Items]                
Convertible Preferred stock converted to common stock       10,285,077        
Series B Preferred stock | Common Stock | Initial Public Offering (IPO)                
Class Of Stock [Line Items]                
Convertible Preferred stock converted to common stock       9,251,793        
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Aug. 12, 2022
Class of Stock [Line Items]          
Common stock, voting rights     Each share of common stock entitles the holder to one vote for each share of common stock held.    
Common stock dividend declared $ 0 $ 0 $ 0 $ 0  
Pre-Funded Warrants          
Class of Stock [Line Items]          
Warrants exercised 0   0    
Private Placement | Pre-Funded Warrants          
Class of Stock [Line Items]          
Share purchase price per pre funded warrant         $ 7.2999
Warrants exercise price per share         $ 0.0001
Private Placement | Pre-Funded Warrants | Maximum          
Class of Stock [Line Items]          
Warrants issued to purchase common stock         2,980,889
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock - Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards (Details) - shares
Jun. 30, 2023
Dec. 31, 2022
Class Of Stock [Line Items]    
Total common stock reserved for future issuance 10,987,238 9,390,736
Shares Available for Issuance Under the 2021 Plan    
Class Of Stock [Line Items]    
Total common stock reserved for future issuance 1,673,053 1,682,909
Shares Available for Issuance Under the 2021 ESPP    
Class Of Stock [Line Items]    
Total common stock reserved for future issuance 572,254 286,127
Pre-Funded Warrants    
Class Of Stock [Line Items]    
Total common stock reserved for future issuance 2,980,889 2,980,889
Common Stock Options    
Class Of Stock [Line Items]    
Total common stock reserved for future issuance 5,761,042 4,440,811
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share - Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Numerator:            
Net loss $ (20,174) $ (19,795) $ (17,015) $ (15,334) $ (39,969) $ (32,349)
Denominator:            
Weighted-average common shares outstanding, basic 38,657,205   28,150,051   38,601,916 27,409,264
Weighted-average common shares outstanding, diluted 38,657,205   28,150,051   38,601,916 27,409,264
Net loss per share attributable to common stockholders, basic $ (0.52)   $ (0.6)   $ (1.04) $ (1.18)
Net loss per share attributable to common stockholders, diluted $ (0.52)   $ (0.6)   $ (1.04) $ (1.18)
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Details) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 5,814,757 4,485,609
Options to Purchase Common Stock – Service Based    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 5,550,413 4,162,669
Options to Purchase Common Stock – Performance Based    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 210,629 210,629
Unvested Restricted Common Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 53,715 112,311
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2023
Sep. 30, 2021
Jul. 31, 2021
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
May 31, 2022
Oct. 31, 2021
Feb. 28, 2021
Lessee Lease Description [Line Items]                  
Operating lease liabilities       $ 14,208 $ 14,208   $ 14,300    
Operating lease right-of-use assets       16,805 16,805 $ 141 $ 17,300    
Variable lease expense       200 400        
Operating lease expense       $ 600 $ 1,100        
Finance lease, weighted-average remaining lease term       1 month 6 days 1 month 6 days        
Operating lease, weighted-average remaining lease term       9 years 4 months 24 days 9 years 4 months 24 days        
Finance lease, weighted-average discount rate       5.14% 5.14%        
Operating lease, weighted-average discount rate       7.55% 7.55%        
Equipment Lease                  
Lessee Lease Description [Line Items]                  
Operating lease term                 24 months
Laboratory Space                  
Lessee Lease Description [Line Items]                  
Operating lease term     1 year            
Operating lease commencement month and year     2021-04            
Operating lease, option to extend         At inception, the Company determined that it was reasonably certain that it would elect options to renew the lease through September 2022 and have included these renewal options into the initial determination of the lease term.        
Operating lease, existence of option to extend [true false]         true        
Lease termination date         Feb. 28, 2023        
Laboratory and Office Space                  
Lessee Lease Description [Line Items]                  
Operating lease term 5 years 10 years              
Operating lease commencement month and year 2023-01       2023-01        
Lease annual payments $ 1,900                
Lease increased annual payments $ 2,100                
Operating lease, option to extend         five-year renewal option.        
Operating lease, existence of option to extend [true false]         true        
Operating lease renewal term   5 years              
Operating lease monthly payment   $ 200              
Percentage of annual escalation   3.00%              
Lease construction allowance   $ 3,700              
Corporate Headquarters                  
Lessee Lease Description [Line Items]                  
Operating lease term               14 months  
Operating lease, existence of option to extend [true false]         true        
Lease termination date         Jan. 31, 2023        
Lease monthly payment       $ 74 $ 74        
Lease security deposit       $ 49 $ 49        
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
May 31, 2022
Leases [Abstract]    
Operating Leases, 2023 $ 886  
Operating Leases, 2024 1,910  
Operating Leases, 2025 1,968  
Operating Leases, 2026 2,027  
Operating Leases, 2027 2,088  
Operating Leases, 2028 and thereafter 11,269  
Operating Leases, Total lease payments 20,148  
Operating Leases, Less: imputed interest (5,940)  
Operating Leases, Total future minimum lease payments 14,208 $ 14,300
Financing leases, 2023 2  
Financing Lease, Total lease payments 2  
Financing leases, Total future minimum lease payments $ 2  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions - Additional Information (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
May 31, 2022
Related Party Transaction [Line Items]        
Operating lease right-of-use assets $ 16,805,000   $ 141,000 $ 17,300,000
Operating lease liabilities 14,208,000     $ 14,300,000
Atlas Venture Fund XII, LP        
Related Party Transaction [Line Items]        
Lease, Cost 50,000 $ 142,000    
Operating lease right-of-use assets 0      
Operating lease liabilities 0      
Accrued expenses, related parties $ 0      
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Millions
1 Months Ended 6 Months Ended
Nov. 30, 2021
Sep. 30, 2021
Jun. 30, 2023
Loss Contingencies [Line Items]      
Discretionary and contributions amount     $ 0.3
Standby Letter of Credit      
Loss Contingencies [Line Items]      
Letter of credit   $ 0.9  
Letter of credit expiration date   Sep. 10, 2022  
Renewed to expire date     Sep. 11, 2023
Letter of credit renewal period   2032-12  
FUJIFILM Diosynth Biotechnologies Texas, LLC      
Loss Contingencies [Line Items]      
Purchase commitment fee $ 3.8    
Purchase commitment statement of work completed percentage     56.00%
Purchase commitment period     2 years
FUJIFILM Diosynth Biotechnologies Texas, LLC | Minimum      
Loss Contingencies [Line Items]      
Purchase commitment fee percentage 0.00%    
FUJIFILM Diosynth Biotechnologies Texas, LLC | Maximum      
Loss Contingencies [Line Items]      
Purchase commitment fee percentage 100.00%    
XML 60 vigl-20230630_htm.xml IDEA: XBRL DOCUMENT 0001827087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001827087 2022-04-01 2022-06-30 0001827087 vigl:SeriesAConvertiblePreferredStockMember 2020-09-18 2020-09-18 0001827087 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001827087 us-gaap:CommonStockMember 2022-06-30 0001827087 us-gaap:CommonStockMember 2023-06-30 0001827087 us-gaap:FairValueMeasurementsRecurringMember vigl:MarketableSecuritiesMember 2023-06-30 0001827087 vigl:SeriesBConvertiblePreferredStockMember 2021-08-13 2021-08-13 0001827087 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001827087 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001827087 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001827087 vigl:SeriesBConvertiblePreferredStockMember 2023-06-30 0001827087 vigl:UnvestedRestrictedCommonStockMember 2022-01-01 2022-06-30 0001827087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001827087 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001827087 2023-01-01 2023-06-30 0001827087 us-gaap:CommonStockMember 2022-12-31 0001827087 vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001827087 vigl:SeriesAPreferredStockTrancheObligationMember 2020-09-18 2020-09-18 0001827087 vigl:OptionsToPurchaseCommonStockPerformanceBasedMember 2023-01-01 2023-06-30 0001827087 vigl:OptionsToPurchaseCommonStockServiceBasedMember 2023-01-01 2023-06-30 0001827087 vigl:SeriesAConvertiblePreferredStockMember 2021-05-28 0001827087 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001827087 vigl:RestrictedCashNonCurrentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001827087 vigl:LaboratoryAndOfficeSpaceMember 2023-01-01 2023-01-31 0001827087 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001827087 vigl:LaboratoryAndOfficeSpaceMember 2021-09-01 2021-09-30 0001827087 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001827087 vigl:SalesAgreementMember 2023-03-21 0001827087 vigl:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001827087 us-gaap:RestrictedStockMember 2023-06-30 0001827087 vigl:LaboratorySpaceMember 2021-07-31 0001827087 us-gaap:CommonStockMember 2023-03-31 0001827087 vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember 2021-11-01 2021-11-30 0001827087 us-gaap:CommonStockMember us-gaap:IPOMember 2022-01-01 2022-03-31 0001827087 2022-05-31 0001827087 vigl:AtlasVentureFundXIILPMember 2022-01-01 2022-06-30 0001827087 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001827087 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001827087 vigl:TwoThousandTwentyEquityIncentivePlanMember 2023-06-30 0001827087 2023-07-31 0001827087 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001827087 vigl:CorporateHeadquartersMember 2023-01-01 2023-06-30 0001827087 vigl:SeriesAConvertiblePreferredStockMember 2021-05-28 2021-05-28 0001827087 2023-01-01 2023-03-31 0001827087 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001827087 vigl:RestrictedCashNonCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001827087 us-gaap:CertificatesOfDepositMember 2023-06-30 0001827087 us-gaap:RetainedEarningsMember 2022-06-30 0001827087 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001827087 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember us-gaap:IPOMember 2022-01-01 2022-01-31 0001827087 us-gaap:EquipmentMember 2021-02-28 0001827087 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001827087 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001827087 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001827087 vigl:MarketableSecuritiesMember 2023-06-30 0001827087 srt:MaximumMember vigl:SeriesAConvertiblePreferredStockPurchaseAgreementMember 2020-09-30 0001827087 vigl:LaboratorySpaceMember 2021-07-01 2021-07-31 0001827087 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001827087 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001827087 us-gaap:FairValueMeasurementsRecurringMember vigl:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001827087 vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember 2023-01-01 2023-06-30 0001827087 vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 2023-01-01 0001827087 2022-01-01 2022-03-31 0001827087 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001827087 us-gaap:SeriesAPreferredStockMember 2020-09-18 2020-09-18 0001827087 2023-04-01 2023-06-30 0001827087 us-gaap:EmployeeStockOptionMember 2023-06-30 0001827087 vigl:RestrictedCashNonCurrentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001827087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001827087 us-gaap:RetainedEarningsMember 2021-12-31 0001827087 us-gaap:StandbyLettersOfCreditMember 2021-09-30 0001827087 vigl:SeriesBConvertiblePreferredStockMember 2021-08-13 0001827087 vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember srt:MaximumMember 2021-11-01 2021-11-30 0001827087 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001827087 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001827087 2022-03-31 0001827087 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001827087 vigl:CorporateHeadquartersMember 2021-10-31 0001827087 us-gaap:FairValueMeasurementsRecurringMember vigl:MarketableSecuritiesMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0001827087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001827087 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001827087 2023-03-31 0001827087 vigl:OptionsToPurchaseCommonStockPerformanceBasedMember 2022-01-01 2022-06-30 0001827087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001827087 vigl:UnvestedRestrictedCommonStockMember 2023-01-01 2023-06-30 0001827087 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001827087 vigl:LaboratoryAndOfficeSpaceMember 2023-01-31 0001827087 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001827087 vigl:SeriesAPreferredStockTrancheObligationMember 2021-05-28 0001827087 us-gaap:ResearchAndDevelopmentExpenseMember vigl:SeriesAConvertiblePreferredStockPurchaseAgreementMember 2020-09-30 0001827087 us-gaap:StandbyLettersOfCreditMember 2021-09-01 2021-09-30 0001827087 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vigl:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001827087 vigl:PreFundedWarrantsMember 2022-12-31 0001827087 2022-06-30 0001827087 vigl:SeriesAConvertiblePreferredStockMember 2020-09-18 0001827087 vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2023-03-01 2023-03-31 0001827087 2022-01-01 2022-01-31 0001827087 vigl:RestrictedCashNonCurrentMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001827087 us-gaap:RetainedEarningsMember 2022-12-31 0001827087 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001827087 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember us-gaap:IPOMember 2022-01-01 2022-01-31 0001827087 vigl:AtlasVentureFundXIILPMember 2023-01-01 2023-06-30 0001827087 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001827087 us-gaap:PrivatePlacementMember 2022-08-01 2022-08-31 0001827087 us-gaap:RetainedEarningsMember 2023-06-30 0001827087 2021-12-31 0001827087 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001827087 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001827087 vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-06-30 0001827087 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2022-01-01 2022-03-31 0001827087 us-gaap:RetainedEarningsMember 2022-03-31 0001827087 vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2023-01-01 2023-01-01 0001827087 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001827087 us-gaap:IPOMember 2022-01-01 2022-03-31 0001827087 2023-06-30 0001827087 vigl:LaboratoryAndOfficeSpaceMember 2023-01-01 2023-06-30 0001827087 vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2022-12-31 0001827087 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vigl:MarketableSecuritiesMember 2023-06-30 0001827087 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001827087 vigl:AtlasVentureFundXIILPMember 2023-06-30 0001827087 us-gaap:CommonStockMember 2022-03-31 0001827087 us-gaap:EmployeeStockOptionMember 2022-12-31 0001827087 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001827087 vigl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-04-01 2023-06-30 0001827087 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001827087 2022-01-01 2022-06-30 0001827087 vigl:MarketableSecuritiesUSGovernmentSecuritiesMember 2023-04-01 2023-06-30 0001827087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001827087 us-gaap:ConvertiblePreferredStockMember us-gaap:IPOMember 2022-01-01 2022-03-31 0001827087 vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember srt:MinimumMember 2021-11-01 2021-11-30 0001827087 vigl:PreFundedWarrantsMember us-gaap:PrivatePlacementMember 2022-08-12 0001827087 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001827087 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vigl:MarketableSecuritiesMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0001827087 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001827087 vigl:SeriesAPreferredStockTrancheObligationMember 2020-12-31 0001827087 vigl:OptionsToPurchaseCommonStockServiceBasedMember 2022-01-01 2022-06-30 0001827087 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001827087 vigl:CorporateHeadquartersMember 2023-06-30 0001827087 vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2022-12-31 0001827087 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001827087 2022-12-31 0001827087 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001827087 vigl:AccruedExpensesAndOtherCurrentLiabilitiesMember 2022-12-31 0001827087 vigl:FujifilmDiosynthBiotechnologiesTexasLlcMember 2023-06-30 0001827087 vigl:MarketableSecuritiesUSGovernmentSecuritiesMember 2022-01-01 2022-06-30 0001827087 vigl:MarketableSecuritiesUSGovernmentSecuritiesMember 2023-01-01 2023-06-30 0001827087 vigl:AccruedExpensesAndOtherCurrentLiabilitiesMember 2023-06-30 0001827087 vigl:CorporateHeadquartersMember 2023-04-01 2023-06-30 0001827087 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001827087 us-gaap:StandbyLettersOfCreditMember 2023-01-01 2023-06-30 0001827087 us-gaap:SubsequentEventMember vigl:SalesAgreementMember 2023-08-07 2023-08-07 0001827087 vigl:MarketableSecuritiesMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0001827087 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001827087 vigl:SeriesAConvertiblePreferredStockMember 2023-06-30 0001827087 vigl:MarketableSecuritiesMember 2023-06-30 0001827087 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001827087 srt:MaximumMember vigl:PreFundedWarrantsMember us-gaap:PrivatePlacementMember 2022-08-12 0001827087 vigl:PreFundedWarrantsMember 2023-06-30 0001827087 vigl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2023-06-30 0001827087 us-gaap:CommonStockMember 2021-12-31 0001827087 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001827087 vigl:LaboratorySpaceMember 2023-01-01 2023-06-30 0001827087 vigl:MarketableSecuritiesUSGovernmentSecuritiesMember 2022-04-01 2022-06-30 0001827087 vigl:LaboratoryAndOfficeSpaceMember 2021-09-30 0001827087 us-gaap:RetainedEarningsMember 2023-03-31 pure shares vigl:Securities iso4217:USD shares iso4217:USD Q2 false --12-31 0001827087 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember 10-Q true 2023-06-30 2023 false 001-41200 VIGIL NEUROSCIENCE, INC. DE 85-1880494 100 Forge Road, Suite 700 Watertown MA 02472 857 254-4445 Common Stock, par value $0.0001 per share VIGL NASDAQ Yes Yes Non-accelerated Filer true true false false 35873421 58741000 186605000 91423000 5555000 11200000 155719000 197805000 1898000 1184000 16805000 141000 60000 70000 927000 927000 266000 175409000 200393000 2362000 1942000 5001000 9194000 802000 153000 2000 23000 8167000 11312000 13406000 21573000 11312000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 150000000 150000000 35906037 35664658 35861714 35620335 4000 4000 334005000 329211000 -70000 -180103000 -140134000 153836000 189081000 175409000 200393000 0 78000 14903000 12097000 28737000 22462000 7010000 4945000 13951000 9912000 21913000 17042000 42688000 32374000 -21913000 -17042000 -42688000 -32374000 1746000 32000 2731000 34000 -7000 -5000 -12000 -9000 1739000 27000 2719000 25000 -20174000 -17015000 -39969000 -32349000 -0.52 -0.52 -0.6 -0.6 -1.04 -1.04 -1.18 -1.18 38657205 38657205 28150051 28150051 38601916 38601916 27409264 27409264 -20174000 -17015000 -39969000 -32349000 -176000 -70000 -20350000 -17015000 -40039000 -32349000 7000 50000 75000 142000 54179688 161939000 1724950 2386000 -71829000 -69443000 -54179688 -161939000 19536870 2000 161937000 161939000 10000000 7000000 1000 87985000 87986000 4995 9000 9000 1021000 1021000 -15334000 -15334000 28266815 3000 253338000 -87163000 166178000 799 2000 2000 1461000 1461000 -17015000 -17015000 28267614 3000 254801000 -104178000 150626000 35620335 4000 329211000 -140134000 189081000 45449 214000 214000 1734000 1734000 106000 106000 -19795000 -19795000 35665784 4000 331159000 106000 -159929000 171340000 195930 589000 589000 2257000 2257000 -176000 -176000 -20174000 -20174000 35861714 4000 334005000 -70000 -180103000 153836000 -39969000 -32349000 3991000 2482000 681000 447000 176000 36000 -1000000 -2593000 235000 -789000 419000 -2390000 -4193000 -473000 -237000 -444000 -37539000 -32137000 102493000 12000000 614000 233000 -91107000 -233000 89872000 21000 21000 803000 11000 782000 89862000 -127864000 57492000 187532000 92347000 59668000 149839000 161939000 1887000 14292000 77000 2887000 129000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vigil Neuroscience, Inc., together with its consolidated subsidiary, Vigil Neuroscience Security Corporation (“Vigil” or the “Company”), is a clinical-stage, microglia-focused biotechnology company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia, the sentinel immune cells of the brain. The Company’s initial focus is on developing a pipeline of therapeutic candidates that it believes will activate and restore microglia function, with an initial focus in genetically defined subpopulations. The Company was incorporated in the State of Delaware in June 2020 and is located in Watertown, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical studies and clinical trials, the ability to raise additional capital to fund operations, obtaining regulatory approval for therapeutic candidates, market acceptance of products, competition from substitute products, protection of proprietary intellectual property, compliance with government regulations, dependence on key personnel, reliance on third-party organizations and the clinical and commercial success of its therapeutic candidates. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of June 30, 2023, the Company had cash, cash equivalents, and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In January 2022, the Company completed its initial public offering (“IPO”) of its common stock which resulted in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In August 2022, the Company completed a private placement financing, which resulted in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its cash and cash equivalents will be sufficient to fund current operations for at least the next twelve months from the issuance of these condensed consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 21, 2023, the Company entered into an Open Market Sales Agreement, or the Sales Agreement, with Jefferies LLC, or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of shares of its common stock, through the Agent, as its sales agent. As of August 7, 2023, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were sold under the Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects to seek additional funding through equity financings, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company’s stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying condensed consolidated financial statements reflect the operations of the Company are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 21, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary. Intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 150200000 -180100000 88000000 71300000 100000000 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022, and notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 21, 2023, or the 2022 Form 10-K. Since the date of those financial statements, there have been no material changes to Vigil’s significant accounting policies except as noted below.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities when purchased of three months or less that are readily convertible to known amounts of cash to be cash equivalents. The carrying values of these instruments approximate their respective fair value due to the short-term maturity of these investments. At June 30, 2023 and December 31, 2022, the Company’s cash equivalents were in money market funds and government securities. As of each balance sheet date and periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company’s lease agreement entered into in September 2021 (see Note 12), the Company is required to maintain a certificate of deposit (“CD”) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the benefit of the landlord.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.08%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,741</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148,912</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash, non-current</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,668</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders’ equity in other comprehensive income. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company’s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even if the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be “other than temporary”, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company qualifies as an ‘‘emerging growth company’’ as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to ‘‘opt out’’ of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to ‘‘opt out’’ of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. The ASU also simplifies the accounting for convertible instruments by removing the beneficial conversion feature and cash conversion feature separation models. This ASU may be applied on a full retrospective or modified retrospective basis. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and all other public entities, this ASU is effective for fiscal years beginning after December 15, 2021. Early adoption permitted. The Company expects to adopt this ASU in fiscal year 2024. The Company does not currently expect the adoption to materially impact its financial position and results of operations.</span></p></div> <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities when purchased of three months or less that are readily convertible to known amounts of cash to be cash equivalents. The carrying values of these instruments approximate their respective fair value due to the short-term maturity of these investments. At June 30, 2023 and December 31, 2022, the Company’s cash equivalents were in money market funds and government securities. As of each balance sheet date and periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company’s lease agreement entered into in September 2021 (see Note 12), the Company is required to maintain a certificate of deposit (“CD”) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the benefit of the landlord.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.08%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,741</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148,912</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash, non-current</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,668</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> 900000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the amounts reported in the condensed consolidated statement of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.08%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,741</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148,912</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash, non-current</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,668</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 58741000 148912000 927000 927000 59668000 149839000 <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders’ equity in other comprehensive income. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company’s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even if the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be “other than temporary”, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span> <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company qualifies as an ‘‘emerging growth company’’ as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to ‘‘opt out’’ of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to ‘‘opt out’’ of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. The ASU also simplifies the accounting for convertible instruments by removing the beneficial conversion feature and cash conversion feature separation models. This ASU may be applied on a full retrospective or modified retrospective basis. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and all other public entities, this ASU is effective for fiscal years beginning after December 15, 2021. Early adoption permitted. The Company expects to adopt this ASU in fiscal year 2024. The Company does not currently expect the adoption to materially impact its financial position and results of operations.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements and Financial Instruments</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the Company’s fair value hierarchy for its asset items that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at June 30, 2023 Using:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,702</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,702</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,589</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,589</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,702</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,589</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,291</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,584</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,584</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash (non-current)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,629</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,012</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,641</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at December 31, 2022 Using:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents (money market)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156,219</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156,219</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash (non-current)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157,146</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157,146</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company’s marketable securities as of June 30, 2023 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.11%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,634</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,584</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,859</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,839</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,493</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company’s marketable securities by maturity as of June 30, 2023 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.488%;"></td> <td style="width:1.801%;"></td> <td style="width:1.0%;"></td> <td style="width:15.710999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities in one year or less</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,107</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities between one and two years</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,316</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2023, the Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> securities, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of which were in an unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company evaluated its securities for potential other-than-temporary impairment and considered the decline in market value to be primarily attributable to current economic and market conditions. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. Given the Company's intent and ability to hold such securities until recovery, and the lack of a significant change in credit risk for these investments, the Company does not consider these investments to be impaired as of June 30, 2023. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any credit losses during the three and six months ended June 30, 2023 and 2022. Additionally, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> realized gains or losses on marketable securities for the three and six months ended June 30, 2023 and 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the Company’s fair value hierarchy for its asset items that are measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022, by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at June 30, 2023 Using:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,702</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,702</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,589</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,589</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,702</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,589</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,291</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,584</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,584</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash (non-current)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,629</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,012</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,641</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at December 31, 2022 Using:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents (money market)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156,219</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156,219</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash (non-current)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">927</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157,146</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157,146</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 50702000 50702000 2589000 2589000 50702000 2589000 53291000 76584000 76584000 14839000 14839000 91423000 91423000 927000 927000 51629000 94012000 145641000 156219000 156219000 927000 927000 157146000 157146000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company’s marketable securities as of June 30, 2023 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.11%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> <td style="width:1.524%;"></td> <td style="width:1.0%;"></td> <td style="width:11.699%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,634</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,584</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,859</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,839</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,493</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 76634000 2000 52000 76584000 14859000 4000 24000 14839000 91493000 6000 76000 91423000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company’s marketable securities by maturity as of June 30, 2023 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.488%;"></td> <td style="width:1.801%;"></td> <td style="width:1.0%;"></td> <td style="width:15.710999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities in one year or less</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,107</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities between one and two years</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,316</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,423</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 86107000 5316000 91423000 33 29 0 0 0 0 0 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Prepaid Expenses and Other Current Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.401%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,615</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,670</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction related prepaid assets</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,769</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business insurance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,178</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">628</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,555</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,200</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.401%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,615</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,670</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction related prepaid assets</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,769</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business insurance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,178</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">628</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,555</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,200</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 3615000 6670000 3769000 762000 133000 1178000 628000 5555000 11200000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.401%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and employee related</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,154</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,512</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,621</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,894</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">931</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction related</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,416</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,001</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,194</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.401%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and employee related</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,154</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,512</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,621</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,894</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">931</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction related</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,416</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,001</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,194</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 2154000 3512000 1621000 2894000 931000 986000 78000 1416000 217000 386000 5001000 9194000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's 2020 Equity Incentive Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2023, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,508,398</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding under the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Stock Option and Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's 2021 Stock Option and Incentive Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> On January 1, 2023, the shares reserved for future grants under the 2021 Plan increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,781,017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pursuant to the 2021 Plan Evergreen Provision. In March of 2023, as part of the Company's annual grant of equity, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,348,380</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options to employees. As of June 30, 2023, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,252,644</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding under the 2021 Plan.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's 2021 Employee Stock Purchase Plan is described in detail within Note 6 of the Notes to the Consolidated Financial Statements in the 2022 Annual Report on Form 10-K.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> On January 1, 2023, the shares reserved for future grants under the 2021 ESPP increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">286,127</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pursuant to the 2021 Plan Evergreen Provision. As of June 30, 2023, a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">572,254</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were reserved for issuance under this plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock-based compensation expense was recognized during the three and six months ended June 30, 2023 related to the 2021 ESPP.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three and six months ended June 30, 2023, respectively, and recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three and six months ended June 30, 2022, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense was classified as follows in the condensed consolidated statements of operations and comprehensive loss (in thousands): </span></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,577</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,049</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,366</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">853</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,414</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,433</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,257</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,461</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,991</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,482</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At June 30, 2023, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrecognized stock-based compensation expense related to unvested options, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.78</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. At June 30, 2023, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrecognized stock-based compensation expense related to unvested restricted stock, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.84</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 2508398 1781017 1348380 3252644 286127 572254 0 0 2300000 4000000 1500000 2500000 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense was classified as follows in the condensed consolidated statements of operations and comprehensive loss (in thousands): </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,577</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,049</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,366</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">853</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,414</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,433</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,257</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,461</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,991</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,482</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 891000 608000 1577000 1049000 1366000 853000 2414000 1433000 2257000 1461000 3991000 2482000 24800000 P2Y9M10D 100000 P0Y10M2D <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Series A preferred stock and Series B preferred stock, described in more detail below, converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,285,077</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,251,793</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock in January 2022 as part of our IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series A Convertible Preferred Stock and Series A Preferred Stock Tranche Obligation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 18, 2020, the Company entered into the Series A Convertible Preferred Stock Purchase Agreement with its initial investors committing to purchase an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in shares of Series A convertible preferred stock. At the initial closing, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,815,467</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A convertible preferred stock were issued by the Company at a purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.547</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The gross proceeds were offset by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of issuance costs and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to the Series A Preferred Stock Tranche Obligation, discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Included in the terms of the September 2020 Series A Convertible Preferred Stock Purchase Agreement were certain rights (“Series A Preferred Stock Tranche Obligation”) granted to the investors who purchased the Series A convertible preferred stock in September 2020. The Series A Preferred Stock Tranche Obligation contingently obligated the investors to purchase, and the Company to sell, up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,852,373</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.547</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share upon the satisfaction of specified research and development milestones by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the Series A Preferred Stock Tranche Obligation met the definition of a freestanding financial instrument, as the Series A Preferred Stock Tranche Obligation was legally detachable and separately exercisable from the Series A convertible preferred stock. Therefore, the Company allocated the proceeds from the September 2020 issuance between the Series A Preferred Stock Tranche Obligation and the Series A convertible preferred stock, including those issued in exchange for the SAFE. As the Series A convertible preferred stock is redeemable upon a deemed liquidation event at the election of the holder-controlled Board, and therefore outside of the control of the Company, the Series A Preferred Stock Tranche Obligation was classified as a liability and recorded at its fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at both inception and as of December 31, 2020. The Series A Preferred Stock Tranche Obligation was remeasured at fair value at each reporting period, with changes in fair value recorded in change in fair value of the Series A Preferred Stock Tranche Obligation in the condensed consolidated statements of operations and comprehensive loss (see Note 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,852,373</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.547</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for which the Company received gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, offset by issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As a result of this issuance, the Series A Preferred Stock Tranche Obligation with a then fair value of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was settled and reclassified to Series A convertible preferred stock in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series B Convertible Preferred Stock Financing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 13, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,657,096</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series B convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5078</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for which the Company received gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Issuance costs were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon issuance of each class of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed upon the issuance date of each class of the Convertible Preferred Stock or as of June 30, 2023 and December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of Convertible Preferred Stock had the followings rights and privileges:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the Convertible Preferred Stock may convert, at any time, each share of the Convertible Preferred Stock into shares of common stock. In addition, upon either (a) the closing of the sale of shares of common stock to the public at a price of at least three times the Series A Original Issue Price (subject to adjustment) in an initial public offering with net proceeds to the Company of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million or (b) the written consent of the holders of the outstanding shares of Convertible Preferred Stock, the Convertible Preferred Stock will automatically convert into common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conversion ratio of each series of the Convertible Preferred Stock is determined by dividing the Original Issuance Price of each series by the Conversion Price of each series. The Original Issuance Price per share is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.547</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for Series A convertible preferred stock and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5078</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for Series B convertible preferred stock. The Conversion Price per share at issuance was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.063</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for Series A convertible preferred stock and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.7278</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for Series B convertible preferred stock, each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, including adjustment if common stock is issued for less than the Original Issue Price of each series of Convertible Preferred Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 10285077 9251793 50000000 9815467 2.547 25000000 200000 200000 7852373 2.547 300000 7852373 2.547 20000000 100000 300000 25657096 3.5078 90000000 400000 50000000 2.547 3.5078 7.063 9.7278 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each share of common stock entitles the holder to one vote for each share of common stock held.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Common stockholders are entitled to receive dividends, as may be declared by the Company’s Board. During each of the three and six months ended June 30, 2023 and the three and six months ended June 30, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared or paid.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pre-funded Warrants</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,980,889</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per pre-funded warrant. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share of common stock, is immediately exercisable and will remain exercisable until exercised in full. The pre-funded warrants have no expiration date and the price of the pre-funded warrants does not include any discounts. The Company evaluated the pre-funded warrants for liability or equity classification in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the pre-funded warrants did not meet the definition of liability instruments and met the criteria for permanent equity. As of June 30, 2023, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded warrants were exercised.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved the following number of shares of common stock for the exercise of outstanding stock options and future issuance of stock-based awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.32%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,761,042</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,440,811</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,980,889</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,980,889</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for issuance under the 2021 Plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,673,053</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,682,909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for issuance under the 2021 ESPP</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">572,254</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">286,127</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,987,238</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,390,736</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> Each share of common stock entitles the holder to one vote for each share of common stock held. 0 0 0 0 2980889 7.2999 0.0001 0 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved the following number of shares of common stock for the exercise of outstanding stock options and future issuance of stock-based awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.32%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,761,042</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,440,811</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,980,889</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,980,889</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for issuance under the 2021 Plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,673,053</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,682,909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for issuance under the 2021 ESPP</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">572,254</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">286,127</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,987,238</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,390,736</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 5761042 4440811 2980889 2980889 1673053 1682909 572254 286127 10987238 9390736 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,174</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,015</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,969</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,349</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,657,205</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,150,051</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,601,916</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,409,264</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.04</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.18</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per common share is the same. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per common share for the periods indicated because including them would have had an anti-dilutive effect: </span></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.32%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock – service based</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,550,413</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,162,669</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock – performance based</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,629</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,629</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,715</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,311</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,814,757</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,485,609</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.903%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> <td style="width:1.123%;"></td> <td style="width:1.0%;"></td> <td style="width:9.152000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,174</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,015</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,969</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,349</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,657,205</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,150,051</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,601,916</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,409,264</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.04</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.18</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table> -20174000 -17015000 -39969000 -32349000 38657205 38657205 28150051 28150051 38601916 38601916 27409264 27409264 -0.52 -0.52 -0.6 -0.6 -1.04 -1.04 -1.18 -1.18 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per common share for the periods indicated because including them would have had an anti-dilutive effect: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.32%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> <td style="width:1.02%;"></td> <td style="width:1.0%;"></td> <td style="width:13.32%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock – service based</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,550,413</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,162,669</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock – performance based</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,629</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,629</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,715</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,311</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,814,757</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,485,609</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 5550413 4162669 210629 210629 53715 112311 5814757 4485609 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2021, the Company entered into an equipment lease with lease term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with rent commencing in the third quarter of 2021. The lease includes an option to purchase the equipment at fair market value at the end of the lease term. The Company has notified the vendor of its intent to exercise the purchase option.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a lease for laboratory space in Cambridge, Massachusetts, with an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> commencing in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with a month-to-month option to renew at the end of the initial lease term. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At inception, the Company determined that it was reasonably certain that it would </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">elect options to renew</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the lease through September 2022 and have included these renewal options into the initial determination of the lease term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In 2022, the Company further extended the lease term through February 28, 2023 and terminated the lease as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> due to the Company's move to Watertown, Massachusetts as noted below.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company entered into a lease for its corporate headquarters in Cambridge, Massachusetts with an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In 2022, the Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the lease through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 31, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and terminated the lease as of January 31, 2023 due to the Company's move to Watertown, Massachusetts as noted below. The lease payments during both the three and six months ended June 30, 2023 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand. The Company received their security deposit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand in the second quarter of 2023.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Watertown, MA Lease</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company entered into a lease for laboratory and office space in Watertown, Massachusetts with an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the rent commencement date of December 2022, and a</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">renewal option</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The lease commenced for accounting purposes in the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> when the leased space was made available for the Company’s use. As of the lease commencement date, the Company has determined that it is not reasonably certain to exercise the option to extend the lease and has not included the extension period in the lease term. The monthly lease payment is approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million with annual escalation of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The lease includes a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million construction allowance. At the lease commencement date, the Company recorded an initial lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a right-of-use asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The components of lease expense for the three and six months ended June 30, 2023 were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in operating lease expense, respectively, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in variable lease expense, respectively. Variable lease expense generally includes common area maintenance, property taxes, and utilities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At June 30, 2023, the weighted-average remaining lease terms related to the finance and operating leases are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.4 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average discount rates used at the time that the leases were evaluated were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for the finance leases and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for the operating leases that were still active as of June 30, 2023.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Watertown lease began in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with minimum base rent payments ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million annually and increasing to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million annually over the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments due under the Company’s operating and finance lease liabilities as of June 30, 2023 are as follows:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.401%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br/>Leases</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing<br/>Leases</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">886</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,910</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,968</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,027</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,269</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,148</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,940</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,208</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> P24M P1Y 2021-04 At inception, the Company determined that it was reasonably certain that it would elect options to renew the lease through September 2022 and have included these renewal options into the initial determination of the lease term. true 2023-02-28 P14M true 2023-01-31 74000 74000 49000 P10Y five-year renewal option. P5Y true 2023-01 200000 0.03 3700000 14300000 17300000 600000 1100000 200000 400000 P0Y1M6D P9Y4M24D 0.0514 0.0755 2023-01 1900000 2100000 P5Y <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments due under the Company’s operating and finance lease liabilities as of June 30, 2023 are as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.401%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> <td style="width:1.502%;"></td> <td style="width:1.0%;"></td> <td style="width:12.797%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br/>Leases</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing<br/>Leases</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">886</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,910</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,968</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,027</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,269</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,148</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,940</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,208</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 886000 2000 1910000 1968000 2027000 2088000 11269000 20148000 2000 5940000 14208000 2000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Atlas</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into various lease agreements with Atlas Venture Fund XII, L.P., a principal stockholder of the Company, and incurred lease costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand for the six months ended June 30, 2023, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand for the six months ended June 30, 2022. The lease payments are included in general and administrative expenses for office space and research and development expenses for lab space in the condensed consolidated statements of operations and comprehensive loss. The Company terminated the lease for the laboratory space as of February 28, 2023 due to the Company's move to Watertown, Massachusetts, and therefore had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating lease right-of-use asset or lease liability recorded as of June 30, 2023. As of June 30, 2023, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> costs in accrued expenses associated with the leases.</span></p> 50000 142000 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a license agreement with Amgen (see Note 12 to the consolidated financial statements of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Letter of Credit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, in connection with the Watertown, Massachusetts lease, the Company entered into a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million standby letter of credit which initially expired on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 10, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was renewed to expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 11, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The standby letter of credit will automatically renew for subsequent annual periods through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2032</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Remittance of funds from the letter of credit was not probable and the full amount was available as of June 30, 2023. The Company did not recognize a liability in the condensed consolidated balance sheet.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase Commitment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into a statement of work ("SOW") with FUJIFILM Diosynth Biotechnologies Texas, LLC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under its existing master services agreement for the manufacturing of VGL101. If the Company terminates the SOW before completion, it may be required to pay fees ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The amount due upon an early termination depends on the length of time prior to the commencement of specific stages of the SOW. The SOW is expected to incur costs over approximately</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of June 30, 2023, approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of work has been completed on this SOW.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenses will be incurred and can be reasonably estimated. As of June 30, 2023, the Company does not have any significant legal disputes that require a loss liability to be recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">401(k) Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code of 1986 (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions are discretionary and contributions in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were made during the six months ended June 30, 2023.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 900000 2022-09-10 2023-09-11 2032-12 3800000 0 1 P2Y 0.56 300000 Includes related party amounts of $0 (accrued expenses and other current liabilities) at June 30, 2023; $78 (accrued expenses and other current liabilities) at December 31, 2022 (see Note 11). Includes related party amounts of $7 and $50 for the three and six months ended June 30, 2023, and $75 and $142 for the three and six months ended June 30, 2022 (see Note 11). EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( / ["%<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #P.PA7D6I91NT K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVE1)'1S43PI""XHWD(RNQMLFI",M/OVIG&WB^@#"+EDYL\W MWT!Z'83V$9^C#QC)8KJ:W3 FH<.&'8B" $CZ@$ZE.B?&W-SYZ!3E:]Q#4/I# M[1':IKD!AZ2,(@4+L HKD:*$C*O+QA#=ZQ8?/.!28T8 #.API :\Y,+E, M#,=YZ.$"6&"$T:7O IJ56*I_8DL'V"DY)[NFIFFJIZ[D\@X7\JZE1T3 MJ5%C?I6LH&/ #3M/?NWN[K97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M\#L(5PNI:Y!&',DS04"9%\<=49 MVZ\]Q]6"_(E/(=^F>Y^)1ID+\55?3(*KCJ5+Q"/N*VW!X,^&>SR*M!.4X[_2 MM%/]IA;N?]ZYW^;P #-G*?=$]#D,U.JJ,^R0@"]8%JD'L?V#ET!][>>+*,W_ M)=OB6=?M$#]+E8A+,90@#I/B+WLJ*V)?0!L$M!30;P1VTR\XI<#)08N2Y5AO MF&*C2RFV1.JGP4U_R.LF5P--F.AFG"D)WX:@4Z,WPL^@511A24!N$A6J9S)) MBNZAJ[E+TA63/+WL*?@UK>GYI?-UX4P;G"_(.Y&H50JN 0]>ZGM0RJJH=%?4 M:XH:_IDEY\2QS@BUJ&,HCW=('H'<-LE?%,>I:L[)_9P&/T]LN"3_C.>IDM 9 M_S754.'@FAWT"'V=KIG/KSHP!%,N-[PS^N4G^\+ZW83W@\Q>P+H5K(NYU]WD M\7G-3:2XW+:Z'TQ(J*HE4K]"ZJ-E&@-/D#/=1FQI8L+U"Q:EIJKP4%E+J(L* MZN*X=KKG,A1Z1 <$Y@5CD^%.U6AK'&ZHOB7GH.(<',=Y&Z8^B\@7SB2YA9O& MB0KW:N)#52WYAA7?\+OXRN9L),3=/E 3'ZIIR?>JXGN%EJA<:1[X,M33)X!. M66SLI;C/I\G;R1V9WGQ\>#_S)C=3[^:,3*;>N8D7=6K):UOU.FL=0^Q!HTIH MT DLBD_D+_YL7%AQ*\NR["$=6,.!"1,7M^7;[\*(BP20H#(V\IT@_=AU_;#R_E+RSF$41N'XI\6YB+I=Z^GD+#FI%/!&O66)N5]RPD?,4."XB(_S!N'1GY#I%-J)U-J)XH-DU)_1B?\62)6],@P>,IN/9F['Q31,7MB6L M4Q$]+A6]Z'RS?&>%O,]4JEBB6]:(_(-R3ED/A5L_=]-[?)N1TQ\.')?"FKPQ M,=:)B!Z5B&8K#@L*,L\>L&F<@G!=VR:L@Q#%D\M>/B#3+)X;%_7K R8PPW1= MFUJ6$? 4 8C6 8@>%8 FB2\DA/9\_^\LC^TP\T(D$AF\NN@^')B'YH$=I!LC M\BDR$*TS$#TJ SVR)S()(.6&B] O]CV1%L8MA_VN/1Q:[BO7R'N*4$3K4$2/ M"D7C( #W]&SW@=S!<^1]8F[7%OG&MBQR*R1,Y ^"!6?$6!6GR$VTSDWTJ-QD MKHK'K3!6!6XYRT(8*H.&P7V* $7K $7QV/,MKJ>O8%0_BFUB1,7M/L.D()59 MZ^':MJAU2J)'[2U5J-4,=B_%)DQ\.3@\>GO+>.)6?-8+C!L&_<*\-5;;'JQ.3@ M4>=.Y'N[*Y%@D>* ">V[7==U^T:^4T0F9^^$#$\[U2[VAXQ)F#"BYW(_T(B) M>S6]?N.RMHAU:'*./1BKW[X11MRL,?KBNN^%[.T=%^OMD?P4/26^#GC%R7%U MMSJI'^?GT[WZ\>*8_QW3NRLIB?@"I-;Y /*-+$[.BPLEUOGA\UPH)>+\XXJS M@$O] 'R_$$+M+O0/5/]_8?0_4$L#!!0 ( / ["%?,]8Z],@< / D 8 M >&PO=V]R:W-H965T&ULM5IM7;M8[(XYZD,@YA]3)!(HX@F#R]8R.\O1GCT>.%3<+N5 MZL)D<;ZCM^R:R2^[CPF<34HOZR!BL0AXC!*VN1A=XM.5G1ED=_P=L'NQ=XP4 ME!O.OZN3U^N+D:5&Q$+F2^6"PK\[=L7"4'F"1180PC MB((X_T]_%D3L&6"[PX 4!J1I,.TPL L#^[D&T\)@^EP#IS#(H$]R[!EQ2RKI MXCSA]RA1=X,W=9"QGUD#7T&L$N5:)O!I '9R'MZ^7E M9SAY-17B=^$?LJCTTZ8K])XQ-D6V-$+&)KS)=F\W:;XQ1.NF?= M:P_%W9^ '+TQ=%_TFI![:VX-_+P$/S>"?QG$-/9[@Y^W1N):#>3&N'V1M^/- M.AYN;%62RS)"_\2$3 (?U%2VY6F%D]5>][)2VS.\6SE M[IY/LWE?332HMU7A;9\1XKH=C%0R$1O%5+&X&Q@A[8=MYDRMYJIN#M,;:SLJ M;&/VW.Z 6XD[;#]+%H4K,M!_6V&LI;G<)**6*S5+ST?9Z" M'D8[^J $HY:^MDPDMDN:.3.H3-3$Q/,IZP"W2E(K%91M:KA:<@MZ6JJHD*#%+T#QGGL@5TE:$!#NS9NO!'*IW)ZH=U) LI!*BQ"Q$KW@4!5)5 ME?F&XO-8I0Z#Y0*VF,/W7#*$R9&6AT$UZJ]X0UJF?M]1GYU7DMN?]] MR\,U2\1?6;DN'_0-SV$[GL.V//^/GB>I=#$Q=SV_Q&LF@MN8JC(0(FP8+%1K M)!2U8W1@G5B@/4#Q)>B.ABD;(VR-X9+Z16)+$Z6+4KGE2? OF%&A%KLW:_TO3$K.G5SYN4,VW/*ZGH"JF"'F8J:ER+,E\MDPYYKA:YJ&YD'TGN1V5%/3T%;E2?U*)=]M MLWS_BK^AU[$?IJ":0&WD:0_;I?K**,J[8[!;'(">.:2]^D='K;WT#-S,/'2( M?L%1:[M"AX(QE%<7^.A$]^1/]M[>B%ARF[TV(U#6\\N_12^OEJ_FO,C>8&E> MMZW3)9"L^P3#)_G+-U6(_%V@=S2Y#6(!-?0&PEDG,\CM)'^])C^1?)>]/W+# MI>11=KAE%#)2W0"?;SB@*TY4@/(EI\5_4$L#!!0 ( / ["%>54+M:J0, M !$, 8 >&PO=V]R:W-H965T&ULK9?M;]H\$,#_%2N; M'K42:]Y(0OL $@6F=>I:5-KMP[0/)CF(U23.; ?:YZ]_;"=DT(;T1>,#^)*[ M\^_.E]S1WU!VSV, @1[2).,#(Q8B/S--'L:08GY"<\CDG25E*1929"N3YPQP MI(W2Q'0LRS=33#)CV-?79FS8IX5(2 8SAGB1II@]GD-"-P/#-K87;L@J%NJ" M.>SG> 5S$'?YC$G)K+U$)(6,$YHA!LN!,;+/QK:C#+3&=P(;OK-&*I0%I?=* MN(@&AJ6(((%0*!=8_JQA#$FB/$F.WY53H]Y3&>ZNM]X_Z^!E, O,84R3'R02 M\<#H&2B")2X2<4,W7Z *R%/^0IIP_8TVE:YEH+#@@J:5L21(25;^XH9=( M.S$<7U]-IE?SZ03)U?SZ\F(RNI7"^>AR=#6>HOF7Z?1VCH[N,EQ$1$!TC(YF MF$$F8A DQ,DQ^H3NYA-T]/$8?40D0[13NYAAQ7)>LC@'6+X6 MV0ERK0YR+,=M,!^WFT\@E.:V-G?VS4V9E3HU3IT:1_OK'O WDP4%C$&$YH*& M]QTD T>420G+1*#O."D S4!>B&5&FL(M_0?:OWJ>UD/KQ+(LNV^N=\-Z46T/ MWZWQW;?A:TR.1H6(*2/_0=2$7/KT=EALJ_P\@7Z%XAYVM\;NO@O[@O.B&;G[ MC.0I:YO&'J170WKO@KPN!!>R^$FV:B+U7B1MT]@C]6M2OY5T3--4OBUYB9F7 M%R_KH)?5-MC#VKVX WLO$PQ;BW?X'E5>LWU^QK-/>I> M3=U[,W4'D8/EVWL&XGJGEF^YP1/B)D7?[_I>KQGXM 8^?0R,3$T+ICJ4>B2 MX 5)B"#0W(Y:-U 3U!G/<0@#0XY('-@:C.$_'VS?^K>Q._TE;_OIV&GD=FLZ MRL@3'7$9==,M./HY?1!JAEPD@*99D0+#:AK\U1AA.TC!/ZTPSL^J M;?4VWR!= &L\W+_CK$R:N3.OJ6'Y&V8KDG&4P%)ZMTX"^;BP&I;J:4$NK]^9<(+9\ M[I7.U?75L73^S/,?8LZ81"]IDHF+SES*Q5FW*R9SEE)QRAE<=;IGY=M=WG_G"]E$F?L+D=BF:8T__6!)?SYHH,[ MKPWW\6PNBX9N_WQ!9VS,Y./B+E=WW=I+%*M7 M[Z.2O"+S1 4;\.1K',GY1:?701&;TF4B[_GS1U81<@M_$YZ(\C]ZKK!6!TV6 M0O*T,E8C2.-L_4M?JD!L&6"[Q8!4!D0W<%L,[,K U@V<%@.G,G#>VH-;&;AO M[<&K#+PR]NM@E9$>4DG[YSE_1GF!5MZ*BW*Z2FL5X#@K,FLL<_4T5G:R/[B] M&=]^OAI>/H1#-'Y0/]?AS<,8W8[0[5UX?_EPI0#H\F:(!K?7=_?AQ_!F?/4E M1)]OQV-T^)C1911+%AVA$_0X'J+#@R-T@.(,/R;E 81:Q"+ /S?:>P;ZKPE/'B+S&:$",#C\MLU-D6\>(6,0& MQC-\NSF!Z/R_WD>_W?M.,.PZ8>S2G]WB[W;!G.W,A%//A&/RWK]7 M'FD^F2/UFJEBNE*KQ$+5? F,\X/9TS?\'9K#M9%7&A4KU*J/G^W*TA^!:V-,Y-D!,XKD:Y"<)VX&*-HW^"0ZP/LE-%/8MAVB,FRB'>+V>QKB)LHGM.S!EOZ;L&RE_YD*@:<[35]H\ M ^GZC),?3TJ\)LO74:T*( M;^O%!?#3DG38V@A&RT@43KM6OI6WG>37ROX0PNC5%,)@+2@C"!2T$-Y2R/@M MU;2D7=%M9XN!Z;4#G6\31?0%$\3@0"<,H-P6PF1#F!@)WZ@/VD354Y @:2S1 M)\3"6[6LH@C@5 7%C6D%<'80> VB$([83MOL;N0L-FJTFBQ2RP82EI$\)0Y(CE>FI^@A6WV*3'W.>1"P7Q\7G;#P!([3NK[<]4NO4)7J UK!@ M%^;IX0&L@'AM"\5&A&*S"GU/=$P) ^C%EO@ M6K8E/J!/,#Z 3W-\-HH5^T;]-N"ITB'S8I=NQ]NHMW*NW MT;Z\[<['1DYCHSXT+WN]-RY[ Y<]@ XN*W9WT:=EQNK=T>/*U'>K"^R0]SHAZ% H MW V7#&%\= JE0G=KOSUE^:P\&1%JJA6+];Y4W5J?OGPHSQRT]@$^&V*@/<1G M(ZC]DN"SD,!/B'I2]M'=#&E]/'1-\UF<"92PJ1J>=>JKUR9?G[BL;R1?E"<$ M3UQ*GI:7'!1K4V8":)B3 MTL2T+:MCIC1FAM/+;3/A]/A&)3&#F2!RDZ94/%U#PG=]HV'L#?-X'2EM,)U> M1M?@@[K+9@)/9J42QBDP&7-&!*SZQJ#1]5H:GP/N8]C)@SW1F2PY?]"'4=@W M+!T0)! HK4!QV<(0DD0+81B_2TVC?(C#E74-[X8 M)(05W21JSGS?>Q!_=>^1VZOOD_([131@K""_(^8P*8"H"%0/WL_*D:S^H":N5[S%;T1 M"W@*Q%=4 ?8/17X.EE(); "_ZIZZ$&O5B^FFV)49#:!O8->3(+9@.!\_-#K6 MU[HZOZ>8^YYBWCN)';U(JWJ1UBEU9XZ*5 01P;\;]LPMSH(L?QEXQ.DB =M[ M@H\5DHP*]53W2(5^)]?7@V;K7/7,[6'E:Q#M8XC[$M*VCB'>2TBC95>8(GGS MH+>E(-;Y4)$DX!NFBJ^TLE9S:Y"WZV?VZT9WV*BQNSCGBK'T5[X8DF,JUC&3 M)($5NK(NK[#UBF+P% ?%L[RS+KG"/IUO(YS5(#0 [U>&PO=V]R:W-H965T&ULM9WMD>W,?J4T2IC9X M 2?=_>L/;,=82):A?;8?&CM!OT=@/8#T2/CR)2^^ED])4FG?EHNL?'_V5%6K M7RXNRME3LHS+G_-5DM5_>7^FG[W^XC9]?*J:7UQ<7:[BQ^0N MJ3ZO;HKZW<6>,D^725:F>:85RCID;)(IE5#2*N?SPGTV2Q:$AU/?[80<_VFDW!P]>O]&"S\_7.?(G+ M9)HO_IO.JZ?W9^,S;9X\Q.M%=9N_1,ENAS85G.6+L:+--L^S/^MCL0!P5T\T@!8U? Z!0PQD<*F+L"9E\%:U? ZBJX1PK8NP)V MIX Y.5+ V15PN@K'CI*[*^!V%8X5&.\*C#L%[&-':;(K,.D4L(X=)7WT^LF- MNAK'CI.^_["WC6[;2C9-S(NK^.JRR%^THMF^YC4O-NUT4[YN66G66.JN*NJ_ MIG6YZFIZ_?/S5 MUVYN_<"_O=UL?WOW+\W_SV=R_S_MC><'9$KNWVIO/F?Q M>IY6R?RM=JY]OO.T-S^]U7[2TDR[?\K799S-R\N+JMZ;IDX7LUW-/VYK;ARI M^7U>Q0M)L:FZV#3/GI.B2K\L$NVFMF]2%,EKE>Q/5!UJZKIZ30ZKK5)]FG MYNSWG&@DF^7+1,(-^W.]Y"&=I94$$JDA)*OWL]G+]9=%.M.N'^JCGF:/VAMR M<_U6@B,_@-.&?<#TQZ24'S_[$7;?QG%1&W[O>F/O>F,C;1V1_A@OXFR6:'%5 M?ZBSGS53?Z<9(T.7N7!+T4M^6.=5G_6MU^;EO].*Y_B6JZ7 Y02 X_& M= NS#]J&;>GNQ!F/^=;A(55])"Q PD(D+$+""!)&D3 &@G&.LO:.L@8YZMVK MI7I92:B5+.,WJCCXQ.Z=9#ZGI(V$!$A8B81$21I PBH0Q$(PSDKTWDJV^ M!TL>TRQK;OCVUZ2[_M24[/2Y*_O_WG3B=N^ M7Z_JE[-%7C:^K,NFNS[::MM'RW=]M'=;I\J,J:SJ4&,B81X2YB-A 1(6(F$1 M$D8=:*R9D.=B(1Y2)B/A 5(6(B$ M14@80<*H*][P3&S3&;N=.QX&4N6,.-X;<3QL(.3O=^:'9;[.9*/%'Y55'>I, M),Q#PGPD+$#"0B0L0L+(6!PZE77J*5*4@6"<,2=[8TX&7"$5X47CP\/ 0?O< M^'#:^O!(GJ#PH;)F0WV(A'E(F(^$!4A8B(1%DU[#802I245-HW/1.U(K=[\9 MYQI]U.;6(Z5O2%FN-\..ZJO7.RU+JLU5ZG7[65Y6\KA9*3C4#E":!Z7Y4%H MI8506K2C'3:_L3OIIG\$*DHEHGK'%4?J91]QQ<%L#OUO=,5K*B9UAU)XL#N0 M- ]*\Z&T $H+H;0(2B-0&MW1#KM5[FCSKVLED"SON'8FA:Z>2N%_2XI96FX< MM^T?Y:MFWH;<1(:P4YW+\U0M-]@9T)D4IZL?0 5#*"V"T@B41J$TAJ+QGF@G M7>CJ61?76P=HR+S9M!ME61EO)EZGGQK7LLF<'[<(;D!R$UJS%]7 MD,&Y!Z7YO?8@@&J&4%H$I1$HC4)I#$7C#=).FM#5LR8^U?V615[*[Z[$J0?G MNFV:5M<*T/D.4)H/I0506MCS^$9050*E42B-H6B\&=IY#[IZXL/!-.[?XF(_ M8J: G\T/YL(=3,\^W;*A03^4YNEB.&R,#<<9 MZT)G IKC0VDAE!9!:01*HU :0]%X2[61OZ[._(>L\MFAN/.A;)F/6G*P/:!Y MNV0?)"M]H)JA[+C)UOI 50F41J$TAJ+QC;Z-TW5UG@Y9\:/6&'Q)F0AMY,B: M'ZBN#Z4%4%H(I450&H'2*)3&4#1^V6B;NAOJU/W'5O^HX4-M94AB5MGZ'ZBJ M#Z4%4%H(I450&H'2*)3&4#3>5&UH;ZA#^Q];":2&#S85-)@WQ!!7OA@(*AM M:2&4%D%I!$JC4!I#T7A7M<&\H0[F52/%AAADGYN&:77#>+7$8#=@'VN I 50 M6@BE15 :@=(HE,90--XR;6YOJ'/[@P$#NL[JR\[H^*B;(4;DNCUR#*=K(6@P MOZ.IQI,E%3-L:SSJQHG0BH42U7-]9 GCZQ%4ED!I%$IC*!K?F-LHW5!'Z4<' ME$\W;61@.H72/$.,RIL!9=?1K:X/D+H!E!9":1&41J T"J4Q%(VW5!N^&R<> M63 @;S0DSP&0Y8UJR<'VL$]?'\2*2?-&:,5"B:HT;X2J$BB-0FD,1>/;R-MU<;XQHD8 M?\AT>$.2CGX.I8506@2E$2B-0FD,1>.-TV;YACK+_Y[9\(88 MMNN6TYT-KQ8>[ ]H;-]K#P*H9@BE15 :@=(HE,90-/[AMFT<;ZKC>%7&L2O* MCTBZHVXG8*J6&&H%*,V'T@(H+>QY?".H*H'2*)3&4#3>#&V,;IZ(T0>D%Z8D MF):E%VK)P>;03XY.22HF32^@%0LEJO+T BI+H#0*I3$4C6_,;7IMGEA6_MWI MA1H\M",!I7FFF+L?22^@N@&4%D)I$91&H#0*I3$4C;?4P5#(:=_L1:LG!]A!5!5^(.;-I3 Q=N#Y@'](O2[>MD2XL_8/*$BB-0FD, M1>,;<07GS%E-DTW:,D6D*O0-H>MU;UX?J!E!:"*5%4!J!TBB4 MQE TWC)M>FVJT^M!T80I!LE&]R9EJA8<; [H0G)3$G-W=R" 2H906@2E$2B- M0FD,1>-]T2;AICH)[Q5/J!F#>Q70P-L4 V_+MKJ3>7VH: "EA5!:!*41*(U" M:0Q%XZW3IMVF.NW^GH#"E#POW!6>4:(6'NP0:.[=:P\"J&8(I450&H'2*)3& M4#3>(&WT;:JC[\]9D<2+]*_:'X]QFFEOFK3BK=9\E_)SG"[BYMFD#WFAE7'] MHDQFZR*M4OD#2$TQA-9'PG@M-/>&TGPH+3#%)Z4+AR.$2D90&H'2*)3&4#3> M-6WN;:IS;V6L)Z;#Y_K$[3Z<<*J6&.P$:,(-I0506MCS^$9050*E42B-H6C\ MUTVV&;>ESKB/3#HW9>:PQ$Q6=W73ZBPWG:HEAYK#$A>B=X=M)14S35VWNX_/ ME>V <%:7;'1>HR;"0T>@NTF@- JE,12-;Z-M]&RIH^=>#Z^2MUCHZFTHS;/$ M5-BT'<=VQT+SAB[?AM)"*"V"T@B41J$TAJ+QEFH#<.N[OJ)>&F=8XA>N2],Z MM>1@>XBJ@B_$O%N:UD$K%DI4Y6D=5)9 :11*8R@:WYC;Z-DZ$3W_4%IG23)? M>5JGKL;@!MY7UX?J!E!:"*5%4!J!TBB4QE TWC('7S.O#KA5?>!=4>Y;XLS) MQ.D^OD,M,=@.2)H/I0506@BE15 :@=(HE,90--XR;?3A+4-[O$/-M MW3;'9G= 52TYV$*BJG#+).;69MV!']G=6R;)@NKN-ZZ&LHWT\4@?=9==0W>3 M0&D42F,H&M]&V[#94H?-O>:URENLF/*:]MC176%:AKH*@]ML7UT?JAM :2&4 M%D%I!$JC4!I#T7B[M &SI0Z8!PU^NN(I73KX"8V6):J"+\2\6#[X*805;LC6I)-I#F<9#LQAY-M M),WAH+M)H#0*I3$4C6^C;59LGU@,_=TYG"T):.4YG+H*@]ML7UT?JAM :2&4 M%D%I!$JC4!I#T;9VN2B?DJ3RXBJ^NES%C\EOG M_9LJ7[T_J[LF7_*JRI>;ET])/$^*9H/Z[P]Y7KV^N:CY+WGQ=:-Q]7]02P,$ M% @ \#L(5RFAEO$_ @ 6 0 !@ !X;"]W;W)K1DDG?;1A4NP:NS,-DW[ M[V<;PC)I[1=\9]_S^+GS'=%1R&=5(6IXK1E7(Z_2^G#G^ZJHL";J6AR0FY.= MD#71QI5[7QTDDM*!:N:'07#KUX1R+X[*>-C.XK;3?\.#J0/>:HMX>U-)[?LY2T1JZHX"!Q-_+&@[O)T,:[@$>*1W5F M@\WD28AGZ\S+D1=80<7G^E!9[;)_:9R]WD\D04 M3@7[24M=C;QO'I2X(PW3F3C>8Y?/C>4K!%/N"\)(BB-(&VW8K.%2=6@CCG+[*+F6YI0:G(ZG MJV62+O,T 6/EJX=Y,MX8)]^899$N-SFL9O;H,HA2;/\$Z0_MO/-+[A,TME\.M]

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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 166 237 1 true 49 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 100030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 6 false false R7.htm 100080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited) Statements 7 false false R8.htm 100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 8 false false R9.htm 100100 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 9 false false R10.htm 100110 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 100120 - Disclosure - Fair Value Measurements and Financial Instruments Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments1 Fair Value Measurements and Financial Instruments Notes 11 false false R12.htm 100130 - Disclosure - Prepaid Expense and Other Current Assets Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssets Prepaid Expense and Other Current Assets Notes 12 false false R13.htm 100140 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 100150 - Disclosure - Stock-Based Compensation Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 100160 - Disclosure - Preferred Stock Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStock Preferred Stock Notes 15 false false R16.htm 100170 - Disclosure - Common Stock Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStock Common Stock Notes 16 false false R17.htm 100180 - Disclosure - Net Loss per Share Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 100200 - Disclosure - Leases Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeases Leases Notes 18 false false R19.htm 100220 - Disclosure - Related Party Transactions Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 100230 - Disclosure - Commitments and Contingencies Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 100250 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100260 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100270 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables Fair Value Measurements and Financial Instruments (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments1 23 false false R24.htm 100280 - Disclosure - Prepaid Expense and Other Current Assets (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssetsTables Prepaid Expense and Other Current Assets (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssets 24 false false R25.htm 100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities 25 false false R26.htm 100300 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation 26 false false R27.htm 100310 - Disclosure - Common Stock (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockTables Common Stock (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStock 27 false false R28.htm 100320 - Disclosure - Net Loss per Share (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare 28 false false R29.htm 100340 - Disclosure - Leases (Tables) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeases 29 false false R30.htm 100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails Nature of the Business and Basis of Presentation - Additional Information (Details) Details 30 false false R31.htm 100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 31 false false R32.htm 100370 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 32 false false R33.htm 100390 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy for Assets and Liabilities (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy for Assets and Liabilities (Details) Details 33 false false R34.htm 100400 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Marketable Securities (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails Fair Value Measurements and Financial Instruments - Summary of Marketable Securities (Details) Details 34 false false R35.htm 100410 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Marketable Securities by Maturity (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails Fair Value Measurements and Financial Instruments - Summary of Marketable Securities by Maturity (Details) Details 35 false false R36.htm 100420 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails Fair Value Measurements and Financial Instruments - Additional Information (Details) Details 36 false false R37.htm 100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 37 false false R38.htm 100470 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 38 false false R39.htm 100480 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 39 false false R40.htm 100530 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) Details 40 false false R41.htm 100540 - Disclosure - Preferred Stock - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails Preferred Stock - Additional Information (Details) Details 41 false false R42.htm 100550 - Disclosure - Common Stock - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails Common Stock - Additional Information (Details) Details 42 false false R43.htm 100560 - Disclosure - Common Stock - Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails Common Stock - Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards (Details) Details 43 false false R44.htm 100570 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails Net Loss per Share - Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders (Details) Details 44 false false R45.htm 100580 - Disclosure - Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Details) Details 45 false false R46.htm 100620 - Disclosure - Leases - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 46 false false R47.htm 100630 - Disclosure - Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details) Details 47 false false R48.htm 100650 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 48 false false R49.htm 100660 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 49 false false All Reports Book All Reports vigl-20230630.htm vigl-20230630.xsd vigl-20230630_cal.xml vigl-20230630_def.xml vigl-20230630_lab.xml vigl-20230630_pre.xml vigl-ex31_1.htm vigl-ex31_2.htm vigl-ex32_1.htm vigl-ex32_2.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vigl-20230630.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 456, "http://xbrl.sec.gov/dei/2023": 31 }, "contextCount": 166, "dts": { "calculationLink": { "local": [ "vigl-20230630_cal.xml" ] }, "definitionLink": { "local": [ "vigl-20230630_def.xml" ] }, "inline": { "local": [ "vigl-20230630.htm" ] }, "labelLink": { "local": [ "vigl-20230630_lab.xml" ] }, "presentationLink": { "local": [ "vigl-20230630_pre.xml" ] }, "schema": { "local": [ "vigl-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 526, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 4, "total": 10 }, "keyCustom": 40, "keyStandard": 197, "memberCustom": 21, "memberStandard": 27, "nsprefix": "vigl", "nsuri": "http://www.vigilneuro.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair Value Measurements and Financial Instruments", "menuCat": "Notes", "order": "11", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments1", "shortName": "Fair Value Measurements and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Prepaid Expense and Other Current Assets", "menuCat": "Notes", "order": "12", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssets", "shortName": "Prepaid Expense and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "13", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "14", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Preferred Stock", "menuCat": "Notes", "order": "15", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStock", "shortName": "Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Common Stock", "menuCat": "Notes", "order": "16", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Net Loss per Share", "menuCat": "Notes", "order": "17", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Leases", "menuCat": "Notes", "order": "18", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "19", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "20", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables", "shortName": "Fair Value Measurements and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "vigl:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Prepaid Expense and Other Current Assets (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssetsTables", "shortName": "Prepaid Expense and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "vigl:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Common Stock (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Net Loss per Share (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:ScheduleOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "vigl:ScheduleOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-5", "first": true, "lang": null, "name": "vigl:CashCashEquivalentsAndMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)", "menuCat": "Details", "order": "30", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-5", "first": true, "lang": null, "name": "vigl:CashCashEquivalentsAndMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_a50a05a2-f2d0-4e5f-ad1f-bc76cfcd7c5f", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SecurityDeposit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "31", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_a50a05a2-f2d0-4e5f-ad1f-bc76cfcd7c5f", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SecurityDeposit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "menuCat": "Details", "order": "32", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vigl:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_7ceaae87-6c2b-49e6-a262-ec63fe2b9410", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_724ec7e4-873a-44bd-b5c1-82a3ebabb849", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy for Assets and Liabilities (Details)", "menuCat": "Details", "order": "33", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy for Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_724ec7e4-873a-44bd-b5c1-82a3ebabb849", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_70e8b6e6-efa8-480c-a39a-84d3664e28d0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Marketable Securities (Details)", "menuCat": "Details", "order": "34", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_70e8b6e6-efa8-480c-a39a-84d3664e28d0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_0ccee02d-c85c-41b4-ac9a-fc16fc407320", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Marketable Securities by Maturity (Details)", "menuCat": "Details", "order": "35", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Marketable Securities by Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_0ccee02d-c85c-41b4-ac9a-fc16fc407320", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "INF", "first": true, "lang": null, "name": "vigl:NumberOfSecurities", "reportCount": 1, "unitRef": "U_Securities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Details)", "menuCat": "Details", "order": "36", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails", "shortName": "Fair Value Measurements and Financial Instruments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "INF", "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vigl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "vigl:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "vigl:PrepaidResearchAndDevelopmentExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "37", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vigl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "vigl:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "vigl:PrepaidResearchAndDevelopmentExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "38", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "39", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_bcc6f369-2bec-4b55-8905-99fc5b04ffdb", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "40", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_c76223ee-bc71-4906-851b-5fd90095993f", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_6b4b4377-c1de-45d4-a2b1-e01976e50228", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Preferred Stock - Additional Information (Details)", "menuCat": "Details", "order": "41", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "shortName": "Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_bcf788b8-e0af-4322-a67e-b2a84f5ead50", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Common Stock - Additional Information (Details)", "menuCat": "Details", "order": "42", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "shortName": "Common Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Common Stock - Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards (Details)", "menuCat": "Details", "order": "43", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "shortName": "Common Stock - Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_be462724-2ff3-4559-ba95-4e8c429c4aca", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders (Details)", "menuCat": "Details", "order": "44", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss per Share - Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Details)", "menuCat": "Details", "order": "45", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails", "shortName": "Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Leases - Additional Information (Details)", "menuCat": "Details", "order": "46", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-5", "lang": null, "name": "us-gaap:VariableLeasePayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details)", "menuCat": "Details", "order": "47", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails", "shortName": "Leases - Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_9a895ce1-9fdd-4b6a-9c8e-2f70025ee7e9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Related Party Transactions - Additional Information (Details)", "menuCat": "Details", "order": "48", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_fcb02e89-73c1-4f5d-a061-c316c93e796b", "decimals": "-3", "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "49", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "div", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-3", "first": true, "lang": null, "name": "vigl:ResearchAndDevelopmentExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "div", "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b71eb83e-e977-41c8-af6e-71afe5f2c7ad", "decimals": "-3", "first": true, "lang": null, "name": "vigl:ResearchAndDevelopmentExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_b62ea903-29f8-4d9e-abcb-771ea511a23a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_f0127c58-7653-40d1-b80b-941983774aac", "decimals": "INF", "lang": null, "name": "vigl:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_cf21b81e-82db-4dc6-9680-701aaec1591b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_cf21b81e-82db-4dc6-9680-701aaec1591b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "menuCat": "Statements", "order": "8", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Nature of the Business and Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vigl-20230630.htm", "contextRef": "C_760ffe20-6904-435b-8e60-3a964cf87987", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r153", "r154", "r259", "r267", "r405", "r620", "r622" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r244", "r245", "r246", "r247", "r291", "r440", "r475", "r514", "r515", "r577", "r583", "r585", "r586", "r597", "r616", "r617", "r626", "r631", "r635", "r641", "r706", "r748", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r244", "r245", "r246", "r247", "r291", "r440", "r475", "r514", "r515", "r577", "r583", "r585", "r586", "r597", "r616", "r617", "r626", "r631", "r635", "r641", "r706", "r748", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r244", "r245", "r246", "r247", "r283", "r291", "r319", "r320", "r321", "r416", "r440", "r475", "r514", "r515", "r577", "r583", "r585", "r586", "r597", "r616", "r617", "r626", "r631", "r635", "r641", "r644", "r699", "r706", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r244", "r245", "r246", "r247", "r283", "r291", "r319", "r320", "r321", "r416", "r440", "r475", "r514", "r515", "r577", "r583", "r585", "r586", "r597", "r616", "r617", "r626", "r631", "r635", "r641", "r644", "r699", "r706", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r153", "r154", "r259", "r267", "r405", "r621", "r622" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r640" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "vigl_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r122", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "terseLabel": "Less: accumulated depreciation", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r28", "r76", "r129", "r464", "r480", "r481" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r2", "r10", "r28", "r360", "r363", "r399", "r476", "r477", "r674", "r675", "r676", "r686", "r687", "r688" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r71" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r328", "r329", "r330", "r493", "r686", "r687", "r688", "r740", "r762" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r52", "r53", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r323", "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation expense", "terseLabel": "Stock-based compensation expense recognized", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r124", "r151", "r184", "r187", "r189", "r225", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r353", "r357", "r378", "r459", "r537", "r640", "r652", "r704", "r705", "r746" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r118", "r131", "r151", "r225", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r353", "r357", "r378", "r640", "r704", "r705", "r746" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, fair value", "totalLabel": "Assets, Fair Value Disclosure, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year", "terseLabel": "Maturities in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r193", "r233", "r454", "r691" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available for Sale securities fair value", "totalLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r67", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r33", "r34", "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r31", "r120", "r618" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r32", "r101" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r31", "r84", "r148" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r84" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents", "verboseLabel": "Cash Equivalents (Money Market)" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r9", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificate of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r115", "r126", "r127", "r128", "r151", "r171", "r172", "r174", "r176", "r182", "r183", "r225", "r249", "r251", "r252", "r253", "r257", "r258", "r264", "r265", "r269", "r272", "r280", "r378", "r483", "r484", "r485", "r486", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r525", "r546", "r568", "r609", "r610", "r611", "r612", "r613", "r660", "r683", "r689" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r126", "r127", "r128", "r182", "r264", "r265", "r267", "r269", "r272", "r278", "r280", "r483", "r484", "r485", "r486", "r631", "r660", "r683" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrants exercised" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r64", "r460", "r524" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r91", "r241", "r242", "r615", "r700" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Aggregate number of shares of common stock reserved for issuance", "totalLabel": "Total common stock reserved for future issuance", "verboseLabel": "Total common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Common Stock and Additional Paid-in Capital" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r642", "r643", "r644", "r646", "r647", "r648", "r649", "r686", "r687", "r740", "r760", "r762" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r70", "r525" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares, issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r70", "r525", "r543", "r762", "r763" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance shares", "periodStartLabel": "Beginning balance, Shares", "terseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r70", "r462", "r640" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2023 and December 31, 2022; 35,906,037 shares issued as of June 30, 2023 and 35,664,658 shares issued as of December 31, 2022; and 35,861,714 shares outstanding as of June 30, 2023 and 35,620,335 shares outstanding as of December 31, 2022", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common stock, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r29", "r137", "r139", "r143", "r455", "r473" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "vigl_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Construction Payable, Current", "terseLabel": "Construction related" } } }, "localname": "ConstructionPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r33", "r34", "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Conversion of Series A & Series B Preferred Stock to common stock, net of Issuance costs" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r264", "r265", "r269", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r16", "r46", "r69", "r94", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Issuance of convertible preference shares" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r632", "r634", "r757" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "auth_ref": [ "r554", "r555", "r598", "r599", "r600", "r677", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Realized Gain (Loss)", "terseLabel": "Realized gain or losses on marketable securities", "totalLabel": "Debt and Equity Securities, Realized Gain (Loss), Total" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded", "terseLabel": "Credit losses recognized on securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r106", "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of securities in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r341" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r54", "r738" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Research and development credits" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r737" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r737" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r54", "r738" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r54", "r738" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r54", "r738" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "auth_ref": [ "r54", "r738" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other", "terseLabel": "Accruals and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r342" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Discretionary and contributions amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r7", "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total", "verboseLabel": "Depreciation expense on property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r7", "r40" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r292", "r296", "r324", "r325", "r327", "r636" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r5", "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Common stock dividend declared", "totalLabel": "Dividends, Common Stock, Total" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r144", "r160", "r161", "r162", "r163", "r164", "r169", "r171", "r174", "r175", "r176", "r180", "r368", "r369", "r456", "r474", "r623" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r144", "r160", "r161", "r162", "r163", "r164", "r171", "r174", "r175", "r176", "r180", "r368", "r369", "r456", "r474", "r623" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r168", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r335" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r152", "r335", "r347" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory U.S. federal rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r736", "r739" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r736", "r739" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "Research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r736", "r739" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes (NoFB)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "vigl_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and employee related", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to unvested restricted stock not recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to unvested stock options not recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Common Stock Options", "verboseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment Lease" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r116", "r140", "r141", "r142", "r155", "r156", "r157", "r159", "r165", "r167", "r181", "r226", "r227", "r282", "r328", "r329", "r330", "r344", "r345", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r379", "r380", "r381", "r382", "r383", "r384", "r399", "r476", "r477", "r478", "r493", "r568" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage of outstanding shares of capital stock" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r371", "r372", "r376" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r371", "r372", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r12", "r58" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r57", "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r260", "r284", "r285", "r286", "r287", "r288", "r289", "r372", "r413", "r414", "r415", "r629", "r630", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r58", "r100" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r371", "r372", "r373", "r374", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements and Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments1" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r260", "r284", "r289", "r372", "r413", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r260", "r284", "r289", "r372", "r414", "r629", "r630", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r260", "r284", "r285", "r286", "r287", "r288", "r289", "r372", "r415", "r629", "r630", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r12", "r58" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r260", "r284", "r285", "r286", "r287", "r288", "r289", "r413", "r414", "r415", "r629", "r630", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r370", "r377" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r387", "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails2": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Financing lease liabilities", "totalLabel": "Finance Lease, Liability, Total", "verboseLabel": "Financing leases, Total future minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r387" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Financing lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r387" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Financing Lease, Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r744" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Financing leases, 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r388", "r394" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments of finance lease obligations", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r386" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Financing lease right-of-use assets", "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r397", "r639" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance lease, weighted-average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r396", "r639" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance lease, weighted-average remaining lease term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r228", "r229", "r230", "r231", "r232", "r234", "r236", "r237", "r262", "r278", "r365", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r472", "r627", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r693", "r694", "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r79", "r548" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering (IPO)" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r239", "r240", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r240", "r553" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r152", "r334", "r336", "r339", "r343", "r346", "r348", "r349", "r350", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r6" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r661", "r681" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r681" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r6" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r80", "r185" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income, net" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r482", "r511", "r512", "r580", "r582", "r589", "r602", "r644", "r652", "r761" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Investment Owned, Cost", "terseLabel": "Investment amortized cost", "totalLabel": "Investment Amortized Cost" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r482", "r505", "r506", "r507", "r509", "r510", "r511", "r512", "r513", "r516", "r517", "r528", "r529", "r576", "r578", "r579", "r581", "r587", "r588", "r590", "r591", "r592", "r595", "r596", "r601", "r603", "r604", "r644", "r652", "r761" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails": { "order": 0.0, "parentTag": "us-gaap_InvestmentOwnedAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in security owned.", "label": "Investment Owned, Fair Value", "periodEndLabel": "Investment Owned, at Fair Value, Ending Balance", "periodStartLabel": "Investment Owned, at Fair Value, Beginning Balance", "terseLabel": "Investment Fair Value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r506", "r508", "r509", "r511", "r513", "r576", "r578", "r584", "r588", "r590", "r593", "r594", "r603", "r605", "r606", "r607", "r608", "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r506", "r508", "r509", "r511", "r513", "r576", "r578", "r584", "r588", "r590", "r593", "r594", "r603", "r605", "r606", "r607", "r608", "r644" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of marketable securities by maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r393", "r639" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost", "totalLabel": "Lease, Cost, Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease termination date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Operating lease, existence of option to extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating Leases, Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating Leases, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Operating Leases, 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Operating Leases, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Operating Leases, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r744" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Operating Leases, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r398" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Operating Leases, Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r743" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r743" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r151", "r225", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r354", "r357", "r358", "r378", "r523", "r624", "r652", "r704", "r746", "r747" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r75", "r104", "r466", "r640", "r684", "r697", "r741" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r119", "r151", "r225", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r354", "r357", "r358", "r378", "r640", "r704", "r746", "r747" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r15", "r103", "r756" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Letter of credit", "totalLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Line of Credit Facility, Expiration Date", "terseLabel": "Letter of credit expiration date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Purchase commitment fee" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Purchase commitment period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r243", "r244", "r245", "r248", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r243", "r244", "r245", "r248", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r670" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r146" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "terseLabel": "Net cash proceeds from financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r146" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r85", "r86" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r77", "r86", "r105", "r117", "r136", "r138", "r142", "r151", "r158", "r160", "r161", "r162", "r163", "r166", "r167", "r173", "r184", "r186", "r188", "r190", "r225", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r369", "r378", "r471", "r545", "r566", "r567", "r625", "r650", "r704" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r184", "r186", "r188", "r190", "r625" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Non-cash operating lease expense", "verboseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r387" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Operating Leases, Total future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r387" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r387" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r389", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease monthly payment" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r386" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r397", "r639" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r396", "r639" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "vigl_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r130", "r640" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r123" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r132", "r133", "r134" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on available for sale securities", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r4", "r76", "r135", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "terseLabel": "Unrealized gain (loss) on available for sale securities" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other liabillities, current" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration": { "auth_ref": [ "r125", "r256", "r404", "r685" ], "lang": { "en-us": { "role": { "documentation": "Indicates related and nonrelated party status for liability classified as other and current.", "label": "Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]" } } }, "localname": "OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r692" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "terseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r147", "r679", "r680" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "terseLabel": "Expense in connection with goods provided", "totalLabel": "Payments to Suppliers and Employees, Total" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-Based Stock Options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r46", "r69" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred Stock, Conversion Basis", "terseLabel": "Convertible preferred stock basis" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Preferred stock conversion price per share" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r69", "r264" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r69", "r525" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r69", "r264" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r69", "r525", "r543", "r762", "r763" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r69", "r461", "r640" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 0 share issued and outstanding at June 30, 2023 and December 31, 2022, respectively", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r673" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r619", "r628", "r698" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Business insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds from issuance initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r3" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of common stock upon initial public offering, net of offering costs", "verboseLabel": "Gross proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Net proceeds from offering" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r3", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from equity financings", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r3", "r13" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r117", "r136", "r138", "r145", "r151", "r158", "r166", "r167", "r184", "r186", "r188", "r190", "r225", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r352", "r355", "r356", "r369", "r378", "r457", "r470", "r492", "r545", "r566", "r567", "r625", "r637", "r638", "r651", "r676", "r704" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r90", "r121", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r458", "r469", "r640" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r8", "r111", "r114", "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment and Related Accumulated Depreciation" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r290", "r403", "r404", "r518", "r519", "r520", "r521", "r522", "r542", "r544", "r575" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r403", "r404", "r745" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r549", "r550", "r553" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r290", "r403", "r404", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r518", "r519", "r520", "r521", "r522", "r542", "r544", "r575", "r745" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r400", "r401", "r402", "r404", "r406", "r489", "r490", "r491", "r551", "r552", "r553", "r572", "r574" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r66", "r333", "r754" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r108", "r669", "r682" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r72", "r96", "r465", "r479", "r481", "r487", "r526", "r640" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r116", "r155", "r156", "r157", "r159", "r165", "r167", "r226", "r227", "r328", "r329", "r330", "r344", "r345", "r359", "r361", "r362", "r364", "r367", "r476", "r478", "r493", "r762" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r395", "r639" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of Deferred Income Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r690" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Basic and Diluted Net Loss Per Common Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Summary of Effective Income Tax Rate Differs from Statutory Federal Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Hierarchy for Assets and Liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r61", "r62", "r549", "r550", "r553" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r293", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r93", "r95", "r96", "r126", "r127", "r128", "r182", "r264", "r265", "r267", "r269", "r272", "r278", "r280", "r483", "r484", "r485", "r486", "r631", "r660", "r683" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r16", "r42", "r44", "r45", "r46", "r47", "r48", "r49", "r69", "r70", "r93", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Reserved Number of Shares of Common Stock for Exercise of Outstanding Stock Options and Future Issuance of Stock-Based Awards" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r669" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Lease security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Group of financial instruments held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.", "label": "Security Owned and Sold, Not yet Purchased, at Fair Value [Axis]" } } }, "localname": "SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of financial instrument held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.", "label": "Security Owned and Sold, Not yet Purchased Fair Value, Security Name [Domain]" } } }, "localname": "SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r671", "r672", "r707" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock", "verboseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r671", "r672", "r707" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock", "verboseLabel": "Series B Preferred stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r6" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Forfeited/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "terseLabel": "Outstanding as of beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested during period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Stock-based compensation fair value assumptions, expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r293", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in common stock reserved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Shares, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Grant of restricted stock", "verboseLabel": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, Outstanding", "periodStartLabel": "Number of Shares, Outstanding", "terseLabel": "Number of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding", "periodStartLabel": "Weighted-Average Exercise Price Per Share, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "periodEndLabel": "Number of Shares, Vested and exercisable", "periodStartLabel": "Number of Shares, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price Per Share, Vested and exercisable", "periodStartLabel": "Weighted-Average Exercise Price Per Share, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Number of Shares, Vested and expected to vest", "periodStartLabel": "Number of Shares, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest", "periodStartLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of cumulative number of shares issued and outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Number of shares issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "All Award Types", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Fair value of common stock" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)", "verboseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Issuance Price per share", "verboseLabel": "Common stock issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r0", "r703", "r758", "r759" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letter of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r115", "r126", "r127", "r128", "r151", "r171", "r172", "r174", "r176", "r182", "r183", "r225", "r249", "r251", "r252", "r253", "r257", "r258", "r264", "r265", "r269", "r272", "r280", "r378", "r483", "r484", "r485", "r486", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r525", "r546", "r568", "r609", "r610", "r611", "r612", "r613", "r660", "r683", "r689" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r26", "r116", "r140", "r141", "r142", "r155", "r156", "r157", "r159", "r165", "r167", "r181", "r226", "r227", "r282", "r328", "r329", "r330", "r344", "r345", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r379", "r380", "r381", "r382", "r383", "r384", "r399", "r476", "r477", "r478", "r493", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r155", "r156", "r157", "r181", "r441", "r482", "r504", "r516", "r518", "r519", "r520", "r521", "r522", "r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r544", "r547", "r548", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r645" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r155", "r156", "r157", "r181", "r441", "r482", "r504", "r516", "r518", "r519", "r520", "r521", "r522", "r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r544", "r547", "r548", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r645" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r11", "r25", "r46", "r96", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock issued during period, shares, conversion of convertible securities", "verboseLabel": "Convertible Preferred stock converted to common stock" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r69", "r70", "r96", "r483", "r568", "r610" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance costs, shares", "verboseLabel": "Common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r69", "r70", "r96", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Shares, Exercised", "terseLabel": "Options exercised during period", "verboseLabel": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r69", "r70", "r96", "r493", "r568", "r610", "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance costs", "verboseLabel": "Issuance of convertible preferred stock, fair value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r11", "r26", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r70", "r73", "r74", "r89", "r527", "r543", "r569", "r570", "r640", "r652", "r684", "r697", "r741", "r762" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 deficit:", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r92", "r150", "r263", "r265", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r279", "r282", "r366", "r571", "r573", "r614" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r385", "r408" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r385", "r408" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r385", "r408" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r385", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r385", "r408" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r407", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r249", "r251", "r252", "r253", "r257", "r258", "r331", "r463" ], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Temporary equity, balance", "periodStartLabel": "Temporary equity, balance", "terseLabel": "Convertible preferred stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Temporary equity, liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r14", "r42" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary equity, par value", "verboseLabel": "Purchase price per share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Temporary equity, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary equity, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Temporary equity balance, shares", "periodStartLabel": "Temporary equity balance, shares", "terseLabel": "Temporary equity, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r262", "r278", "r365", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r472", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r693", "r694", "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. Government Securities", "verboseLabel": "Available for sale securities (U.S. government securities)" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Summary of marketable securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized tax positions, interest and penalties", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits, that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r37", "r38", "r39", "r109", "r110", "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeasePayment": { "auth_ref": [ "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.", "label": "Variable Lease, Payment", "terseLabel": "Variable lease expense" } } }, "localname": "VariableLeasePayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r170", "r176" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r169", "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonShareAttributableToCommonStockholdersDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited1" ], "xbrltype": "sharesItemType" }, "vigl_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "vigl_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities [Member]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "vigl_AccruedExpensesRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses related parties.", "label": "Accrued Expenses Related Parties", "terseLabel": "Accrued expenses, related parties" } } }, "localname": "AccruedExpensesRelatedParties", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 0.0, "parentTag": "vigl_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development current.", "label": "Accrued Research And Development Current", "terseLabel": "Research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_AdditionalMaximumConsiderationForLicenseAgreementUponAchievementOfSpecifiedRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional maximum consideration for license agreement upon achievement of specified regulatory milestones.", "label": "Additional Maximum Consideration For License Agreement Upon Achievement Of Specified Regulatory Milestones", "terseLabel": "Additional maximum consideration for license agreement upon achievement of specified regulatory milestones" } } }, "localname": "AdditionalMaximumConsiderationForLicenseAgreementUponAchievementOfSpecifiedRegulatoryMilestones", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_AmgenAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amgen agreement.", "label": "Amgen Agreement [Member]", "terseLabel": "Amgen Agreement" } } }, "localname": "AmgenAgreementMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_AmgenIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amgen Inc.", "label": "Amgen Inc [Member]", "terseLabel": "Amgen, Inc." } } }, "localname": "AmgenIncMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_AmortizationOfPremiumDiscountOnMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of premium discount on marketable securities.", "label": "Amortization of Premium Discount on Marketable Securities", "terseLabel": "Amortization of premium/discount on marketable securities" } } }, "localname": "AmortizationOfPremiumDiscountOnMarketableSecurities", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_AtlasVentureFundXIILPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Atlas Venture Fund XII LP.", "label": "Atlas Venture Fund X I I L P [Member]", "terseLabel": "Atlas Venture Fund XII, LP" } } }, "localname": "AtlasVentureFundXIILPMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available-for-sale securities, debt maturities, one through two years, fair value.", "label": "Available-for-Sale Securities, Debt Maturities, One Through Two Years, Fair Value", "terseLabel": "Maturities between one and two years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "monetaryItemType" }, "vigl_CashCashEquivalentsAndMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and marketable securities.", "label": "Cash Cash Equivalents and Marketable Securities", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecurities", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_ChangeInFairValueOfRelatedPartyAntidilutionObligation": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of related party antidilution obligation.", "label": "Change In Fair Value Of Related Party Antidilution Obligation", "terseLabel": "Change in fair value of the related party antidilution obligation" } } }, "localname": "ChangeInFairValueOfRelatedPartyAntidilutionObligation", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_ComputerSoftwareAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer software and equipment.", "label": "Computer Software And Equipment [Member]", "terseLabel": "Computer Software and Equipment" } } }, "localname": "ComputerSoftwareAndEquipmentMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "vigl_ConstructionRelatedPrepaidAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Construction related prepaid assets current.", "label": "Construction Related Prepaid Assets Current", "terseLabel": "Construction related prepaid assets" } } }, "localname": "ConstructionRelatedPrepaidAssetsCurrent", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vigl_ContractManufacturingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract manufacturing costs.", "label": "Contract Manufacturing Costs", "terseLabel": "Contract manufacturing costs" } } }, "localname": "ContractManufacturingCosts", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of convertible preferred stock to common stock upon closing of initial public offering", "label": "Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering", "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering,shares" } } }, "localname": "ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "vigl_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible preferred stock to common stock upon closing of initial public offering,amount", "label": "Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering,Amount", "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering,amount" } } }, "localname": "ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingAmount", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "vigl_CorporateHeadquartersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters.", "label": "Corporate Headquarters [Member]", "terseLabel": "Corporate Headquarters" } } }, "localname": "CorporateHeadquartersMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_CumulativeChangeInOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative change in ownership percentage.", "label": "Cumulative Change In Ownership Percentage", "terseLabel": "Cumulative change in ownership percentage" } } }, "localname": "CumulativeChangeInOwnershipPercentage", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vigl_DeferredOfferingCostsDueToVendor": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "vigl_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs due to vendor.", "label": "Deferred Offering Costs Due to Vendor", "terseLabel": "Deferred IPO" } } }, "localname": "DeferredOfferingCostsDueToVendor", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_DeferredOfferingCostsPaidInThePriorYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs paid in the prior year.", "label": "Deferred Offering Costs Paid in the Prior Year", "terseLabel": "Deferred offering costs paid in the prior year" } } }, "localname": "DeferredOfferingCostsPaidInThePriorYear", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_DeferredTaxAssetsStartUpCosts": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets start-up costs.", "label": "Deferred Tax Assets Start Up Costs", "terseLabel": "Start-up costs" } } }, "localname": "DeferredTaxAssetsStartUpCosts", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_DeferredTaxLiabilitiesDepreciation": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities depreciation.", "label": "Deferred Tax Liabilities Depreciation", "negatedLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesDepreciation", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right of use asset.", "label": "Deferred Tax Liabilities Right Of Use Asset", "negatedLabel": "Right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation other permanent differences.", "label": "Effective Income Tax Rate Reconciliation Other Permanent Differences", "terseLabel": "Other permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateDiffersFromStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "vigl_ExpectedValueAdjustmentIfSecondTrancheMilestonesAreNotMet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected value adjustment if second tranche milestones are not met.", "label": "Expected value adjustment if second tranche milestones are not met", "terseLabel": "Expected value adjustment to Series A if second tranche milestones are not met" } } }, "localname": "ExpectedValueAdjustmentIfSecondTrancheMilestonesAreNotMet", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "percentItemType" }, "vigl_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal and state research and development tax credit carryforwards expire period.", "label": "Federal And State Research And Development Tax Credit Carryforwards Expire Period", "terseLabel": "Federal and state research and development tax credit carryforwards expire period." } } }, "localname": "FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirePeriod", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vigl_FederalResearchAndDevelopmentTaxCreditCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Federal research and development tax credit carryforwards.", "label": "Federal Research And Development Tax Credit Carryforwards", "terseLabel": "Federal research and development tax credit carryforwards" } } }, "localname": "FederalResearchAndDevelopmentTaxCreditCarryforwards", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_FujifilmDiosynthBiotechnologiesTexasLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FUJIFILM diosynth biotechnologies Texas, LLC.", "label": "FUJIFILM Diosynth Biotechnologies Texas LLC [Member]", "terseLabel": "FUJIFILM Diosynth Biotechnologies Texas, LLC" } } }, "localname": "FujifilmDiosynthBiotechnologiesTexasLlcMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued expenses and other current liabilities.", "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_IncreaseDecreaseInTrancheObligation": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in tranche obligation.", "label": "Increase Decrease In Tranche Obligation", "terseLabel": "Change in fair value of Series A preferred stock tranche obligation" } } }, "localname": "IncreaseDecreaseInTrancheObligation", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_InvestmentUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentOwnedAtCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment unrealized gain.", "label": "Investment Unrealized Gain", "terseLabel": "Investment Gross Unrealized Gains" } } }, "localname": "InvestmentUnrealizedGain", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_InvestmentUnrealizedLosses": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentOwnedAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment Unrealized Losses", "label": "Investment Unrealized Losses", "negatedLabel": "Investment Gross Unrealized Losses" } } }, "localname": "InvestmentUnrealizedLosses", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_IssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance costs.", "label": "Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "IssuanceCosts", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_IssuanceOfConvertiblePreferredStockWithFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of convertible preferred stock with fair value.", "label": "Issuance Of Convertible Preferred Stock With Fair Value", "terseLabel": "Issuance of convertible preferred stock with fair value" } } }, "localname": "IssuanceOfConvertiblePreferredStockWithFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "Lab Equipment [Member]", "terseLabel": "Lab Equipment" } } }, "localname": "LabEquipmentMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "vigl_LaboratoryAndOfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory and office space.", "label": "Laboratory And Office Space [Member]", "terseLabel": "Laboratory and Office Space" } } }, "localname": "LaboratoryAndOfficeSpaceMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_LaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory space.", "label": "Laboratory Space [Member]", "terseLabel": "Laboratory Space" } } }, "localname": "LaboratorySpaceMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_LeaseAnnualPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease annual payments.", "label": "Lease Annual Payments", "terseLabel": "Lease annual payments" } } }, "localname": "LeaseAnnualPayments", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_LeaseConstructionAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease construction allowance.", "label": "Lease Construction Allowance", "terseLabel": "Lease construction allowance" } } }, "localname": "LeaseConstructionAllowance", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_LeaseIncreasedAnnualPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease increased annual payments.", "label": "Lease Increased Annual Payments", "terseLabel": "Lease increased annual payments" } } }, "localname": "LeaseIncreasedAnnualPayments", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_LeaseMonthlyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease monthly payment.", "label": "Lease Monthly Payment", "terseLabel": "Lease monthly payment" } } }, "localname": "LeaseMonthlyPayment", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due year five and thereafter.", "label": "Lessee Operating Lease Liability Payments Due Year Five and Thereafter", "terseLabel": "Operating Leases, 2028 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vigl_LettersOfCreditRenewalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letters of credit renewal period.", "label": "Letters Of Credit Renewal Period", "terseLabel": "Letter of credit renewal period" } } }, "localname": "LettersOfCreditRenewalPeriod", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "vigl_LineOfCreditFacilityRenewedExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility renewed expiration date1.", "label": "Line Of Credit Facility Renewed Expiration Date1", "terseLabel": "Renewed to expire date" } } }, "localname": "LineOfCreditFacilityRenewedExpirationDate1", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "vigl_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "marketable securities.", "label": "Marketable Securities [Member]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vigl_MarketableSecuritiesUSGovernmentSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities U.S. Government Securities [Member]", "label": "Marketable Securities U.S. Government Securities [Member]", "terseLabel": "Marketable Securities (U.S. Government Securities)", "verboseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesUSGovernmentSecuritiesMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfMarketableSecuritiesByMaturityDetails" ], "xbrltype": "domainItemType" }, "vigl_MaximumAggregateMilestonePaymentsUponAchievementOfSpecificCommercialMilestonesAcrossAllMabProducts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate milestone payments upon achievement of specific commercial milestones across all mab products.", "label": "Maximum Aggregate Milestone Payments Upon Achievement Of Specific Commercial Milestones Across All Mab Products", "terseLabel": "Maximum aggregate milestone payments upon achievement of specific commercial milestones across all mab products" } } }, "localname": "MaximumAggregateMilestonePaymentsUponAchievementOfSpecificCommercialMilestonesAcrossAllMabProducts", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_MaximumStockValueToBeIssuedUnderAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum gtock value to be issued under agreement.", "label": "Maximum Stock Value to be Issued under Agreement", "terseLabel": "Maximum shares value to be issued under agreement" } } }, "localname": "MaximumStockValueToBeIssuedUnderAgreement", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_NonCashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash operating lease expense.", "label": "Non Cash Operating Lease Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "NonCashOperatingLeaseExpense", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_NoncashUnrealizedGainsOnAvailableForSaleSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash unrealized gains on available for sale securities.", "label": "Noncash Unrealized Gains on Available for Sale Securities", "terseLabel": "Unrealized gains on available for sale securities" } } }, "localname": "NoncashUnrealizedGainsOnAvailableForSaleSecurities", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_NumberOfSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities.", "label": "Number of Securities" } } }, "localname": "NumberOfSecurities", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vigl_OperatingLeaseCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease commencement month and year.", "label": "Operating Lease Commencement Month And Year", "terseLabel": "Operating lease commencement month and year" } } }, "localname": "OperatingLeaseCommencementMonthAndYear", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "vigl_OperatingLeaseCommencementYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease commencement year.", "label": "Operating Lease Commencement Year", "terseLabel": "Operating lease commencement year" } } }, "localname": "OperatingLeaseCommencementYear", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vigl_OptionsToPurchaseCommonStockPerformanceBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock performance based.", "label": "Options To Purchase Common Stock Performance Based [Member]", "terseLabel": "Options to Purchase Common Stock \u2013 Performance Based" } } }, "localname": "OptionsToPurchaseCommonStockPerformanceBasedMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "vigl_OptionsToPurchaseCommonStockServiceBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock service based.", "label": "Options To Purchase Common Stock Service Based [Member]", "terseLabel": "Options to Purchase Common Stock \u2013 Service Based" } } }, "localname": "OptionsToPurchaseCommonStockServiceBasedMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "vigl_OtherAssetsInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other assets in accounts payable and accrued expenses.", "label": "Other Assets in Accounts Payable and Accrued Expenses", "terseLabel": "Other assets in accounts payable and accrued expenses" } } }, "localname": "OtherAssetsInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_PendingTaxExaminations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pending tax examinations.", "label": "Pending Tax Examinations", "terseLabel": "Pending tax examinations" } } }, "localname": "PendingTaxExaminations", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_PercentageOfAnnualEscalation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual escalation.", "label": "Percentage Of Annual Escalation", "terseLabel": "Percentage of annual escalation" } } }, "localname": "PercentageOfAnnualEscalation", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vigl_PercentageOfCapitalStockToIssueTemporaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of capital stock to issue temporary equity.", "label": "Percentage Of Capital Stock To Issue Temporary Equity", "terseLabel": "Percentage of capital stock to issue temporary equity" } } }, "localname": "PercentageOfCapitalStockToIssueTemporaryEquity", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vigl_PeriodForCumulativeChangeInOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for cumulative change in ownership.", "label": "Period For Cumulative Change In Ownership", "terseLabel": "Period for cumulative change in ownership" } } }, "localname": "PeriodForCumulativeChangeInOwnership", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vigl_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants.", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "vigl_PreferredStockTrancheObligationClassifiedAsLiabilityAndRecordedAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred Stock Tranche Obligation classified as liability and recorded at fair value.", "label": "Preferred Stock Tranche Obligation Classified as Liability and Recorded at Fair Value", "terseLabel": "Preferred stock tranche obligation classified as liability and recorded at fair value" } } }, "localname": "PreferredStockTrancheObligationClassifiedAsLiabilityAndRecordedAtFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_PreferredStockTrancheObligationRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock tranche obligation risk free interest rate", "label": "Preferred Stock Tranche Obligation Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "localname": "PreferredStockTrancheObligationRiskFreeInterestRate", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "percentItemType" }, "vigl_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "vigl_PrepaidRentReclassifiedToRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid rent reclassified to right-of-use assets.", "label": "Prepaid Rent Reclassified to Right-of-use Assets", "terseLabel": "Prepaid rent reclassified to right-of-use assets" } } }, "localname": "PrepaidRentReclassifiedToRightOfUseAssets", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_PrepaidResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development expense current.", "label": "Prepaid Research And Development Expense Current", "terseLabel": "Research and development" } } }, "localname": "PrepaidResearchAndDevelopmentExpenseCurrent", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vigl_PrepaidReservationFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid reservation fees.", "label": "Prepaid Reservation Fees", "terseLabel": "Prepaid reservation fees" } } }, "localname": "PrepaidReservationFees", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_ProbabilityOfMeetingMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probability of meeting milestones.", "label": "Probability of meeting milestones", "terseLabel": "Probability of meeting Series A milestones" } } }, "localname": "ProbabilityOfMeetingMilestones", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "percentItemType" }, "vigl_PurchaseCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase commitment fee percentage.", "label": "Purchase Commitment Fee Percentage", "terseLabel": "Purchase commitment fee percentage" } } }, "localname": "PurchaseCommitmentFeePercentage", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vigl_PurchaseCommitmentStatementOfWorkCompletedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase commitment statement of work completed percentage.", "label": "Purchase Commitment Statement of Work Completed Percentage", "terseLabel": "Purchase commitment statement of work completed percentage" } } }, "localname": "PurchaseCommitmentStatementOfWorkCompletedPercentage", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vigl_RelatedPartyAntidilutionObligationExpectedTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party antidilution obligation expected term1.", "label": "Related Party Antidilution Obligation Expected Term1", "terseLabel": "Expected term (years)" } } }, "localname": "RelatedPartyAntidilutionObligationExpectedTerm1", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "durationItemType" }, "vigl_RelatedPartyAntidilutionObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party antidilution obligation.", "label": "Related Party Antidilution Obligation [Member]", "terseLabel": "Related Party Antidilution Obligation" } } }, "localname": "RelatedPartyAntidilutionObligationMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables", "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "vigl_RelatedPartyAntidilutionObligationProbabilityOfFinanceEventOccurringPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party antidilution obligation probability of finance event occurring percentage.", "label": "Related Party Antidilution Obligation Probability of Finance Event Occurring Percentage", "terseLabel": "Probability of finance event occurring" } } }, "localname": "RelatedPartyAntidilutionObligationProbabilityOfFinanceEventOccurringPercentage", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "percentItemType" }, "vigl_RelatedPartyAntidilutionObligationRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party antidilution obligation risk free interest rate.", "label": "Related Party Antidilution Obligation Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "localname": "RelatedPartyAntidilutionObligationRiskFreeInterestRate", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "percentItemType" }, "vigl_RelatedPartyLicenseAgreementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party license agreement disclosure.", "label": "Related Party License Agreement Disclosure [Text Block]", "terseLabel": "Related Party License Agreement" } } }, "localname": "RelatedPartyLicenseAgreementDisclosureTextBlock", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "vigl_ResearchAndDevelopmentExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense related party.", "label": "Research And Development Expense Related Party", "terseLabel": "Research and development expense related party" } } }, "localname": "ResearchAndDevelopmentExpenseRelatedParty", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "vigl_RestrictedCashNonCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash non-current.", "label": "Restricted Cash Non Current [Member]", "terseLabel": "Restricted Cash, Noncurrent", "verboseLabel": "Restricted Cash (Non-Current)" } } }, "localname": "RestrictedCashNonCurrentMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "vigl_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "localname": "SalesAgreementMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash, cash equivalents and restricted cash.", "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "vigl_ScheduleOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum lease payments due under operating and finance lease liabilities.", "label": "Schedule Of Future Minimum Lease Payments Due Under Operating And Finance Lease Liabilities Table [Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments Due under Operating and Finance Lease Liabilities" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsDueUnderOperatingAndFinanceLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "vigl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and other current assets.", "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePrepaidExpenseAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "vigl_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_SeriesAConvertiblePreferredStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock purchase agreement.", "label": "Series A Convertible Preferred Stock Purchase Agreement [Member]", "terseLabel": "Series A Convertible Preferred Stock Purchase Agreement" } } }, "localname": "SeriesAConvertiblePreferredStockPurchaseAgreementMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_SeriesAPreferredStockTrancheObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock tranche obligation.", "label": "Series A Preferred Stock Tranche Obligation [Member]", "terseLabel": "Series A Preferred Stock Tranche Obligation" } } }, "localname": "SeriesAPreferredStockTrancheObligationMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_ServiceBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service-based stock options.", "label": "Service Based Stock Options [Member]", "terseLabel": "Service-Based Stock Options" } } }, "localname": "ServiceBasedStockOptionsMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingUnvestedSharesExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options outstanding unvested shares expected to vest.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Unvested Shares Expected To Vest", "terseLabel": "Outstanding unvested shares, expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingUnvestedSharesExpectedToVest", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingVestingPeriodForUnvestedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options weighted-average remaining vesting period for unvested shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Vesting Period For Unvested Shares", "terseLabel": "Remaining weighted-average vesting period for unvested shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingVestingPeriodForUnvestedShares", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "durationItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award fair value assumptions weighted-average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value", "terseLabel": "Weighted-average fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsOnWeightedAverageBasisToDetermineFairValueOfStockOptionsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToDetermineFairValueOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options, exercised, weighted-average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options, expired, weighted-average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expired Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options, forfeited, weighted-average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options, outstanding, weighted-average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Outstanding", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options, vested and exercisable, weighted-average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Vested and exercisable", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "vigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options, vested and expected to vest, weighted-average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Vested and expected to vest", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsActivityToPurchaseCommonStockDetails" ], "xbrltype": "perShareItemType" }, "vigl_SharePurchasePricePerPreFundedWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share purchase price per pre funded warrant.", "label": "Share Purchase Price Per Pre funded Warrant", "terseLabel": "Share purchase price per pre funded warrant" } } }, "localname": "SharePurchasePricePerPreFundedWarrant", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "vigl_StateNetOperatingLossCarryforwardsExpirePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State net operating loss carryforwards expire period.", "label": "State Net Operating Loss Carryforwards Expire Period", "terseLabel": "State net operating loss carryforwards expire period" } } }, "localname": "StateNetOperatingLossCarryforwardsExpirePeriod", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vigl_StateResearchAndDevelopmentTaxCreditCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "State research and development tax credit carryforwards.", "label": "State Research And Development Tax Credit Carryforwards", "terseLabel": "State research and development tax credit carryforwards" } } }, "localname": "StateResearchAndDevelopmentTaxCreditCarryforwards", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vigl_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vigl_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity conversion of convertible preferred stock to common stock upon closing of initial public offering.", "label": "Temporary Equity Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering", "terseLabel": "Temporary Equity Conversion of convertible preferred stock to common stock upon closing of initial public offering,Shares" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "vigl_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity conversion of convertible preferred stock to common stock upon closing of initial public offering, amount", "label": "Temporary Equity Conversion of Convertible Preferred Stock to Common Stock Upon Closing of Initial Public Offering, Amount", "terseLabel": "Temporary equity Conversion of convertible preferred stock to common stock upon closing of initial public offering,Amount" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingAmount", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "vigl_TemporaryEquityStockPurchaseCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock purchase commitment.", "label": "Temporary Equity Stock Purchase Commitment", "terseLabel": "Purchase an aggregate shares" } } }, "localname": "TemporaryEquityStockPurchaseCommitment", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vigl_TimeUntilSeriesAMilestoneYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time until series A milestone years.", "label": "Time Until Series A Milestone Years", "terseLabel": "Time until Series A milestones (years)" } } }, "localname": "TimeUntilSeriesAMilestoneYears", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsUsedInValuationModelDetails" ], "xbrltype": "durationItemType" }, "vigl_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan", "verboseLabel": "Shares Available for Issuance Under the 2020 Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one employee stock purchase plan.", "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan", "verboseLabel": "Shares Available for Issuance Under the 2021 ESPP" } } }, "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty once stock option and incentive plan.", "label": "Two Thousand Twenty One Stock Option And Incentive Plan [Member]", "terseLabel": "2021 Stock Option and Incentive Plan", "verboseLabel": "Shares Available for Issuance Under the 2021 Plan" } } }, "localname": "TwoThousandTwentyOneStockOptionAndIncentivePlanMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedNumberOfSharesOfCommonStockForExerciseOfOutstandingStockOptionsAndFutureIssuanceOfStockBasedAwardsDetails", "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vigl_UnpaidOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unpaid offering costs.", "label": "Unpaid Offering Costs", "terseLabel": "Offering costs included in accounts payable and accrued expenses" } } }, "localname": "UnpaidOfferingCosts", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "vigl_UnvestedRestrictedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted common stock.", "label": "Unvested Restricted Common Stock [Member]", "terseLabel": "Unvested Restricted Common Stock" } } }, "localname": "UnvestedRestrictedCommonStockMember", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "vigl_UpfrontConsiderationForLicenseArrangement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront consideration for license arrangement.", "label": "Upfront Consideration For License Arrangement", "terseLabel": "Upfront consideration for license arrangement" } } }, "localname": "UpfrontConsiderationForLicenseArrangement", "nsuri": "http://www.vigilneuro.com/20230630", "presentation": [ "http://www.vigilneuro.com/20230630/taxonomy/role/Role_DisclosureRelatedPartyLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org//840/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.E.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481961/940-320-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r654": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r655": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r656": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r657": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r658": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r659": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 67 0000950170-23-039366-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-039366-xbrl.zip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�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end